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Abstract 
Cyclophilin A (CypA), an 18 kDa cystolic inimunophilin protein, is the receptor for 
the immunosuppressant drug cyclosporin A (CsA), as well as a potential target for 
anti-parasitic and anti-HIV drugs. 	Although the CypA binding and 
immunosuppressant action of many natural and synthetic CsA derivatives have been 
studied, there are relatively few examples of the binding of low molecular weight 
organic molecules to CypA. 
A number of dimedone-based ligands have been synthesised and the binding affinities 
for CypA investigated using one or more of the following methods: crystal 
preparation and determination of the crystal structure of the ligand:CypA complex; 
fluorescence assay; PPIase assay; and observation of the ligand:CypA complex by 
mass spectrometry. 
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X = alkyl, aryl group 
Y = amino acid side chain, or dialkyl substituent 
Z = alkyl, aryl group 
Based on the highest affinity ligand I (K=22 jIM), discovered during preliminary 
screening, a parallel array of ligands have been generated around the library template 
II using automated methods. 
Progress towards the development of a resin-bound cyclohexane-1,3-dione species, 
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This thesis concerns the design and synthesis of high affinity ligands for 
cyclophilin A (CypA). By way of introduction, certain aspects of ligand design 
within the drug discovery process have been discussed. The functions of CypA have 
been described along with a review of the literature on CypA substrates/inhibitors, 
culminating in an account of the discovery of the lead compound for this project, 
dimedone. 
1.1 Drug Discovery 
1.1.1 Classical Lead Discovery 
Historically, natural products were the most important source of new drug leads. 
Active compounds were isolated from plants and their derivatives; from animal 
toxins; or from secondary metabolites of microorganisms: a relevant example being 
the discovery of the immunosuppressants cyclosporin A, FK 506 and rapamycin' by 
the screening of microbial broths. 
In traditional drug research, these natural product leads were systematically modified 
using standard medicinal chemistry methods based on cycles of synthesis and 
screening to obtain analogues with improved activity, selectivity, bioavailability, 
biological half life and/or reduced toxicity and fewer side effects. 
The face of drug discovery has changed dramatically in recent years due to the 
development of technologies in several fields. Currently, the complementary 
approaches of chemical synthesis, protein engineering and computational 
technologies form a design cycle of drug discovery, in which rational structure based 
design is becoming increasingly important.2 
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1.1.2 Chemical Synthesis 
In recent years the high throughput screening of combinatorial libraries has become 
an important tool in the discovery of drug candidates. Combinatorial chemistry, 
most simply defined as "the synthesis of all possible combinations of a set of 
building blocks began began with the concept of huge libraries of compound mixtures 
and deconvolution of biologically active mixtures to detect new leads. Modem 
research concentrates more on automated parallel synthesis of focused small libraries 
of single compounds, in both the lead discovery and lead optimisation stages. 
1.1.3 Protein Engineering 
In recent years there has been a substantial increase in the number of known 3D 
protein structures4  due to improvements in gene technology,5  protein biochemistry 
and structure elucidation techniques .6  Advances in protein isolation and purification 
by cloning and expression in bacterial or cell culture have meant that key proteins are 
now available in sufficient quantities for biological assays, NMR studies and 
structure determination by X-ray crystallography. Recombinant DNA methods allow 
isolation of stable domains for crystallisation, while site directed mutagenesis allows 
specific changes in target enzymes or other receptors to make them more useful for 
clinical applications .7  The sequence and primary structure of a protein can be 
derived from the sequence of the corresponding gene. Gene manipulation 
(modulation by amplifying or destroying a gene) produces transgenic animals, which 
can be used to investigate the relevance of a gene in certain diseases.8 
With the full characterisation of the human genome9  will come many new potential 
targets for disease therapy and an increase in demand for new structures. Advances 
in combinatorial chemistry and protein engineering have an important role in this 
revolution in drug discovery, in combination with new computational technologies 
for lead structure searching and optimisation. 
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1.1.4 Structure Based Design'°  
It is in the area of rational drug design that molecular graphics and computer aided 
drug design come in to play. In biological systems, physiological processes depend 
on specific molecular interactions, which are in turn governed by the specific 
features that enable molecules to recognise and bind to each other. Structure based 
design aims to identify compounds that bind to key regions of biologically active 
molecules, such as enzymes or receptors, for which the 3D structures are known. 
The compound leads should inhibit or stimulate the biological action of the target. 
Using the wide base of structural information on known biologically active 
compounds, it has been possible to correlate aspects of biological activity with 
models of specific intermolecular interaction. Proteins bind ligands in specific 
conformations. The topographies of the complementary surfaces of protein and 
ligand determine both affmity and specificity. For binding to occur, the drug and 
receptor molecules must have a complementary shape and charge distribution to 
achieve the required negative interaction energy. Equation 1, relating the binding 
energy (AG) to the binding constant, K, shows that a small increase in binding 
energy can lead to an almost tenfold increase in potency. The factors influencing 
these energy differences include molecular shape, hydrogen bonding, electrostatic 
interactions, van der Waals interactions, and solvent (hydrophobic interactions)." 
AG = -RTInK 	 (Equation 1) 
A combination of these factors is considered in the rational design of a ligand for a 
particular receptor site. Use of a molecular modelling programme to model the 
binding site involves consideration of many points in space and calculation of the 
energetics of binding at these points. Values for van der Waals bonding, hydrogen 
bonding, and electrostatic effects must be taken into account. This information may 
be used to build up a picture showing areas where particular atoms will bind most 
strongly. Computer graphics allow us to visualise the placing of a molecule in the 
binding site in order to determine the strongest interactions. 
3 
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Thus, structure based design is an iterative process of computational design, 
synthesis, screening, testing, structure elucidation and data analysis. 3D structures 
can be used as a basis for drug design in several ways: 
1.1.4.1 Design of novel leads 
Using known structures of protein receptors, ligands and/or protein-ligand 
complexes, computational graphics can be used to design novel ligand molecules (de 
novo design). This may involve the screening of 3D databases of small molecules 
for predicted binding to a known protein target (computational virtual screening). 
1.1.4.2 Modjfication of existing leads 
Structure based and computer aided design methods can also be applied to optimise 
leads, discovered by X-ray crystallography or NIvIR methods, for affinity and 
selectivity. This approach is based on the principle that small structural modifications 
or extensions will result in ligands with similar conformation that should bind to the 
target in a similar manner. 
1.1.5 Protein-Ligand Interactions 
Quantitative prediction of binding affmity based on non-bonded protein-ligand 
interactions is very difficult, but several structure-activity relationship studies 
indicate that the following criteria are important for strong interactions: 
12 
Enhanced binding affinity is frequently observed by enlargement of the lipophilic 
contact surface of the ligand by addition of a lipophilic substituent, capable of 
forming hydrophobic interactions with the protein surface. 
Although not always leading to improved binding affinities, additional hydrogen 
bonds between polar groups may improve the selectivity and make the ligand 
more water soluble. 
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The displacement of water molecules always occurs upon ligand binding to a 
protein. Strong binding can be achieved if the ligand forms more hydrogen 
bonds than the water molecules that are released. 
When binding occurs, there is a corresponding entropy loss due to freezing of 
internal degrees of freedom. Thus, conformationally constrained ligands often 
bind more strongly than flexible ligands. 
A number of programs have become available which enable de novo design of 
ligands for specific protein active sites. These methods are generally classified as 
three types: 
Automated docking of the whole molecule in the active site. 
Fitting molecules to precalculated potentials at grid points within the active 
site. 
Docking fragments or atoms and either joining or growing them into 
molecules. 
According to Kubinyi,'3 a computer-assisted approach to de novo design should 
include the following functionalities: 
Ability to search large 3D databases for potential ligands. 
Consideration of conformational flexibility, at least of the ligand. 
The option to create new ligands or to modify existing leads by fusion of groups, 
fragments or rings. 
A scoring function which is appropriate to evaluate and sort the hits. 
1.1.6 Modification of Existing Leads 
Many methods are employed to improve the therapeutic profile of a lead compound. 
Some classical concepts for the rational optimisation of lead structures include: 
14 
Bioisosteric replacement (the exchange of atoms and groups by isoelectronic 
groups). 
Optimisation of lipophilicity, electronic properties and hydrogen bond 
donor/acceptor properties. 
Variation of substituents at aromatic or heteroaromatic rings, or at heteroatoms. 
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Introduction or elimination of heteroatoms 
Variation of chain lengths or ring sizes. 
Conformational stabilisation by ring formation, intramolecular association of 
hydrophobic groups, branching, or addition of bulky substituents in order to form 
more rigid molecules. 
Increasing flexibility by ring opening. 
Introduction or elimination of chiral centres. 
1.1.7 Peptidomimetics 15,16 in Structure Based Design 
Most peptides have poor bioavailability and are easily degraded by enzymatic 
proteolysis, making them unsuitable candidates for pharmaceutical development. 
Peptidomimetics are compounds with peptide characteristics but non-peptide 
structures, which maintain the ability to bind to peptide receptors. Peptide leads are, 
therefore, good starting points for the design of peptidomimetics, which may display 
more favourable pharmacological properties than the natural ligand.'7 The advantage 
of this approach is that a peptide with known biological activity is used as the 
starting point for design. A peptide lead is identified by screening libraries of 
synthetic peptides, by phage display, or from the primary structure of a binding 
partner. Peptidomimetics can then be designed to mimic the conformation of the key 
amino acids in the parent peptide, often by incorporation of unnatural or pseudo 
amino acids, in order to imitate or block the biological action. Ideal peptidomimetics 
should show increased potency, selectivity and metabolic stability over the parent 
peptide. Often peptidomimetic ligands are much smaller than the original peptide 
lead as often only a small set of the peptide residues make energetically significant 
contact in the complex. The other interactions may be primarily associated with 
specificity or conformation.'8 
Many methods are used to modify peptide structures to generate efficient drug 
candidates.19  Peptidomimetic libraries can be constructed by introduction of amino 
acid analogues; peptide backbone modifications, such as isosteric replacements of 
the amide bond; conformational restrictions, such as cyclic or bridging dipeptides; 
and other structural additions which maintain the overall peptide scaffold but 
increase affinity and stability. 
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1.1.8 SAR by NMR (structure-activity relationships by nuclear magnetic 
resonance spectroscopy). 
This new experimental technique for structure based design, pioneered by Stephen 
Fesik,2°  involves the combination of fragments which bind to proximal subsites of a 
certain protein. Libraries of small molecules are screened for binding to the subsite 
of a specific protein. The ligand binding is observed by shifts in the corresponding 
amide proton signals of the '5N-labelled protein. The protein is then saturated with 
the highest affinity ligand for this site, and the screening process repeated for another 
proximal site using a different library. When two ligands have been successfully 
identified they can be combined with an appropriate linker which connects them in a 
relaxed conformation. In this manner, construction of a high affinity ligand for FK-
506 binding protein (FKBP) was achieved by combining two low affinity small 
molecules with a linker. Although SAR by NMR can be a relatively fast method for 
drug design, it does depend on the time taken for assignment of the protein NH 
signals. Large amounts of pure '5N-labelled protein with sufficient aqueous 
solubility are required, and the technique is limited to proteins of molecular weight 
< 53-40 kD. Some constraints on the distance between the two subsites must be 
employed to avoid linkers which are too large, and the design of the linker is also 
important to ensure that it does not interfere with binding affinity. 
Fesik has reported a related method which does not require '5N-labelled protein. By 
monitoring the T, relaxation times, binding of small molecules in a library to a 
protein can be observed.2 ' 
1.1.9 Conclusion 
Perhaps the greatest limitation in designing molecules based on protein-ligand 
interactions is that because the molecular features determining affmity and selectivity 
are so little understood, it becomes apparent that ligand design does not equate to 
drug design. Different binding effects observed by small changes in a lead ligand are 
often non-additive, and very similar members of a series may bind in an entirely 
different manner due to different hydrophobic, electrostatic, H-bonding and charge 
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distributions, resulting in a varying and unpredictable biological action. Structure 
based design gives no information on pharmacological profile or toxicity. This 
limitation has been further complicated by the switch from using animal models to in 
vitro models for pharmacological screening, which means that some complicated 
disease pathways or side effects cannot be properly investigated. It therefore 
becomes important that other properties of the drug candidate affecting transport, 
bioavailability, metabolic stability, toxicity and synthetic accessibility be expressly 
addressed from the very beginning by consideration of the properties of the 
fragments in the early stages. 
Traditional drug discovery by natural product screening and systematic modification 
is therefore likely to remain important as the leads identified may show closer 
resemblance to the natural ligand or substrate, possibly corresponding to greater 
selectivity. An additional advantage is the enormous structural diversity found in 
nature. However, the effort required to isolate active compounds and elucidate 
structures from these sources, does constitute a major limitation. 
Cycles of structure based design and lead optimisation will probably become 
increasingly important in the future as the amount of structural information on 
proteins rises and more of the factors controlling affinity and specificity are 
understood. The powerful combination of emerging new techniques and traditional 
methods employed within an increasingly interdisciplinary environment promises an 
exciting future for drug design. 
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1.2 PPlases (immunophilins) 
Peptidyl-prolyl cis-trans isomerases (PPlases) catalyse the interconversion of the cis 
and trans isomers of the peptidyl-prolyl (Xaa-Pro) bonds in peptide and protein 
substrates (Scheme 1.1). These enzymes are present in all cell types examined and in 
most subcellular compartments. PPlases can constitute up to 1-2 % of the total 




PPIase activity was first reported for an 18 kDa protein isolated from a porcine 
kidney cortex by Fischer et al.22 At this time another 18 kDa protein from 
mammalian thymocytes23  was found to be the major intracellular receptor for the 
immunosuppressant drug cyclosporin A (Figure 1.1), and this receptor protein was 
named cyclophilin A (CypA). Several further cyclophilins were characterised and by 
1989, it had been demonstrated that cyclophilins and PPlases were species variants 
of the same protein.24 At the same time another prolyl isomerase was discovered25'26 
during the search for the receptor of the immunosuppressive drug FK506 (Figure 
1.1). This receptor protein was named FK506-binding protein (FKBP). FK506 is a 
polyketide produced by Streptomyces tsukubaesis,27 a species discovered in a soil 
sample. FK506 is structurally related to rapamycin (Figure 1.1), an antifungal agent 
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It became obvious that PPlases could be divided into different classes according to 
their binding affinity. Three structurally unrelated families have thus far been 
classified: the cyclophilins, which selectively bind CsA; the FKBP's which bind 
FK506 and rapamycin with selective high affmity; and a third group known as the 
parvulins, whose first member was isolated from Escherichia coli.29 It was recently 
discovered that juglone (Figure 1.1), 5-hydroxy- I ,4-naphthoquinone, irreversibly 
inhibits the enzymatic activity of several parvulins.3° The three structurally unrelated 
families differ in subsite specificity, inhibitor sensitivity, molecular mass and amino 
acid sequence. Within each family however, there is a highly conserved core region, 
and additional C-and N-terminal extensions bear sequence motifs. CypA and FKBP 
are known as immunophilins because they bind the immunosuppressive drugs CsA, 
FK506 and rapamycin. CypA binds CsA with a reported dissociation constant 
Kd = 30 nM.3 ' FKBP binds FK506 and rapamycin with Kd's  of 0.4 nM and 0.2 nM 
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respectively.32  Both FKBP and CypA have been shown to bind a number of proline-
containing peptides, including the PPIase assay substrate Suc-Ala-Ala-Pro-Phe-pNa 
(succinyl-Ala-Ala-Pro-Phe-p-nitroaniline). 
1.2.1 Cyclosporin 
Cyclosporin A (Figure 1.1) is a lipophilic 11 amino acid cyclic peptide originally 
isolated from the fungus Tolypocladium inflatum. Its immunosuppressive properties 
were first described in 1978 ' and it is currently the drug of choice in transplantation 
surgery to prevent graft rejection, and in the treatment of autoimmune diseases. CsA 
(Sandimmun ®) also has anti-fungal, anti-parasitic and anti-inflammatory properties. 
The free and CypA-bound structures of CsA are very different. In solution, free CsA 
exhibits a cis MeLeu9-MeLeulO amide bond, whereas the CypA-bound form has a 
trans bond in this position. Free CsA in the crystal state or non-polar solvents has a 
tightly folded structure with hydrophobic surface, mediated by four intramolecular 
hydrogen bonds between non-methylated amide-NH groups. The CypA-bound CsA 
has an open ring structure with one intramolecular hydrogen bond between MeBmtl-
MeLeu4. 
1.2.2 The Cyclophilin A-Cyclosporin A Complex 
NMR spectroscopy and X-ray diffraction data indicate that CypA is an 
approximately spherical molecule composed of an 8-stranded anti-parallel n-barrel 
with ends closed off by two a-helices. The core is filled with hydrophobic side 
chains preventing ligand binding in the centre of the barrel. At the active site of 
CypA, two loops protrude from the globular protein core and form the sides of the 
binding groove on top of two 13-strands .34 The CsA binding site has been confirmed 
as the PPIase active site.35 
CypA-bound CsA has a flat disc-shaped structure which docks into the binding 
pocket of CypA. Only residues 9,10,11, 1,2 and 3 of the CsA ligand are in contract 
with CypA. The remaining residues protrude out from the CypA surface and are 
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implicated in specific interactions with calcineurin. The X-ray crystal structure 
reveals that the side chain of MeVall I is completely buried in the hydrophobic 
pocket of CypA, and this residue dominates the non-bonded contacts to CypA. 
There are five direct hydrogen bonds between CypA and CsA, and five well-defined 
water molecules mediating intermolecular interactions. 
Other Cyp's show features that are fairly conserved overall. CypB (22 kDa) and 
CypC (23 kDa) are localized in the endoplasmic reticulum, while CypD (18 kDa) is 
found in the mitochondria.36 
1.2.3 PPIase Activity 
Most amide bonds in peptides adopt the trans configuration. In the case of proline-
containing peptides, however, about 10 % of the peptidyl-prolyl bonds are in the 
unusual cis conformation, compared to an estimated occurrence of less than 1.5 % 
cis-amides in other amino acids.37 This anomaly can be explained by the much 
smaller free energy difference between the cis and trans conformations of the amide 
bond preceeding the proline residue, in comparison to non-proline amide bonds. 
Cis/trans isomerisation of amide bonds is necessary for protein folding, and 
isomerisation of peptidyl-prolyl bonds has been shown to be rate limiting38 in some 
cases. PPlases are therefore thought to catalyse this slow rate-determining 
isomerisation step. The PPIase activity of these enzymes is abolished upon binding 
the respective immunosuppressants, which are thought to mimic an intermediate state 
of the cis-trans peptidyl-prolyl bond interconversion of peptide and protein 
substrates. 
1.2.3.1 Enzymatic mechanism of CypA 
Several mechanisms have been proposed to explain the cis-trans interconversion. In 
general, conjugation of the C-N amide bond with the carbonyl group to form a planar 
amide bond, results in a C-N bond with considerable double bond character. 
Consequently, cis-trans isomerisation of the prolyl amide bond has to overcome the 
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barrier to rotation, and any factors which can weaken the C-N double bond character 
can be expected to accelerate isomerisation. 
In the covalent tetrahedral intermediate mechanism, 24  a cysteine or a nucleophilic 
reside was assumed to form a covalent bond with the carbonyl carbon as the 
intermediate, however since no candidate nucleophile has been located in the vicinity 
of the amide bond, this mechanism seems unlikely. A "catalysis by distortion" 
mechanism 39 has also been proposed in which the N-C=O plane is distorted in 
binding to CypA and the intermediate is stabilised by bonding to CypA. A further 
mechanism assumes that the side chains of serine, threonine, or tyrosine protonate or 
form a hydrogen bond to the amide nitrogen to deconjugate the O=C-N amide bond. 
This suggestion is backed up by molecular orbital calculations which indicate that 
protonation of the nitrogen lowers the barrier for cis-trans rotation .40 The "catalysis 
by desolvation" mechanism41 is based on the observation that the rate of cis-trans 
isomerisation is significantly accelerated in non-polar solvents, a theory supported by 
the hydrophobic character of the active site. Lastly, a "solvent-assisted" mechanism 
has been proposed on the basis of the CypA:Ala-Pro structure.42 This mechanism 
assumes two steps of catalysis: desolvation by binding to the hydrophobic pocket and 
stabilisation of the intermediate by a solvent molecule. 
Although there is a wealth of information available on the structures of CypA 
complexed with proline-containing di-, tn- and tetrapeptides, it is still unclear 
whether CypA catalyses cis-trans isomerisation with equal rates for both directions. 
Studies on the three dimensional structure of CypA complexed with the tripeptide 
Suc-Ala-Pro-Ala-pNa43 indicate that CypA preferentially recognises a cis-proline 
isomer, since the proline ring can more easily fit into the hydrophobic pocket than in 
the trans—isomer. Distortion of the trans isomer could lead to better binding, but at 
an energetic cost of the distortion energy. Zhao et al.44 have revealed that only the 
cis isomer of the substrate Suc-Ala-Ala-Pro-Phe-pNa binds to the active site of CypA 
in a stoichiometry of 1:1, while model docking implied that the trans conformer does 
not fit into the active site. On the basis of these results they propose that the 
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isomerisation occurs predominantly in the trans to cis direction, via a hydrogen 
bonding mechanism. 
1.2.4 Mechanism of Immunosuppression 
The immunosuppressive mechanism of CsA requires formation of a tightly bound 
CsA-CypA complex which inhibits Ca2 dependent events, resulting in failure to 
activate genes encoding interleukin-2 and other lymphokines, and ultimately 
preventing T-cell activation in response to antigen recognition (Figure 1.2). 
Figure 
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During T-cell activation calmodulin (CaM) binds to the serine/threonine phosphatase 
calcineurin (CN) as a result of elevated levels of free intracellular calcium. This 
complex dephosphorylates the nuclear factor of activated T cells (NF-AT), which in 
the dephosphorylated form is able to cross the nuclear membrane. In the nucleus 
NF-AT acts as a transcriptional activator for interleukin-2 (IL-2) transcription. The 
CypA-CsA complex binds to calcineurin and blocks the phosphatase activity of the 
CN/CaM complex. Neither CsA nor CypA alone affects the calcineurin activity and 
the complexed CypA-CsA with protruding CsA effector region is required.46 
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Despite exhibiting no structural similarity to the CypA-CsA complex, the FKBP-
FK506 complex can similarly interfere with this signal transduction pathway by 
binding to calcineurin and inhibiting phosphatase activity. The complexes are 
competitive inhibitors of CN, thought to bind at overlapping but not identical sites 
near the active site of the enzyme. While the crystal structure of the FK506-FKBP-
CN complex has been published '47  no such structure for a CsA-CypA-CN complex 
has been reported. The mechanism of immunosuppression is independent of PPJase 
activity, established by studies on active site mutants of CypA .48 Despite their 
structural similarities, rapamycin and FK506 have very different mechanisms of 
immunosuppression. In fact, the specific target of the FKBP:rapamycin complex is 
not known, although it is believed to inhibit T-cell protein synthesis by blocking a 
ribosomal kinase.49 The immunosuppressant activity of FK506 and rapamycin is 
approximately 100-fold greater than that of CsA.5°  
1.3 Other Functions of Cyclophilin 
The high abundance of cyclophilins and their wide distribution implies that 
cyclophilins have more general functions than modulating the activation of T cells. 
Facilitating the folding, assembly and trafficking of polypeptides may constitute 
some of their major functions, but evidence suggests that cyclophilins are involved in 
regulation of a variety of other cellular processes, some of which will now be 
described. 
1.3.1 HIV 
Cyclophilin A has been reported to bind human immunodeficiency virus type 1 
(MV-1) gag protein, and is required for the infectious activity of REV-i virions. In 
1994, Luban et al.5' demonstrated that CypA is integrated within the viral core of 
11EV-1 and is essential for the release of viral RNA and hence for multiplication of 
the virus. HIV gag is a polyprotein and CypA interacts specifically with the capsid 
domain of the dimerised gag, to promote assembly of the viral core. In subsequent 
steps the polyprotein is cleaved into several functional proteins: matrix (MA), capsid 
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(CA), nucleocapsid (NC) and small peptides.52 The crystal structure of CypA 
complexed with a 25 amino acid peptide of HIV-1 gag protein has been 
determined .53  The sequence A1a88-G1y89-Pro9O-11e91 of the gag fragment is the 
major portion to bind within the active site of CypA. Residues Pro90-Ile9l of the 
25-mer bind to CypA in a similar manner to two residues (Pro-Phe) of the CypA 
substrate Sue-Ala-Ala-Pro-Phe-p-Na. However, the peptidyl-prolyl bond between 
Gly89-Pro9O adopts a trans conformation, in contrast to the cis conformation usually 
observed in CypA-peptide complexes. The unfavourable backbone conformation 
adopted by the Gly89 residue suggests that this Gly-Pro sequence may be a 
requirement for CypA-gag binding, since a conformation of this sort is usual only for 
glycine. This finding has been confirmed by several groups,54 with different peptide 
substrates. As expected, the pyrrolidine ring of Pro90 binds within the hydrophobic 
pocket of CypA, and a trans-Gly-Pro conformation is adopted due to stereo chemical 
constraints, resulting in full occupancy of this pocket. 
The exact function of CypA in the HIV- 1 viral cycle remains controversial. It is not 
yet understood whether the cis-trans isomerase activity of CypA plays a role in 
HIV-1 virion activity, but results thus far indicate that it may be more likely to 
function as a chaperone or functional component. Genetic and biochemical studies 
show that CypA is required for HIV-1 replication and infectivity, but not for virion 
assembly. 55  Some results suggest that it disrupts the viral core and enables virus 
uncoating, but this theory has been recently questioned.56 It has been observed that 
virus which contains less CypA, either as a result of treatment with CsA 57  during 
virion budding, or because of a mutation in the capsid region of gag, is less 
infectious. 
Nevertheless, it is obvious that CypA plays an important role in HIV-1 viral 
infection. As a consequence, inhibition of the CypA-HIV-1 interaction is a 
promising target for the design of anti-AIDS drugs. A further intriguing fmding is 
that CsA, the selective high-affmity ligand of CypA, can inhibit the CypA-gag 
interaction.58 The immunosuppressant function of CsA is not however responsible 





SDZ NIM8 11 (Table 1.1) inhibits 111 V-replication to a similar extent as CsA 
(Figure 1 •3)59 
Figure 1.360 When IIIV-1 infected cells are treated with CsA or SDZ NTM81 1, the 
resulting virions are depleted of cyclophilins and are therefore only poorly infectious. 
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CsA derivatives are interesting as inhibitors because of the selective high affmity of 
CsA for CypA, although the synthesis of cyclic undecapeptides is generally difficult 
and time-consuming. Furthermore, the concentrations of CsA analogues required to 
inhibit HIV-1 replication may be toxic to cellular events in vivo, and given the 
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abundance of cyclophilins, they are probably involved in many cellular processes. 
However, part of this problem may be overcome by using sub-optimal amounts of 
CsA derivatives in conjunction with other anti-HIV-1 drugs. 
Another possible strategy is the design of small linear peptides or pseudopeptides 
that mimic a fragment of the HI V-gag protein that interacts with CypA. This course 
of action has been investigated by several groups. 6' Li et al.62 focused on the linear 
heptapeptide Ac-Val-His-Ala-Gly-Pro-Ile-Ala-NH2, which binds to CypA with low 
affinity (1050 = 850 ± 220 tM) but potentially useful selectivity for CypA relative to 
the PPIase FKBP-12. On the basis of X-ray structures of gag fragments-CypA 
complexes, they generated a series of modified peptides in order to select one 
displaying a higher affinity for CypA than the capsid domain of HIV-gag. They 
discovered that the histidine residue was important for interaction, and that 
substitution of the N- and C-terminal residues with deaminovaline (Day) and 
benzylamide respectively, led to a significant improvement in affinity. Combination 
of both modification gave the most potent inhibitor Dav-His-Ala-Gly-Pro-Ile-NHBn, 
which has a higher affinity for CypA (K, = 3 ± 0.5 p.M) than the entire capsid protein 
(K, = 16 ± 4 jiM) and greater selectivity for CypA over FKBP-12. Results also 
suggest that this gag analogue preferentially binds CypA in a trans-Gly-Pro 
conformation and is not a substrate of CypA. Design of compounds based on the gag 
protein, like this modified pentapeptide, or non-immunosuppressant derivatives CsA, 
may represent an attractive starting point for the discovery of peptidomimetic anti-
HIV-1 agents. 
1.3.2 Multidrug Resistance 
Multidrug resistance (MDR) is a major cause of cancer treatment failure. Tumour 
cells survive by exhibiting intrinsic resistance to multiple drugs on exposure to a 
single drug.63 Overexpression of P-glycoprotein (P-gp), a plasma membrane protein 
that functions as a drug efflux pump for chemotherapeutic agents, is believed to be 
one of the main mechanisms of MDR .64  Multidrug-resistant cancer cells have also 
been shown to display elevated levels of the glycolipid glycosylceramide.65  
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A major challenge in cancer therapy today is to find drugs that inhibit MDR, 
rendering cancer cells sensitive to chemotherapy. Some MDR reversing agents, such 
as tamoxifen,66  are thought to work by direct binding to P-gp, thus interfering with 
the binding and export of anticancer agents and restoring cytotoxicity. However, 
these agents may also affect glycolipid metabolism within the cell,67 by inhibition of 
ceramide glycosylation, resulting in a lowering of glycosylceramide levels. 
Ceramide is suggested to be involved in programmed cell death (apoptosis), a 
mechanism important for cytotoxic response to anticancer agents. 
CypA and its derivative SDZ PSC 833, [3'-keto-Bmt-1]-IjVal-21-cyclosporin (Table 
1.1), have been shown to be MDR reversing agents,68 with PSC 833 proving to be 
the more potent of the two. The action of PSC 833 is believed to involve inhibition 
of drug efflux by P-gp, and direct interaction between PSC 833 and P-gp has been 
demonstrated.69  PSC 833 also has a profound impact on ceramide formation, 
whereas CypA has little influence. The increase in cell ceramide caused by PSC 833 
results in a parallel decrease in cell survival. Although the exact mechanism of 
action of PSC 833 on MDR resistant cells is not yet known, results imply that its 
influence on ceramide synthesis may be independent of P-gp. It is hoped that further 
studies in this area may provide new insights into the mechanisms by which MDR 
modulators reverse drug resistance. 
1.3.3 Antiparasitic Activity 
It is now clear that multiple forms of cyclophulin exist in parasites.70'7' Since 
cyclophilins are known to catalyse the rate-limiting cis-trans isomerisation of 
proline-containing peptides and accelerate their refolding mechanisms, it has been 
suggested that they may play an important role in parasitic development. In past 
years CsA has been shown to exhibit potent antiparasitic activity independent of its 
immunosuppressant action. Since this discovery, CsA has been shown to adversely 
affect a large number of protazoa and helminths both in vivo and in vitro, although 
not all parasites tested are susceptible.72 The precise mechanism of action of CsA 
and reasons for its apparent species/or stage specificity are not yet understood, but 
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the mode of action may involve inhibition of endogenous cyclophilins, or of an 
essential signal-transduction pathway. It has been demonstrated that CsA can bind to 
parasite cyclophilin.73 Although the biological function of parasite cyclophilins and 
their role in the host-parasite relationship is unclear, it is possible that these proteins 
may modulate the host's immune response during infection. There is still much to be 
learned in this area but recent findings concerning the potent anti-malarial74 action of 
non- immunosuppressant CsA analogues, indicate that this may be an important field 
in the design of novel antiparasitic drugs. 
1.4 Review of Cyclophilin A Substrates 
The reported substrates/inhibitors for cyclophilin A can be divided into four main 
categories: 
modified CsA derivatives 
substrates isolated from natural sources 
peptide ligands 
non-peptide ligands 
1.4.1 Modified CsA Derivatives 
Table 1.1 summarises some of the information available on the CypA-binding of 
CsA derivatives and, where possible, their immuno suppressive activity. The Kd, K1 
and IC50 results have been difficult to correlate as each paper uses a slightly different 
assay technique (see references for a description of assays used) resulting in 
discrepancies even in the calculated Kd of CypA-bound CsA. The values have 
therefore been tabulated as ratios, relative to the value obtained for CsA (eg. 1050 for 
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Comparison of solution Residue 5, 2.21 
data with X-ray data of a 
I CypA-bound derivative 
NR= 	 F indicates that solution 
structure does not 
correspond to the bioactive 
conformation. 
Conformational Residue 5, 2.37 
stabilisation of soln. 
structure is possible by 
- removal of NH ValS H- 
________  bond. 
NH-5 plays crucial role in Residue 5, 1.84 
CsA's calcineurin binding. 
NR= 
PPIase IL-2 Individual modifications 81 
I (Rel. K1) (Rel. resulted in decreased 







R7= OH 1 1.75 Modifications combined - 1' led to tighter CypA R8= binding than CsA, with 
full immuno. effect 
retained. 
R3= I  R7= I R8= 0.5 1.69 Substituent effects on I 	OH 
1' PPIase inhibition and immuno. activity are non- 
additive. 
NBDL- R8= MDR 
82 
CsA Used to measure Pgp 
NH  secretion of CsA. 
iIIIIN/ 
NO2 
R8= Retains Radiolabelled and - 83 
partial photoreactive 
biologi- immunosuppressive CsA 
cal analogue. 
activity 
of CsA  
R8= Fluo. Identification of actin and 
H Assay HSP 70 as CsA binding 
(Rel. Kd) proteins using 
0.17 photoaflinity labelling. c  Fluorescent CsA used in displacement assay to 
measure binding constants 
to bovine actin and yeast 
__________  homologue of HSC 70. 
0.07 
R8= 





(Re!. determined by competition 
experiment with 
0.8 3.33 fluorescent CsA. 
R8= 0.8 10 Significant lowering of 
calcineurin affinity for 
CypA-complex. 
H 	H 
R1= 108 2 Poor CypA binding but 
OH minimal change in 





'P Pro Residues 1 &2 cyclised to PPIase No Formation: acetylation of 
85 
oxazolidine or thiazolidine. (Rel. results 2-threonine hydroxyl 
CSC 0 IC50) reported group and the preceeding 
Deny- —MeBmt 
ar-1 
Values amide nitrogen by 
atives 2 indicate dimethyl acetals. 
R 	o moderate HPLC/NMR suggest 
to weak enhanced backbone 
R binding rigidity of 'V Pro CsC 









R2 R2= ELISA IL-2/ Formation: coupling of N- 
deny- (Rel. MLR protected aa2, with 
atives 1. CHCHCH3 (CsG) IC50) decapeptide, followed by 
2.CH2CH(OH)CH3  1.4 1.2.6/ deprotection and ring 
CH(OH)CH2CH3  2.207 1.6 closure. 
CHCHCl2 3. 5.2 2.57/45 Disubstitution at y-C of 
 4.250 3.3/2.3 Abu-2 in CsA is 
cH2— < 5. 250 4.200 detrimental for binding 
/135 CypA. Reduced binding 
5. 225 in this case correlates with 
/120 reduced immuno. activity. 
Ri R2= ELISA IL-2 Abu2 pocket appears large 
deny- (Rel. (Re!. enough to accommodate 
atives j__0 IC50) IC50) bulky groups, however 80 200 
only unbranched chains R2= 3 5 
OH bearing polar substituents 
are acceptable. 
Thought to be due to steric R2= 5 86 
\ 	OH and physicochemical 
influence of water mots. 
0 
R6= 
PPIase IL-2 Designed as non-immuno. 81 
(Re!. K1) (Re!. analogues with anti-HI V-I 
2.3 IC50) activity. 
>1250 
Promising lead compounds R1= 	OH 95.7 57.5 
for anti-HIV-ltreatment. 






OH R4 R6= 5 >1250 - 
RI= 
OH R11= No >1250 
R1= D-MeVaI binding 
R4 R4= NEtLeu Spectro. IL-2 Designed as non-immuno. 
deny- Assay (Re!. analogues with anti-HIV- I 
atives (Re!. IC50) activity. 
IC50) 
1.2 1.6 
Comparable binding R4= NEtVaI 0.67 >2500 
affinities to CsA for CypA. 
R4= NEtile 0.83 300 
R4= NEtThr not det. Not det. 
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R6= dihydro 2.88 
R7= dihydro 
R8= methylated 




Nva- R2 4.29 
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 R4 R4= ELISA IL-2 Lipophilic & hydrophilic 
91 
deny- (Re!. (Re!. substituents detrimental for 
atives IC50) IC50) immunosuppression. 
0.5 2500 
Indicates CN tight-binding R4= 1.2 163 
pocket for this region. 
R4= 2.8 5.3 
R4= 1.8 4.0 
R4=;~ 1.9 9.0 





Lactam R3,R4 (Re!. Stabilised 11'0-turn 
J1)J 0
IC50) analogue. Weak biological 
activity probably due to 
20 steric hindrance. 
CH3 o 	H 
R7,R8= PPIase T cell Tricyclic immuno. variant 93 
assay assay of CsA, designed with 
0 
H 
(Re!. K) (Rel. conformational constraint. 
IC50) Enhanced binding and 
immuno. activity. 
S 0.3 0.5 
H 
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1.4.1.1 Discussion 
It should be noted that over two hundred CsA derivatives, both natural94 and 
synthetic, 95,96  have been reported. Table 1.1 is therefore by no means an exhaustive 
review of CsA analogues. Nonetheless, several trends can be discerned from the data 
available for the derivatives in Table 1.1. Analysis of the binding constants and 
corresponding immunosuppressant activity of selected modified CsA derivatives 
support the belief that residues 9, 10, 11, 1, 2, and 3 are required for CypA binding, 
while residues 4, 5, and 6 form the effector loop to CN. Consequently, modification 
of residues 4-8 has, in general, little effect on CypA binding, but may radically alter 
the observed immunosuppressant activity. It is also widely observed that residue 
modifications leading to a drastic change in conformation of the derivative compared 
to CsA are not tolerated without significant loss of binding and/or biological activity. 
1.4.2 Substrates isolated from Natural Sources 
1.4.2.1 Sang1flserins97' 98 
The sang lifherins (Table 1.2) were discovered by screening of actinomycete strains 
with a cyclophilin-binding assay, and are produced by Streptomyces sp. A92-
308110. The chemical structures and absolute stereochemistries of sanglitherins 
A,B,C and D have been determined by NMIR and X-ray crystallography of the 
complex with CypA. Sanglifherins A and B are genuine metabolites whereas C and 
D are artefacts formed during the isolation process. 
Interestingly, the sanglitherins did not inhibit the phosphatase activity of calcineurin, 
showing no activity in the reporter gene assay for IL-2 gene expression. There 
results indicate that this compound class has a different mode of immunosuppressive 
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Cymbimicins A and B were isolated from a strain of Micromonospora sp. by 
screening actinomycete strains for Cyp binding metabolites. The binding affinity of 
cymbimicin A to CypA is about six times lower than that of CsA, whereas the 















Neither cymbimicin A or B complexed to CypA affected calcineurin activity, 
measured by the calmodulin dependent dephosphorylation of a 19 amino acid 
phosphopeptide substrate in a cell-free enzymatic assay. However, cymbimicin A 
did inhibit calcineurin activity when complexed with CypB (1050 4 .iM). Neither 
cymbimicin A or B were active in cellular immunoassays measuring T-lymphocyte 
activation (although this may be due to an inability to enter the cell), or in the IL-2 






The natural occurring cyclic peptide cyclolinopeptide A, cyclo(-Pro-Pro-Phe-Phe-
Leu-Ile-Ile-Leu-Val-) (CLA), isolated form linseed oil, and its synthetic analogue 
cyclo(-Pro-Pro-Phe-Phe-Aib-Aib-Ile-D-Ala-Val-) (CLAIB), were found to bind 
CypA, inhibiting its peptidyl-prolyl cis-trans isomerase activity. Direct binding of 
CLA was confirmed using tryptophan fluorescence studies and PPIase assays, as no 
crystal structure is available. Phosphatase assays reveal that CLA is able to bind 
CypA and inhibit calcineurin phosphatase activity, although higher concentrations 
are required that with CsA:CypA.'°° CLA is thus the third natural product that can 
target calcineurin via a PPIase. Interestingly, it would appear that the CLA/CypA 
interface shares no obvious similarity with the CsAICypA and FK506/FKBP12 
interfaces, which interact with calcineurin at slightly different sites. Gallo et al.'°' 
have synthesised a number of synthetic CLA analogues, but fluorescence 
experiments indicate dissociation constants about 20-fold lower than for CsA binding 
CypA. A further cyclic peptide, isolated from linseed mill cake, is cyclo(-Pro-Pro-
Phe-Phe-Ile-Leu-Leu-X-) (CLX), which contains the non-proteinaceous amino acid, 
N-methyl-4-aminopro line (X). This amino acid substitutes for two amino acid 
residues of CLA, mimicking a dipeptide moiety with a non-planar cis amide bond. 




1.4.3 Peptide Ligands 
Crystal structures have been determined for complexes of CypA-dipeptides: His-Pro, 
Ser-Pro, Ala-Pro, Gly-Pro.'°3 The following larger peptides have also been 
characterised in complex with CypA: 
Ac-Ala-Ala-Pro-Ala-amc'04 
Succ-Ala-Pro-Ala-p-Na105 
Succ-Ala-Xaa-Pro-Phe-p-Na44 (where Xaa = Ala, Leu etc.) - used in 
chymotrypsin coupled PPIase assay 
WO 
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All peptides discussed form the CypA complex with a cis peptidyl-prolyl Xaa-Pro 
amide bond, and it has been observed that the main interactions are widely 
conserved: 
Proline binds in hydrophobic binding pocket 
CypA residues His126, Phell3, Phe60, (Met6l, Leu122) are involved in 
hydrophobic interactions 
H-bonds to AsnlO2 from prolyl amide C=O and NET of the next N-terminal 
amino acid. 
Two H-bonds to Arg55 from proline C0 
Larger peptides also show H-bonding to Trpl2l and GIn 63, from amide 
C=O's 
Comparison of the CypA binding of CsA with that of proline-containing peptide 
ligands reveals that many of the interactions are conserved: 
MeVall 1 binds in hydrophobic pocket 
H-bond to Asn102 from Abu2 NH 
Two H-bonds to Arg55 from CO of MeLeulO 
H-bonding to Trpl2l and G1n63 from amide C=O's (E.coli Cyp does not 
have a Trp residue and is 1000 IbId less sensitive toCsA). 
It is interesting to note that CsA and the proline-peptides studied were found to bind 
with the respective peptide chains running in opposite directions. In general, proline-
peptides bind CypA with a cis peptidyl-prolyl amide bond, whereas CsA and its 
derivatives bind CypA with a widely conserved trans 9-10 amide bond. It has also 
been reported that the peptides studied have lower affinity for CypA than CsA 
.34 
1.44 Non-Peptide Ligands 
Relatively few examples of rationally designed CypA ligands are available. Several 
are based on structures that mimic the Xaa-Pro cis amide bond. It has been 
suggested that CypA binds the Xaa-Pro substrate and distorts the amide bond by 
pyramidilising the prolyl nitrogen through hydrogen bonding,106 with the active site 
Arg55 acting as the hydrogen donor. As discussed previously, structural studies 
31 
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indicate that Cyp is highly selective for cis substrates, binding several Xaa-Pro 
peptide substrates in the cis conformation. 
Hart and Etzkorn'°7 have reported cyclophilin inhibition by a (Z)-alkene cis-proline 
isostere of the Ala-Pro dipeptide. This structure was found to overlay the dipeptide 
with a RMS deviation of 0.17 A, indicating that it is an ideal conformationally 
locked mimic of the bound substrate. The inhibitor 2 was designed based on the 
succ-AAPF-pNa peptide substrate by replacing the central Ala-Pro core with (Z)-
alkene cis-Pro mimic 1. The PPIase assay indicated that the substrate mimic inhibits 
the enzymatic activity of CypA with an 1050 of 6.5 ± 0.5 PM. The peptide mimic 
was incorporated as shown in Scheme 1.2. Alanine and phenylalanine were coupled 
in solution using HBTU in the first two steps, and the succinyl N-terminus was 
installed with succinic anhydride. 
Scheme 1.2 
Phe-pNa, HBTU, HOBt 
DIPEA, DCM/DMF 
Boc NH CO2H 	 73% 	 Boc NI-I CO-Phe-pNa 
I 
TFA, DCM 
HBTU, HOBt, DIPEA, 
Boc-Ala-OH, DCM/DMF 







Conformationally constrained analogues (l-(R), 1-(S) and 2-(R), 2-(S)) of the Suc-
Ala-Gly-Pro-Phe-pNa tetrapeptide have been synthesised by incorporation of 
fluoroolefm peptide isosteres to control the peptide conformation. 108 Fluoroolefms, 





the conformation of the Gly-Pro amide bond in the cis and trans conformations. The 
fluoroolefm was synthesised according to the procedure shown in Scheme 1.3. 
Scheme 1.3 
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Bissilylation of the a-fluoroacetate 3 by excess lithium diisopropylamide and 
chiorotrimethylsilane, followed by hydrolysis of the 0-silyl group with aqueous 
tartaric acid solution provided the a-fluoro-u-silylacetic acid ester 4. Peterson 
olefmation of the 2-hydroxymethylcyclopentanone derivative S with the acid ester 4 
yielded a 6:1 mixture of the E-and Z-isomers, 6 and 7. These isomeric esters were 
reduced with diisobutylaluminium hydride to the corresponding alcohols 8 and 9, 
before separation by chromatography on silica gel. Mitsunobu transformation 
yielded the protected amine 10, followed by removal of the TBDMS group with 
boron trffluoride etherate and oxidation with Jones reagent to form the N-protected 
dipeptide isostere 11. The acid 11 was coupled to L-phenylalanine-tert-butyl ester 
using DCC in the presence of HOBt and NMM to form 12. The phthaloyl group was 
removed and the free amine coupled with Boc-L-alanine to form a diastereomeric 
mixture of isosteres, which were separated by column chromatography and 
deprotected to give the 1 -(R) and 1 -(S) tetrapeptide isosteres 13. A similar method 
provided the 2-(R) and 2-(S) isosteres 14. 
The Z-isomers mimic the trans conformation of the natural peptide, while the E-
isomers correspond to the cis conformation. In a preliminary PPIase assay, the two 
E-isomers and one of the two Z-isomers were found to inhibit cyclophilin. 
Wang et al.109 have described the synthesis of ground- 15 and transition-state 16 
analogue inhibitors of CypA, based on the structures of proline containing peptides. 
Design of the inhibitors was based on the "twisted amide" transition-state mechanism 
for CypA-catalysed peptide isomerisation, proposed by Stein39 and others. In this 
catalysis by distortion, the substrate is thought to adopt a transition-state 
conformation in which the carbonyl group and the nitrogen lone pair of the Ala-Pro 
amide bond are orthogonal to each other as shown in Scheme 1.4. After binding to 
the enzyme in the trans conformation, the substrate is distorted by the active site and 
the amide bond is twisted out of planarity, with simultaneous formation of a 
hydrogen bond between the active site and the pyramidal Pro nitrogen. Again, the 
Arg55 residue of CypA is the proposed hydrogen bond donor. 
34 
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Scheme 1.4 
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ground state 	15 (ground state 	 transition state 	16 (transition state 
analogue) analogue) 
The ground-state inhibitors were based on a bicyclic lactam structure since it was 
previously found to display structural similarity to cis-Gly-Pro in the cyclophilin-
bound conformation, and bind to the active site of CypA with K( = 200 M."° The 
transition-state analogues incorporated an amine functionality in place of the lactam, 
in order to provide a tertiary amine nitrogen capable of interacting with the Arg55 
residue. Synthesis commenced with the bicyclic lactam 17 synthesised previously by 
this group from L-proline." The benzaldehyde imine 18 was prepared and 
stereoselective alkylation of the lithium enolate with benzyl bromide or 2-
bromomethylnaphthyl furnished the a-aryl lactams 19 (a,b) (Scheme 1.5). 
Hydrolysis of the imine, followed by reaction of the resulting free amine with a set of 
acylating agents yielded the ground-state inhibitors 20 (a-!). 
Scheme 1.5 (a) TFA; (b) PhCHO, Et3N; (c) LDA, R'X, -78 °C; (d) MeOH, HCI; (e) R2COX. 
R1  = 2-CH2C10H7 
R2 = t-BuO 
R1  = CH2C6H5 
R2 = BnO 
RI = 2-CH2C10H7 
R2 = BnO 
R1  = 2-CH2C10H7 
R2 = 
R1  = CH2C6H5 
R2 =t-BuO 
2Of R1 = H 









R1  = 2-CH2C10H7 
R1  = CH2C6H5 










The transition-state inhibitors 22 (a,b) and 26 were prepared by selective reduction 
of the thioamide derivative of the amide (Scheme 1.6). Thioamides 23 (a,b) and 25 
were formed from the corresponding lactams 21 (a,b) and 24 by treatment with 
Lawesson' s reagent. 
Scheme 1.6 (a) Lawesson's reagent, PhCH3, 80°C; (b) Raney nickel, H2. 




CO2Me 	 CO2Me 
21a:X=0,R1 =H 	 22a:R1 =H 
21b: X = 0, R1  = 2-CH2C10H7 	22b: R1  = 2-CH2C10H7 
a 
X = S, R1  = H, 
X = S, R1  = 2-CH2C10H7 
BocHN,,, ND 
CO2Me 
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With the rational design of the first transition-state analogue PPIase inhibitors, the 
authors hoped to observe greater affinity for CypA. Binding of the inhibitors was 







20d 1.5 ±0.05 
20e 140±32 
20f >200 
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Several ground-state analogues bound to the enzyme with low micromolar affinity 
(Kd = 1.5 tM for 20d), but unexpectedly the transition-state analogues did not 
display any significant affinity for the active site (Kj = 77 .iM for 22b). Analysis of 
the binding of bicyclic amides 21, and amines 22 and 26 to CypA did reveal several 
distinct structure-activity trends. Little information on the effect of stereochemistry 
at the position alpha to the lactam carbonyl could be discerned due to the low affinity 
for analogues 21a and 24, and 22a and 26 for the enzyme. However, with the same 
a-alkyl group, the affinity of the bicyclic amide was found to increase as the size of 
the amino substituent, R2, decreased. With the same alkylamide group, increasing 
the size of the alkyl substituent, R', resulted in a corresponding increase in binding 
affinity. These findings were consistent with the proposed binding model based on 
the structure of dipeptide:CypA complexes. In this model there is a relatively narrow 
groove for incorporation of the amino substituent, R2, in the region of the active site 
where the N-terminus of a peptide substrate would be located. The alkyl group, R', 
would project into the hydrophobic pocket of the active site, where larger and more 
hydrophobic groups form favourable interactions. Hence, the highest affinity ligand, 
20d, combined the smallest amide substituent (N-acetyl) with the most hydrophobic 
cc-alkyl group (2-methylnaphthyl). Postulated explanations for the lower affinity of 
transistion-state analogues include the possibility that a conformational change in the 
enzyme on binding of bicyclic ligands may disfavour formation of the stabilising 
hydrogen bond to Arg55, or the lone pair of the analogue 22b may not be 
appropriately geometrically aligned to form interactions with the active site residues. 
A second possibility is that the carbonyl oxygen of the lactam is important for 
binding, perhaps forming a hydrogen bond. Alternatively, it may be that CypA has a 
different catalytic mechanism to the proposed twisted amide model. 
This work represents another example of small molecular weight compounds with 
the ability to form tight complexes with CypA. The affinity of analogue 20d is 





Choi et al.' 12  have reported the synthesis of non-peptidic cyclophilin binding 
compounds for use in neuronal cell regeneration and neurodegenerative conditions. 
Structures of the form 27-29 of Scheme 1.7 were found to bind to cyclophilin (and in 
some cases FKBP) inhibiting their Plase activity with an IC50 of 1 pM or less. 
Scheme 1.7 
















X = N, NH, O,Setc. 
Y = N, NH, O,S,etc. 
R1  = C1-C6 (branched)alk(en)yl groups 
with optional cyclic substituents. 
R2 = as R1  
R3 = halo, OH, NO2, CF3, NI-12  
C1-C6 (branched) alkyl, 
Cl -C4 alk(enyl)oxy, phenoxy  
R4 = NS02R, S02NR2, OR, CONR, COR 
where R is H, substituted cyclic, 
or as R1  
R5 = as R4 
The cyclic urea 30 has been designed to be a potential competitive inhibitor of 
CypA-Gag binding, thus interfering with I{IV virus replication."3  






1.5 Lead Discovery 
In the discovery of the lead ligand for the current work, two methods were used for 
ligand design: de nova construction of novel ligands from atoms using the docking 
programme LIDAEUS; and modification of lead structures obtained from database 
searching using the principles of structural similarity. An overview of the entire 
process is included in Figure 1.4. 
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The LIDAEUS programme, developed by Dr Paul Taylor at Edinburgh University, 
calculates the interaction energy between a "probe atom" and the protein on a 3D 
grid of site points around the protein active site. In the calculation carbon and oxygen 
atoms are used as probe atoms, with favoured hydrophilic interactions mapped out by 
the carbon atoms, to generate areas of low energy in the protein active site. A 
negative template of the active site of the target protein can then be generated, by 
39 
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turning the areas of low energy into site points. The template obtained contains 
information on the geometrical and chemical properties of putative ligands. The data 
can then be then used to search the Maybridge Fine Chemicals database to select the 
best-fitting ligand for the site points. The list of commercially available compounds 
obtained is subjected to a second selection process on the basis of molecular weight 
and hydrophobicity. The most hydrophobic ligands with molecular weight less than 
300 are chosen, since smaller, hydrophobic ligands can more easily penetrate the 
crystal to reach the binding site. 
Using the LIDAEUS programme, the first non-peptide ligands of CypA were 
discovered and their X-ray structures determined. 
114  The novel ligands, which all 
bind in the same site, belong to three families: the piperidine family (3-acetyl-1-
methyl piperidine 31 and ethyl piperidine glyoxylate 32); the DMSO family 
(dimethyl sulfoxide 33, tetramethylene sulfoxide 34 and cyclopentanone 35); and the 
dimedone family (5,5-dimethyl-1 ,3-cyclohexanedione 36), as indicated in Table 1.5. 
This thesis will focus on the dimedone family. 
Table 1.5 
Piperidine family DMSO family Dimedone family 
o 0 
11 
01; 	0  36 












1.5.1 The Discovery of Dimedone 
The LIDAEUS programme indicated that 2,2,5-trimethyl-1,3-dioxane-4,6-dione 37 
(Scheme 1.8) could potentially bind to the protein active site. However, crystal 
soaking experiments proved unsuccessful and no evidence of the ligand could be 
observed in binding site by X-ray crystallography. The lead 37 was then partially 
modified (Scheme 1.8), based on knowledge of the binding of other families of 
ligands and on modelling studies, which indicated that the side of the molecule 
facing the binding site should be hydrophobic. The two ether oxygens of the lead 37 
were therefore replaced by carbon atoms, in order to increase the hydrophobicity in 
that domain. The new molecule 38 was then used to search for structurally similar 
molecules in the ISIS database and dimedone 36 was found to be the most 
structurally similar and commercially available compound. 
Scheme 1.8 
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The computationally designed lead structure, dimedone, was then tested 
experimentally for binding to the CypA protein. A K( of 22 mM was determined for 
the inhibition of CypA by dimedone using the PPIase assay. For comparison, the K41  
of CsA has been measured as 36.8 nM115 using the same assay. The crystal structure 
of dimedone bound to the active site of CypA was obtained after soaking CypA 
crystals in a solution of the dimedone ligand, according to the method described in 
Chapter 2. Figure 1.5 shows the crystal structure of the dimedone(green):CypA 
complex, with the CsA(white):CypA complex superimposed. The dimedone geminal 
dimethyl groups bind within the hydrophobic pocket of the CypA active site, 
mimicking the hydrophobic interaction of the MeVall I residue of CsA with CypA. 





One of the carbonyl groups of dimedone is within range of Arg55 to mimic this 







'Armistead, D. M.; Harding, M. W., Ann. Rep. Med Chem., 1993, 28, 207. 
2  Klebe, G., J. Mo!. Med., 2000, 78, 269-28 1. 
Wieland, T., J. Math. Chem., 1997, 21, 141-157. 
4 Laskowski, R. A.; Hutchinson, E. G.; Michie, A. D.; Wallace, A. C.; Jones, M. L.; Thornton, J. M., 
Trends Biochem. Sc., 1997, 22, 488-490. 
Venuti, M. C., Ann. Rep. Med Chem., 1990, 25, 289. 
6  Clore, G. M.; Gronenborn, A. M., Science, 1991, 252, 1390. 
Whittle, P.; Blundell, T., Ann. Rev. Biophys. Biomol. Struct., 1994, 23, 349-375. 
8  Swanson, M. E.; Grass, D. S., Ann. Rep. Med Chem., 1994, 29, 265. 
Trainor, G. L., Anal. Chem., 1990, 62, 418-426. 
10  Babine, R. E.; Bender, S. L., Chem. Rev., 1997, 97, 1359-1472. 
1  Walkinshaw, M.D.; Weber, H. P.; Widmer, A., Triangle, 1986,25,131-142. 
12  Gubernator, K.; Boehm, M., Methods Princ. Med Chem., 1998, 6,1-13. 
13  Kubinyi, H., Curr. Opin, Drug Disc. Dev., 1998, 1, 1, 16-27. 
14  Kubinyi, H., Chimica Oggi, 1998, 16,17-22. 
15  Ripka, A. S.; Rich, D. H., Curr. Opin. Chem. Biol., 1998, 2, 441-452. 
16  Beeley, N. R., Drug Disc. Today, 2000, 5, 3 54-363. 
17  Flirschmann, R, Angew. Chem. mt. Ed Engl., 1991, 30, 1278. 
18  Kessler, H., Angew. Chem. mt. Ed Engl., 1982, 21, 512. 
19 
 
Grøn, H.; Hyde-DeRuyscher, R, Curr. Opin. Drug Disc. Dev., 2000,3, 5, 636-645. 
20  Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W., Science, 1996,274,1531-1534. 
21  Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W., I Am. Chem. Soc., 1997,119,12257-12261. 
22  Fischer, U.; Bang, H.; Mech, H., Biomed Biochim. Acta, 1984, 43, 1101-1111. 
23  Handschurnather, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D. W., Science, 1984, 
226, 544-546. 
24  Fischer, G.; Wittrnann-Liebold, B.; Land, K.; Kiefhaber, T.; Schmid, F. X., Nature, 1989,337, 476-
478. 
25  Harding, M. W.; Galat, A.; Ueling, S. L.; Schreiber, S.; Nature, 1989, 341, 761-763. 
26  Sikierka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, S. C.; Singal, N. H., Nature, 1989, 341, 755-757. 
27  Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M., I Antibiotics, 
1987, 40, 1249-1255. 
28  Sthgal, S. N.; Baker, H.; Vezina, C., I. Antibiotics, 1975, 28, 727-732. 
29 phfe1d J. U.; Schierhorn, A.; Mann, K.; Fischer, G., FEBS Len., 1994, 343, 64-69. 






Liu, J.; Albers, M. W.; Chen, C. M.; Schreiber, S. L.; Walsh, C. T., Proc. Nat!. Acad. Sd. US.A., 
1990,87,2304-2308. 
32  Bierer, B. E.; Mattila, P. S.; Standaert, R. F.; Herzenberg, L. A.; Burakoff, S. J.; Crabtree, 0.; 
Schreiber, S. L., Proc. Nail. Acad. Sci. US.A., 1990, 87, 9231-9235. 
33  Bore!, J. F., Pharmacol. Rev., 1989, 41, 259-371. 
34  Taylor, P.; Husi, H.; Kontopodis, G.; Walkinshaw, M. D., Prog. Biophys. Molec. Biol., 1997, 67, 
151-181. 
35 Kallen, J.; Mikol, V.; Taylor, P.; Walkinshaw, M. D.,i Mol. Biol., 1998, 283,435-449. 
36  Göthel, S. F.; Marahiel, M. A., Cell Mol. Life Sci., 1999, 55,423-436. 
37  Stewart, D. E.; Sarkar, A.; Wampler, J. E., J. Mol. Biol., 1990,214,253-260. 
38  Kiethaber, T.; Quaas, R.; Hahn, U.; Schmid, F. X., Biochemistry, 1990, 29, 3061-3070. 
39 Harrison, R K.; Stein, R. L., Biochemistry, 1990, 29,1684-1689. 
° Kofron, J. L.; Kuzmic, P.; Kichore, V.; Colon-Bonilla, E.; Rich, D. H., Biochemistry, 1991, 30, 
6127-6134. 
41  Radzacki, A.; Acheson, S. A.; Wolfenden, R.; Bioorg. Chem., 1992, 20, 382-386. 
42  Ke, H. M.; Mayrose, D.; Cao, W., Proc. Nail. Acad Sci US.A., 1993,90,3324-3328. 
43  Konno, M.; Ito, M.; Hayano, 1.; Takahashi, N., .1 Mol. Biol., 1996, 256, 897-908. 
44  Zhao, Y.; Ke, Ii, Biochemistry, 1996, 35,7356-7361. 
' GOthel, S. F.; Marahiel, M. A., Cell Mol. Life Sci., 1999, 55, 423-436. 
46  Kallen, J.; Mikol, V.; Taylor, P.; Walkinshaw, M. D., J. Mol. Biol., 1998, 283, 435-449. 
' Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thompson, J. A.; Fitzgibbon, M. J.; Fleming, 
M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A., Cell, 1995, 82, 507. 
48  Zydowsky, L. D.; Etzkorn, F. A.; Chang, H. Y.; Ferguson, S. B.; Stolz, L. A.; Ho, S. I.; Walsh, C. 
T., Protein Sci., 1992, 1, 1092-1099. 
49  Morris, R.E., Ther. Drug Monit., 1995,17, 564-569. 
° Starzl, T.; fling, J.; Venkataramman, R; Todo, S.; demetris, A. J.; Jam, A., The Lancet, 1989, 1000. 
51  Franke, E. K.; Yuan, H. E.; Luban, J., Nature, 1994, 372, 359-362. 
52  Gelderblom, H. R., AIDS, 1991, 5, 617-638. 
53  Zhao, Y.; Chen, Y.; Schutkowski, M.; Fischer, G.; Ke, H., Structure, 1997, 5,139-146. 
54  Vajdos, F. F.; Yoo, S.; Houseweart, M.; Sundquist, W. 1.; Hill, C. P., Protein Sci., 1997, 6,2297-
2307. 
51  Braaten, D,; Frank; E. K.; Luban, J.,J Virol., 1996, 70, 3551-3560. 
56  Wiegers, K.; Rutter, G.; Schubert, U.; Grattinger, M.; Krausslich, H.-G., Virology, 1999, 257,261-
274. 
57  Luban, J.; Bossolt, K. L.; Franke, E. K.; Kalpana, G. V.; Goff, S. P., Cell, 1993, 73, 1067-1078. 
58  Frank; E. K.; Luban, J., Virology, 1996, 229,279-282. 





60  Thali, M., Mol. Med Today, 1995,287-291. 
61  Schutkowski, M.; Drewello, M.; Wöllner, S.; Jakob, M.; Reimer, U.; Scherer, G.; Schierhorn, A.; 
Fischer, G., FEBS Lett., 1996,394,289-294. 
62  Li, Q.; Moutie M.; Charbonnier, J.-B.; Vaudry, K.; Ménez, A.; Quémdneur, E.; Dugave, C., J. 
Med Chem., 2000, 43, 1770-1779. 
63  Bradley, G.; Juranka, P. F.; Ling, V., Biochim. Biophys. Acta, 1988, 948, 87-128. 
64 Gottesman, M. M.; Pasta, 1., Biochim. Biophys. Acta, 1993, 948, 385-427. 
65  Lavie, Y.; Cao, H.; Burnsen, S. L.; Giuliano, A. E.; Cabot, M. C., J. Biol. Chem., 1996, 271, 19530-
19536. 
66 Nayfielcl, S. G., J. Cell Biochem., 1995, 22, 42-50. 
67  Lavie, Y.; Cao, H.; Volner, A.; Lucci, A.; Han, T.; Geffen, V.; Giuliano, A. E.; Cabot, M. C., J. 
Biol. Chem., 1997,272,1682-1687. 
68  Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S., J Clin. Invest., 1986, 77, 1405-1408. 
69 Archinal-Mattheis, A.; Rzepka, R. W.; Watanabe, T.; Kokubu, N.; Itoh, Y.; Combates, N. J.; Blair, 
K. W.; Cohen, D., Oncol. Res., 1998, 7, 603-610. 
70  Page, A. P.; Kumar, S.; Carlow, C. K. S., Parasitology Today, 1995, 11,385-388. 
71  Taylor, P.; Page, A. P.; Kontopidis, G.; Husi, H.; Walkinshaw, M. D., FEBS Lett., 1998, 425, 361-
366. 
72  Chappell, L. H.; Wastling, J. L., Parasitology, 1992, 105, S25-S40. 
Leech, J. FL, J. Exp. Med, 1984, 159, 1567-1575. 
74  Hsiao, L. L., Biochem. J., 1991, 274, 121-132. 
Ke, H.; Mayrose, fl; Belshaw, P. J.; Alberg, D. G.; Schreiber, S. L.; Chang, Z. Y.; Etzkorn, F. A.; 
Ho, S.; Walsh, C. T., Structure, 1994, 2, 33-44. 
76  Kallen, J.; Mikol, V.; Taylor, P.; Walkinshaw, M. D., J. Mo!. Biol., 1998, 283, 435-449. 
77  Billich, A.; Hammerschmid, F.; Peichi, P.; Wenger, R.; Zenke, G.; Quesniaux, V.; Rosenwirth, B., 
.1 Virology, 1995,69,2451-2461. 
78  Cabot, M. C.; Han, 1.; Giuliano, A. E., FEBS Lett., 1998, 431,185-188. 
n Mikol, V.; Taylor, P.; KalIen, J.; Walkinshaw, M. D., .1. Mo!. Biol., 1998, 283, 451-461. 
80  Papageorgiou, C.; Kallen, J.; France, J.; French, R., Bioorg. Med Chem., 1997, 5, 187-192. 
81  His, M.-K.; Badger, A.; Rich, D. H., I Med Chem., 1995,38,4164-4170. 
82  Schramm, U.; fricker, G.; Wenger, R; Miller, D. S., American I Physiology, 1995, 37, F46-1752. 
83  Moss, M. L.; Palmer, R E.; Kuzmió, P.; Dunlap, B. E.; Henzel, W.; Kofron, J. L.; Mellon, W. S.; 
Royer, C. A.; Rich, D. H., I. Biol. Chem., 1992, 267, 22054-22059. 
84 Nelson, P. A.; Akselband, Y.; Kawamura, A.; Su, M.; Tung, R D.; Rich, D. H.; Kishore, V.; 
Rosborough, S. L.; DeCenzo, M. T.; Livingston, D. J.; Harding, M. W., .1 Immunology, 1993, 150, 
2139-2147. 





81 Papageorgiou, C.; Florineth, A.; French, R.; Haltiner, R.; Borer, X., Bioorg, & Med. Chem. Lett., 
1993,3,2559-2564. 
87  Papageorgiou, C.; Weber, H.P.; French, R.; Borer, X., Bioorg. & Med Chem. Lett., 1995, 5,213-
218. 
88  Bartz, S. R.; Hohenwalter, E.; Hu, M.-K.; Rich, D. H.; Malkovsky, M., Proc. Nat!. Acad Sd. 
U.S.A., 1995,92,5381-5385. 
89  Hubler, F.; RUckle, 1.; Patiny, L.; Muamba, T.; Guichou, J.-F.; Mutter, M.; Wenger, R., TeL Lett., 
2000, 41, 7193-7196. 
90  Husi, R.; Zurini, M. G. M., Anal. Biochem., 1994, 222, 251-255. 
91  Papageorgiou, C.; Borer, X.; French, RA, Bioorg. & Med Chem Lett., 1994, 4,267-272. 
92  Aebi, J.D.; Guillaume, D.; Dunlap, B.E.; Rich, D.H.,J. Med Chem., 1988, 31, 1805-1815. 
n Alberg, D. G.; Schreiber, S. L., Science, 1993,262, 248-250. 
94 Traber, R.; Hothiann, H.; Loosli, H-R.; Ponelle, M.; von wartburg, A., Helvetica ChimicaActa, 
1987,70,13-34. 
95 Ko, S.Y.; Wenger, R.M., Helvetica ChimicaActa, 1997, 80, 695-705. 
96  Lawen, A.; Iraber, R.; Geyl, D.; Zocher, It; Kleinkauf, H., J. Antibiotics, 1989, 42,1283-1289. 
97  Sanglier, J.-J.; Quesniaux, V.; Fehr, 1.; Hofirtann, H.; Mahnke, M.; Memmert, K.; Schuler, W.; 
Zenke, G.; Gschwind, L.; Maurer, C.; Schilling, W., I Antibiotics, 1999, 52, 466-473. 
98  Fehr, T.; Kallen, J.; Oberer, L.; Sanglier, J.-J.; Schilling, W., I Antibiotics, 1999, 52, 474-479. 
99 Fehr, T.; Quesniaux, V.F. J.; Sanglier, J.-J.; Oberer, L.; Gschwind, L.; Ponelle, M.; Schilling, W.; 
Wehrli, S.; Enz, A.; Zenke, G.; Schuler, W., I Antibiotics, 1997, 50, 893-899. 
100 Gaymes, T. J.; Cebrat, M.; Sietnion, I. Z.; Kay, J. E., FEBS Let!., 1997, 418,224-227. 
101 Gallo, P.; Rossi, F.; Saviano, M.; Pedone, C.; Colonna, G.; Ragone, R., .1 Biochem., 1998, 124, 
880-885. 
102 Picur, B.; Lisowski, M.; Siemion, I. Z., Lett. Pept. Sci., 1998, 5, 183-187. 
103 Than, Y.; Ke, H., Biochem. 1996,35, 7362-7368. 
104 Zurini, M.; Kallen, J.; Mikol, V.; Pfluegl, G.; Jansonius, J. N.; Walkinshaw, M. D., FEBSLett., 
1990, 276, 1, 63-66. 
105 Konno, M.; Ito, M.; Hayano, T.; Takahashi, N., I Mo!. Biol., 1996, 256, 897-908. 
106 Fischer, S.; Dunbrack, It L., Jr.; Karplus, M., I An Chem. Soc., 1994, 116, 11931-11937. 
107 Hart, S. A.; Etzkorn, F. A., I Org. Chem., 1999, 64, 2998-2999. 
108 Boros, L. G.; De Corte, B.; Gimi, It H.; Welch, I T.; Wu, Y.; Handschumacher, R. E., Tett. Let!., 
1994, 35, 6033-6036. 
'09 Wang, FL C.; Kim, K; Bakhtiar, It; Germanas, J. P., 1. Med Chem., 2001, 44,2593-2600. 
110 Germanas, J. P.; Kyonghee, K.; Dumas, J.-P., Adv. Amino Acids Peptidomimetics, 1997, 1,233- 
250. 





112 Choi, C.; Hamilton, G.; Steiner, J.; Vaa,. M.; Ling, W., PCTJnI. Appi., 2001, 57. 
113 bye T.; Van Veidhuizen, J., Abstracts of Papers Amer. Chem. Soc., 1999, 217,278. 
114 Thesis: Kontopidis, G.A., Immunophilin Ligand Design, Edinburgh University, 1999, 7.13. 




Results and Discussion I 
2 	Results and Discussion I 
2.1 Aim 
The overall aim of this project was to use combinatorial methods to generate a 
library of potential CsA mimics based on the lead compound dimedone. The 
compounds generated would have potential application as probes for the biological 
mechanisms of action of cyclophilins and CsA. Initial studies concentrated on the 
development of robust dimedone chemistry, which could then be adapted for 
automated library generation. 
There are several advantages to using dimedone as a lead structure for library 
synthesis. Firstly, dimedone is commercially available and inexpensive, and 
secondly, the symmetrical molecule makes a good scaffold for further reaction. 
Additionally, there are several positions at which dimedone can be derivatised in 
order to prepare a diverse range of combinatorial building blocks. Investigation of 
the literature on reactions concerning dimedone, revealed that a wealth of different 
derivatives had been prepared. With such a choice available it was necessary to 
begin with a more simplified approach for creation of a few structures that would 
potentially give us some preliminary information on the interaction of dimedone with 
the CypA binding site. Rather than attempting to generate many different analogues, 
our initial strategy was to design ways to build out from the dimedone core in several 
directions, in order to gain a better understanding of the available space within the 
CypA binding site. The 1 ,3-dicarbonyl group is compatible with a range of synthetic 
chemistry both at the carbonyl group and methylene group, while still preserving the 
two points of interaction with the protein active site (Figure 2.1). 
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Figure 2.1 
H02CH peptide 





The first design decision was to prepare peptide analogues of dimedone. Since the 
natural ligand CsA is an undecapeptide, it seemed reasonable that we could locate 
our core dimedone scaffold within the hydrophobic binding pocket of the CypA 
binding site and then expect to mimic some of the hydrogen bond contacts between 
the peptide backbone of CsA and the protein, by attachment of amino acids to this 
fixed core. The initial task was therefore to design a method of incorporation of the 
dimedone structure into the peptide chain. With library generation in mind, the 
reaction conditions established at this stage should then be applicable to a range of 
dimedone derivatives. It should be noted that the idea was not to try to mimic the 
whole structure of CsA, since only one half of CsA (residues 9-11, 1-3) is involved 
in binding to CypA, while the remaining residues form the effector loop and bind to 
calcineurin phosphatase. Consequently the aim was not to mimic the biological 
immunosuppressant action of CsA, as this involves the entire CsA ring. It should 
also be noticed that the proposed ligands are not "drug-like" molecules, since the 
limitations of peptides as drug candidates are widely known and were discussed in 
the introduction. However, the potential to substitute unnatural or constrained amino 
acids, or replacements, in order to form dimedone-based peptidomimetics remains a 
possibility. The advantages and disadvantages of using the peptidomimetic strategy 
in drug design were also covered in the introduction. 
From these first ligands, we hoped to fulfil the following objectives: firstly, 
development of some reproducible dimedone chemistry suitable for library 
generation; secondly, preparation of a number of dimedone-based ligands; thirdly, 
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development of a means for investigating the binding of these ligands to the CypA 
protein, and perhaps quantifying this in the form of a measured dissociation constant, 
Kj; and generally, an idea of the available space and important interactions within 
the binding site. 
2.2 	Amino Acid Derivatives of Dimedone 
2.2.1 Analogues Based on the Dde Protecting Group 
As stated previously, the initial objective was to establish reaction conditions for the 
incorporation of dimedone into the peptide chain. The N-1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl (Dde) primary amine protecting group (39, RCH3), and 
its derivatives, developed by Chhabra et al.', are used in the protection of amino 
acids in solid phase peptide synthesis. These dimedone-based protecting groups are 
readily synthesised by acylation of dimedone with the appropriate DCCIDMAP 
activated carboxylic acid as shown in Scheme 2.1. The amine, in this case the side 
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The success of this synthetic strategy suggested that it may be possible to incorporate 
dimedone into peptides using the route shown in Scheme 2.2. Initial studies used the 



















The dimedone adduct 41 was synthesised by acylation of dimedone with N-Cbz-
glycine, activated using DCC/DMAP, to form the alcohol 40, followed by 
condensation with butylamine. The yield for the initial C-acylation step was only 
13% and attempts to perform this reaction with protected amino acids other than 
glycine resulted in recovery of starting material, or low (<10 %) yields of O-acylated 
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No previous examples of the C-acylation of dimedone with an cc-substituted 
carboxylic acid using this method were found in the literature. It was thought at this 
stage that the cc-substituted amino acids might have a steric barrier to reaction. 
The O-acylated enol ester derivatives 42 constituted a novel class of ligands which 
could be tested for binding to CypA. This part of the project was taken on by Yuan 
De Yang at Edinburgh University, who at this point started to investigate potential 
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While the assay methods were being developed, work continued towards 
optimisation of enol ester formation by the O-acylation mechanism, and also towards 
direct C-acylation of the dimedone C-2 position to produce activated alcohols such 
as 40. This second class of C-acyl derivatives were considered important as this 
strategy involved incorporation of the dimedone scaffold within the amino acid 
chain, thus affording greater scope for building out from the dimedone core than was 
possible with the O-acylated analogues. Studies were therefore performed in order to 
establish conditions for both 0- and C-acylated species, by investigation of differing 
modes of activation of the amino acid C-terminus. 
2.2.2 Amino Acid Activation Methods - Attempts to Effect C- versus 
O-acylation of Dimedone 
2.2.2.1 Azidefornation 
The method for the preparation of acyl azides reported by Chorev et al.2 was 
employed in the activation of amino acids for attempted coupling to dimedone as 
shown in Scheme 2.4. The mixed anhydride 44 was formed by treatment of Cbz-L-
valine 43 with ethyl chloroformate in the presence of triethylamine. In situ addition 
of sodium azide and aqueous work-up resulted in a colourless oil which exhibited a 
strong azide peak at 2140 cm' in the IR spectrum, although an additional peak at 
2252 cm' suggested that some rearrangement of azide 45 to the isocyanate 46 may 
be occurring. However, 'H NMR of the oil gave inconclusive data as a solid 
precipitated out after sample preparation resulting in broad spectral peaks. It was 
postulated that the acyl azide species 45 may be prone to hydrolysis to regenerate 
valine in the presence of any water remaining from the work-up. Reaction of the 
colourless oil with dimedone was therefore attempted immediately without further 
analysis. The oil was treated with dimedone in the presence of DMAP, with the aim 
of forming either or both of the dimedone derivatives 42,47 shown in Scheme 2.4. 
Unfortunately the yellow solid obtained was found to be a mixture of Cbz-L-valine 
and dimedone starting materials by 1H NMR. 
52 
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Scheme 2.4 
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2.2.2.2 Mixed anhydride formation 
It was proposed that direct coupling of dimedone to the amino acid mixed anhydride 
might be possible without formation of the azide. Reaction of dimedone with the 
anhydride of leucine 49, generated by reaction of Cbz-L-leucine 48 with ethyl 
chioroformate in the presence of triethylamine (Scheme 2.5), resulted in the 
O-acylated product 50. Solvent effects are known to be important in determining the 
ratio of keto to enol forms of dimedone,3 but changing the solvent did not alter the 
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Scheme 2.5 
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Solvent: 
EtOH dimedone: [enol]/Iketo] = 169 
CHCI3 dimedone: [enol]Ilketo] = 0.05 
51 
It was also noted that the both carbonyl groups of the anhydride were attacked by 
dimedone resulting in both the amino acid derivative 50 and the carbonate by-
product 51. Carbonate by-product was observed even when isobutyl chioroformate 
was substituted for the ethyl chioroformate. 
Enol ester 52 was prepared by reaction of dimedone with the mixed anhydride of 
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Problems were encountered in the purification step as a small amount of the impurity 
53 was formed by attack of dimedone on the mixed anhydride as described 
previously, and this proved to be difficult to separate by column chromatography. 
2.2.2.3 Acylfluoride formation 
The acylation was then attempted via the N-Cbz-amino acid fluorides using 
conditions described by Carpino et al.4 , as shown in Scheme 2.7. 	N- 
Benzyloxycarbonyl-L-leucine 48 was treated with cyanuric fluoride and pyridine to 
form the acid fluoride 54, which then reacted with dimedone under basic conditions 
















The overall yields were much improved by proceeding directly to the dimedone 
addition step after aqueous wash of the acyl fluoride reaction mixture, rather than 
isolation and characterisation of the acyl fluoride itself. 
Despite investigation of different conditions, all attempts to form the C-acylated 
product directly at this stage were unsuccessful. The next alternative appeared to be 
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2.2.3 Rearrangements 
2.2.3.1 Lewis Acid catalysis 
An alternative route to 2-acylcyclohexane-1,3-diones 56, reported by Akhrem et 
involves O—C isomerisation of the enol ester 55 in the presence of aluminium 
chloride (Scheme 2.8). The enol esters were synthesised by reaction of an equimolar 
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Attempted rearrangement of the enol ester 42 using aluminium chloride was 
unsuccessful, resulting in recovery of starting material (Scheme 2.9). 
Scheme 2.9 
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2.2.3.2 Cyanide catalysis 
Eventually, however, cyanide catalysed rearrangement6 of enol ester 42 using 
acetone cyanohydrin and triethylamine resulted in the C-acylated product 58 in good 
yield (Scheme 2.10). Treatment of the 2-acyl-1,3-cyclohexanedione 58 with L-
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The dipeptide 59 was found to be a 60:40 mixture of diastereomers by 'H NIvIR. 
When the synthesis was repeated using racemic N-Cbz-valine, the same ratio of 
diastereomers was obtained indicating that epimerisation occurs at the initial amino 
acid (in this case valine). Formation of the amide 60 by reaction of the enol ester 42 
with a second amino acid resulted in a single diastereomer, which confirmed that the 
stereochemistry was conserved in forming the enol ester, but suggested that 
epimerisation may occur during the cyanide catalysed rearrangement step. This 
reaction proceeds via the acyl cyanide 61, which may enolize7 resulting in the loss of 
chirality at this centre (Scheme 2.11). The alternative explanation is that the acidic 
nature of the a-proton (*) may result in spontaneous epimerisation on formation of 
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At this stage it was important to establish whether preservation of the 
stereochemistry at this position would be possible. Additionally, we wanted to 
investigate the possibility of preparing solid supported dimedone derivatives using 
58 
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this route, in combination with some solid phase chemistry previously developed by 
Dr Anita Long at Edinburgh University, for the synthesis of C-terminally modified 
peptides. 
2.2.4 Solid Phase Chemistry 
Solid phase combinatorial chemistry has found wide application in the field of 
protein-ligand interactions for the generation of large numbers of peptidomimetics 
used as probes in the investigation of structure-activity relationships. 	The 
advantages offered by solid phase chemistry over the solution phase equivalent are 
widely reported.8 With regard to library generation, the main advantage is in the 
ease of purification of resin bound libraries in comparison to purification of the last 
step of a library synthesis in solution. When compounds are synthesised on solid 
support, excess reagents can be used to drive the reaction to completion and then 
washed out in a simple filtration step. The use of excess reagents has obvious 
advantages when preparing a combinatorial library where one reaction will be 
performed on all combinations of a set of building blocks, but may only be optimised 
for a small trial set of these components. The disadvantages of solid phase are often 
discovered in the transferral of established solution reactions to a solid phase system, 
because reagents can often behave very differently in the solid phase environment. 
With regard to the proposed library of dimedone-based ligands, a method for the 
attachment of amino acids to solid support had already been established, so it seemed 
sensible to investigate the possibility of using this strategy in combination with the 
solution phase synthesis detailed in section. 
Scheme 2.12 shows the method, adapted by Dr Anita Long from the published 
methods of Roussel et aL 9 and Henkel et aL,'° for immobilisation of an amino acid 
on polystyrene resin, by attachment via the N-terminus. This strategy uses the Wang 
linker. 
59 






















Wang resin 63 was activated by reaction with p-nitrophenol chioroformate 64 to 
form the resin-bound carbonate 65. Formation of the carbonate was indicated by the 
distinctive JR (C=O) stretch at 1765 cm. Resin loading could also be established at 
this stage by cleavage of the p-nitrophenol group using 20 % piperidinefDMF, and 
photometric analysis. The activated resin 65 was then reacted with the p-toluene 
sulfonic acid salt of L-valine fluorenyl methyl ester 66 to yield the resin-bound amino 
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give the free acid 68. Resin loading was established at this stage by UV analysis of 
the dibenzofulvene piperidine adduct. The synthesis of dimedone-based ligands was 
then attempted using the strategy shown in Scheme 2.13. The resin-bound acyl 
fluoride 69 was formed from the acid 68 by reaction with cyanuric fluoride and 
pyridine in DCM at room temperature. A strong acyl fluoride peak was observed in 




















The enol ester 70 was formed by treatment of the acyl fluoride 69 with dimedone in 
the presence of DIPEA. This step was accompanied by disappearance of the acyl 
fluoride stretch in the IR. 
61 
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Attempts to perform the proposed cyanide catalysed rearrangement step on resin 
(Scheme 2.14) resulted in incomplete conversion, with a mixture of unreacted enol 
ester 70 and rearranged product 71, observed by Gel '3C NMR (identified by 
comparison with solution '3C NIvIIR spectra of the previously characterised 
compounds 42 and 58 (Scheme 2.10)). 
Scheme 2.14 
O1N  
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It should be noted that during the rearrangement step, the mechanism of which is 
outlined in Scheme 2.11, dimedone is cleaved from the resin on formation of the 
tethered acyl cyanide, and then re-attaches via the C-2 position. Due to the 
comparatively lower concentrations of reagents when working with solid support as 
opposed to solution chemistry, it was anticipated that incomplete rearrangement may 
have been attributable to a dilution effect where a low concentration of free 
dimedone is available for re-reaction with the supported acyl cyanide species. In 
order to compensate for this, the reaction was repeated with a 20-fold excess of 
dimedone added during the rearrangement step, however the same mixture of 
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In order to attempt complete rearrangement of the resin-bound enol ester 42, further 
studies were performed on the established chemistry in solution. Firstly, this step 
was optimised in a 'one-pot' reaction which proceeded in 94 % yield to the C-
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However, the solid phase yields of C-acylated product could not be improved upon 
and it became obvious that an alternative route for direct C-acylation of dimedone 
with the acyl fluoride was required, in order to dispense with the cyanide catalysed 
rearrangement step. Formation of derivatives such as 59 using a strategy of this sort 
also had the potential to clarify the step at which epimerisation of the chiral centre 
(*) of 59 occurs. 
A search of the literature suggested that employment of alkyl ammonium fluoride 
salts could offer a promising alternative. 
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2.2.5 TBAF Salt 
The tetrabutylammonium fluoride (TBAF) salt of dimedone, 72 (Scheme 2.16) was 
formed using the method described by Clark et al.", by simply stirring a 
stoichiometric mixture of TBAF and dimedone in DMF in the presence of molecular 
sieves. Interestingly, the 'H NMR spectrum of the salt 72 in deuterated chloroform 
reveals that the TBAF-complexed dimedone is present exclusively in the enol form. 
The opposite situation occurs with uncomplexed dimedone in chloroform, where 
dimedone exists predominantly in its keto form. 12  The authors findings indicate that 
formation of the salt predisposes dimedone to C-acylation, by formation of a tightly 
hydrogen bonded complex anion with fluoride. The enhanced reactivity presumably 
arises by transfer of the electron density from the fluoride anion via the hydrogen 
bond. The overall result is, therefore, to shield the oxygen atom of dimedone, hence 
inhibiting O-alkylation while at the same time increasing the effectiveness of the 
compound as a nucleophile. 
Reaction of the salt 72 with the acyl fluoride of benzyloxycarbonyl-L-valine 57, 
resulted in a 3:2 ratio of C- to O-acylated products (58,42) by 'H NMR, the first time 
that direct C-alkylation of dimedone had been observed. Chromatographic 
purification of this mixture proved difficult so the mixture was reacted directly with 
L-phenylalanine methyl ester (Scheme 2.16). Four compounds were isolated from 
the resulting mixture: unreacted C-acylated compound 58; the dipeptide 60 (as a 
single diastereomer) from reaction of O-acylated compound 42; and dimedone 
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The dipeptide 59 was observed to be a mixture of diastereomers by 'H NMR. This 
result suggests that epimerisation of the chiral centre (*) occurs spontaneously on 
formation of C-acylated dimedone 58, due to the acidic nature of proton H. 
It is interesting to note that dimedone required to be "fixed" in the enol form by 
complexation with TBAF for C-acylation to occur. Contrast this finding with the 0-
acylation that occurred when dimedone was reacted in ethanol, where the enol form 
almost exclusively predominates. These results further confirm that there is an 
additional, probably electronic, effect operating in the TBAF-dimedone reaction. 
At this point, several assay results became available indicating the possible binding 
of the preliminary ligands tested to CypA. These results, reported in Chapter 3, 
suggested that the 0-acylated derivatives were a more promising template for further 
adaptation than the C-acylated species. Additionally, it was obvious that additional 
investigation would be required in order to achieve 100 % C-acylation on solid 
support, in order to build a library. For this reason, it was decided that work towards 
a solid supported library would be suspended at this stage. Nevertheless, this 
investigation was valuable in solving the question of when the epimerisation was 
occurring, and an additional application of this chemistry, which will be discussed in 
Chapter 5, was also suggested. 
2.2.6 Further Solid Phase Investigation 
Further work in this area could concentrate on optimising the reaction of TBAF-
dimedone with the acyl fluoride of benzyloxycarbonyl valine in order to maximise 
C-acylation. If 0-acylation occurs due to the presence of uncomplexed dimedone 
(perhaps formed as a result of water in the reaction), then more efficient elimination 
of moisture from the reaction should increase the yield of desired product. 
If a reasonable yield of the resin-bound C-acylated species 71 could be generated, it 
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acid as its p-TSA salt, in order to form the dipeptide 73 on resin (Scheme 2.17). The 





















The p-toluene sulfonic acid salt of L-valine fluorenyl methyl ester 66 can be 
synthesised by the method shown in Scheme 2.18. The protected ester 76 is formed 
by reaction of Boc-L-valine 74 with 9-fluorenemethanol 75 using DIC/DMAP. The 
Boc protecting group can then be removed using TFA, and the fluorenyl methyl 
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amino acids are suggested because previous work carried out by Dr Anita Long 
13  has 
















2.2.7 Formation of Additional Dimedone Ligands 
2.2.7.1 Vinylogous amide 
Two other ligands were prepared at this stage, the first of which was the vinylogous 
amide 77, formed by the route shown in Scheme 2.19, by simply treating dimedone 
with the hydrochloride salt of L-valine methyl ester in the presence of triethylamine, 
as reported by Halpern et al. 14 
Scheme 2.19 
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This reaction was chosen from the literature because it is a simple way of generating 
dimedone-amino acid conjugates and the mild conditions are suitable for library 
generation. The attachment of the amino acid via the amino as opposed to the acid 
terminus obviously alters the backbone arrangement of the hydrogen donor and 
acceptor atoms with respect to their distance from the dimedone core. Preparation of 
a range of these derivatives would constitute a complimentary family of ligands to 
the O-acyl ligands previously described. This was therefore an interesting molecule 
for testing in the initial CypA binding assay. 
2.2.7.2 Di-protected amino acids 
In order to establish whether it is indeed the dimedone core that is important for 
binding, the diprotected amino acid 79 was prepared, by the method shown in 
Scheme 2.20. N-(Benzyloxycarbonyloxy)succinimide 78 was reacted with the 
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2.2.8 Summary 
Several ligands had so far been prepared using the routes summarised in Scheme 
2.21 below. 
Scheme 2.21 
It now became possible for these to be tested for binding affinity to CypA using a 
fluorescence assay set up by Yuan De Yang. The preliminary screening results are 
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3 	Results and Discussion II 
3.1 	Analysis of Ligand Binding 
Having prepared a number of dimedone-based ligands, the next stage of the process 
was to establish whether any of these molecules could penetrate the binding site of 
CypA and form interactions with the protein. Several methods for determining 
protein-ligand binding were investigated and will now be described. All assay and 
crystallography work was carried out by Yuan Dc Yang. 
3.1.1 Crystal Structure 
3.1.1.1 Crystal soaking 
CypA protein was produced from E.coii bacteria and purified in house by Yuan De 
Yang. The hanging drop vapour diffusion method was used to grow crystals of 
CypA. The principle of vapour diffusion crystallisation is that a droplet containing 
protein, buffer, crystallising agent and additives, is equilibrated against a reservoir 
containing a solution of crystallising agent at higher concentration than the droplet. 
Equilibration occurs by diffusion of the water until vapour pressure in the droplet 
reaches that of the reservoir. A crystal soaking procedure was employed to introduce 
ligands into the CypA active site. This method involved placing a well-diffracting 
CypA crystal into a solution containing an appropriate ligand concentration. A 
number of CypA:ligand complexes were obtained by this method and the crystal 
structures analysed by X-ray diffraction. The limitations of this technique with 
regard to screening of ligands for binding to CypA are firstly, that several time and 
labour intensive steps are involved in isolation and purification of the protein, 
preparation of the CypA crystals, soaking in the ligand solutions, and collection and 
manipulation of X-ray data. Additionally, crystals must be able to withstand the 
soaking conditions, for reasonable periods of time, without cracking or dissolving. A 
further consideration is that the ligand must be small and flexible enough to pass 
through solvent channels in the crystal lattice in order to access the active site. The 
great advantage of obtaining crystallographic data on CypA:ligand complexes is that 
72 
Chapter 3 	 Results and Discussion II 
very detailed information on the binding of the ligand within the CypA active site, 
including ligand orientation and potential protein:Iigand interactions can be acquired. 
However, crystals of CypA:ligand complexes can only be obtained under certain 
conditions, and the failure to produce a crystal of a particular protein: ligand complex 
by soaking experiments, does not necessarily mean that the ligand is unable to bind 
to the protein active site. For example, a large ligand might not be suitable for 
soaking into the CypA crystal if its hulk restricts passage through solvent channels in 
the crystal lattice. However, a large ligand might be able to enter the CypA active 
site in the solution form of the protein, and in this situation co-crystallisation might 
prove more useful. Alternatively, a ligand that is only sparingly soluble under the 
chosen soaking conditions can also cause problems since only a comparatively low 
concentration of ligand can be achieved. 
3.1.1.2 Go-crystallisation 
Co-crystallisation is another method of obtaining CypA:ligand crystals, especially 
useful where a complex with a large ligand is required. In co-crystallisation the 
conditions for crystal growth of the protein:ligand complex may be different from 
that of the native molecule, so that screening of many conditions may be required. 
For this reason, the co-crystallisation method was used less than the crystal soaking 
technique. 
3.1.2 Fluorescence Assay 
Fluorescence spectroscopy can be used to detect interactions between proteins and 
other molecules, provided that the optical properties of the protein-ligand complex 
differ from those of free ligand and free protein.' Aromatic residues such as 
phenylalanine, tyrosine and tryptophan are responsible for fluorescence of proteins in 
the near ultraviolet region, with tryptophan fluorescence dominating at 2-emit  340 urn 
in most proteins. 
CypA has a single tryptophan residue located about 8 A from the centre of the active 
site, which makes a hydrogen bond to CsA when bound. The fluorescence spectrum 
can therefore be used to detect changes in the environment of this tryptophan. If the 
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binding of a ligand within the active site causes sufficient perturbation of the 
microenvironment in the region of the tryptophan, then a corresponding change in 
the fluorescence emission will be observed. 
The fluorescence titration was performed using a Perkin Elmer LS50B fluorescence 
spectrophotometer, by fluorescence measurement on a solution of protein with 
successive additions of ligand dissolved in 100 % ethanol. Measurements were taken 
at a single wavelength and recorded when the reading became stable. The excitation 
wavelength was 280 nm. Using the method reported by Handschumacher ci al.2  
numerical evaluation of the emission readings allowed calculation of the dissociation 
constant Kd for some ligands. 
After each addition of ligand, the portion of protein bound is proportional to the 
fractional fluorescence change. When 50 % of the binding sites are filled, the 
fractional fluorescence change is 50 %, when the protein:ligand stoichiometry is 1:1. 
The Kd is estimated by assuming a 50 % occupancy of the protein at a fractional 
fluorescence change of 50 %. At this point the concentration of the bound ligand 
equals that of the free protein.3 The most meaningful values in a titration curve are 
those near to 50 % of fractional fluorescence change because they allow more 
accurate determination of ligand concentration at that point. 
The mathematical formula is as follows: 
P + L = PL 
[P] = free protein concentration 
[P]b = bound protein concentration 
[U] = free ligand concentration 
[PL] = protein ligand complex concentration 
[P]0 = total protein concentration 
[U 0 = total ligand concentration 
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Kd = [P][L]/[PL] 
When 50 % fluorescence change occurred: [P] = [PL] = Y2[P]0 
[Lb = ILib + [L] 
[Lib = ['lb = V2[Pi0 
Kd 	=[P].[L]/[PL] 
= Y2[P]o.([L]0-[L]h)/(l/2[P]0) 
= [110 - [T] 
Kd 	= ILl0  -'/21P10 Equation 3.1 
A typical plot of ligand concentration against fluorescence quenching is given in 
Figure 3. 1, from measurements taken for Ligand 42. 
Figure 3.1 
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From the graph [U]0 =2 pM. Experimentally [P]0 =2 M and the Kd was then 
calculated using Equation 3.1. 
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3.1.2.1 Limitations offluorescence assay 
Other causes of fluorescence quenching must he taken into account in fluorescence 
titration when the ligand concentration becomes high: 
Quenching effect 
Apparent quenching of fluorescence can occur if the excitation and/or the emitted 
light is/are absorbed by the solution containing the fluorophore, resulting in less light 
reaching the detector. This effect was accounted for by conducting a control 
experiment using tryptophan instead of protein, and increasing the concentration of 
ligand under identical experimental conditions. New corrected fluorescence values 
were obtained by calculation of the difference between protein and control values. 
Scattering effect 
Insoluble ligands can form precipitates which scatter the emission and the excited 
light, so less quenching is recorded. 
Dilution effect 
After each addition of ligand the final volume of protein solution increases, and the 
protein concentration decreases, resulting in a decrease in fluorescence intensity. 
The control experiment was also used to correct for this dilution effect due to 
addition of ligand. 
3.1.2.2 Discussion 
Different, sometimes contrasting, effects on the fluorescence were observed on 
binding of the ligands. In some cases fluorescence quenching was observed, which 
can be accounted for by fluorescence transfer from the excited tryptophan residue to 
a group or groups on the ligand (eg. an aromatic ring). With other ligands (including 
CsA) an increase in emission from the tryptophan was observed. This may be 
explained if we postulate that a water molecule is displaced from the vicinity of the 
tryptophan on binding of the ligand. If the water molecule was close enough to 
enable fluorescence transfer from the tryptophan, then its removal means that a 
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reduced quenching effect is observed, especially in the case where the bound ligand 
itself is too far removed from the tryptophan for quenching to occur. 
The main limitation of this technique when used for determination of ligand binding, 
is that the ligand must either bind close enough to the tryptophan to cause a direct 
change in its fluorescence (by quenching or displacement of a water molecule), or 
the ligand must cause sufficient change in the protein conformation and consequently 
in the environment of the tryptophan, in order to show a corresponding fluorescence 
change. The assay results shown in Table 3.1 (Section 3.2) are therefore useful for 
indicating those ligands which do hind to the protein (and for calculation of Kj in 
some cases), but ligands which show no change in fluorescence are not necessarily 
uncomplexed. For this reason the fluorescence assay results were used as a guide, 
rather than irrefutable proof of ligand binding, when designing later ligands. 
However, this set of information was very useful as it was the first data available to 
indicate ligand binding. The results were especially informative when used in 
conjunction with crystallographic information. 
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R = Suc-Ala-Ala- 	 trans-Xaa-Pro-Phe 
The PPIase activity of CypA in the presence of the novel inhibitors was assessed 
using an a-chymotrypsin-coupled enzymatic assay (Figure 3•2)•5 The substrate used 
was Suc-Ala-Ala-Pro-Phe-pNa, which exists in an equilibrium between the cis and 
trans forms. The C-terminal 4-nitroaniline group is cleaved instantaneously by 
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a-chymotrypsin if the Ala-Pro bond is in the trans form. Release of the chromogenic 
4-nitroaniline is monitored by measuring the absorbance with time at 390 rim. The 
assay is carried out at 4 °C in order to limit thermal isomerisation of the substrate. 
The trans peptide present initially is then cleaved within the deadtime, so that this 
cleavage does not contribute to the measurement of cis/trans isomerisation observed 
in the slower second step of the reaction. In the presence of CypA the rate of 
isomerisation of the substrate is accelerated, resulting in faster release of 4-
nitroaniline. Conversely, addition of a CypA inhibitor will retard the rate of 
nitroanilide release. Analysis of the reaction kinetics can be used to determine the 
rate constants for the reaction and ultimately, the dissociation constant for the 
inhibitor. A plot of the rate of enzymatic isomerisation against ligand concentration 
was used to determine the total concentration of ligand at which 50 % inhibition 
occurred. In a similar manner to the fluorescence assay calculations, Equation 3.1 
was used to determine the K4j by assuming a 50 % occupancy of the protein when the 
rate of enzymatic isomerisation changes by 50 %. Limitations of this protease-
coupled, irreversible assay include: 
The calculations assume that the rate of cis to trans isomerisation is directly 
comparable to the rate of 4-nitroaniline release. 
Only the cis to trans and not the reverse trans to cis isomerisation can be 
investigated. 
Due to the fact that only about 10 % of the substrate (the cis content) is 
monitored, the signal-to-noise ratio can cause problems as well as the solubility of 
the substrate. 
The assay is fairly time consuming and several repetitions were required in order 
to achieve reproducible results. 
Different solvents can be used to shift the cis/trans equilibrium, and the cis content 
of the substrate is increased to about 70 % by using LiCIITFE as solvent .6 This 
allows for more precise measurement of kinetics and inhibition parameters. 
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3.1.4 Mass Spectrometry 
The technique of electrospray ionisation mass spectrometry (ESI-MS) has the 
capability to transfer even weakly bound noncovalent complexes intact from solution 
to the vacuum of the mass spectrometer. Ganem ci al 
.7  have used EST-MS 
(performed in water without co-solvent) to detect gas-phase complexes of FK506 and 
rapamycin with FKBP. A competition experiment between FKBP and equimolar 
amounts of the two ligands showed both receptor-ligand complexes with relative 
peak integration 1:2, in agreement with the relative Kd values (FK506 K=0.4 nM, 
rapamycin Kd=0.2 nM). Further evidence of specific FKBP-ligand interactions was 
obtained by MS studies at varying pH.8  FKBP is known to undergo reversible 
denaturation at low pH. Unfolding the protein's binding pocket by acidifying the 
FKBP-FK506 solution to pH 3.3 caused the complex ion signal to disappear, while 
restoration of the pH to 7.5 restored the complex ion signal. Although absolute 
determination of the binding affinities of FK506 and rapamycin for FKBP by MS has 
not yet been reported, the utility of MS for measuring solution association constants 
has been demonstrated for complexes between vancomycin group antibiotics and 
bacterial cell wall peptide analogues. Jorgensen ci aL report the determination of 
solution KA's  from the relative ion abundances in the EST mass spectra. The 
solution-phase equilibrium concentrations of the various complexes were determined 
from the ratio of the ion peak intensity of the given complex relative to the summed 
peak intensities of all the complexes and the free antibiotic. The measured values 
were found to he in good agreement with previously reported values obtained by 
standard spectroscopic titration techniques. 
The literature precedence for observing protein-ligand interactions by mass 
spectrometry, coupled with the information obtained on comparative binding of 
ligands by competition experiments, was very promising with repect to testing the 
dimedone analogues prepared for binding to CypA. Ligand:CypA complex 
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3.2 	Results of Binding Assay 
Table 3.1 
Structure interaction Resolution of 
Ligand with hCyp hCypA- I(d Ligand 
Complex 
58 No binding ND  
L 0 
59 No binding ND 
o 
IAco 
42 IRM 1.85A 














77  No binding ND  
JL O 





* Kd determined by fluorescence assay 
# Kd  determined by PPIase assay 
ND not determined 
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As explained previously (3.1.2.2), the fluorescence assay results were used as a guide 
to indicate possible binding of the ligands tested to CypA. From Table 3.1 it can he 
deduced that ligands such as 58 and 59, where the dimedone core has been 
fuctionalised at C-2, appear less likely to bind within the CypA active site. On the 
other hand, structures in which dirnedone is functionalised at oxygen were shown to 
be more likely to complex with CypA, although most of these structures have been 
marked as exhibiting 'possible binding' because the change in fluorescence 
measured was close to the range of experimental error. 
To our delight the first round of screening using the fluorescence assay highlighted a 
ligand, 42 (Table 3.1), with a dissociation constant (Kd) of 1 pM, a 22,000 fold 
improvement on the dissociation constant of the lead ligand, dimedone (K22 mM. 
A slightly higher, but comparable value (K22 pM) was obtained using the PPIase 
assay. Crystals of the CypA:42 complex were obtained by the co-crystallisation 
method. The crystal structure was refined to 1.85 A and is shown in Figure 3.3. 
Figure 3.3: Ligand 42 and CsA superimposed 
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The ligand 42 is shown in green. The X-ray structure of the CsA (white):CypA 
complex has been superimposed on the crystal structure of CypA:42. The main 
interactions between the dimedone lead and CypA, detailed in Chapter 1, have been 
preserved. Ligand 42 and CsA have similar positioning within the active site and 
several other interactions are conserved, as illustrated in Figure 3.4. 
Figure 3.4 
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Examination of the X-ray structure indicates space available within the CypA active 
site for further extension of the dimedone core (represented in Figure 3.4 by the red 
arrow). With this in mind, a route to 4-alkyldimedone derivatives was developed, in 
order to enable incorporation of these analogues into future ligands of the type 82 
(Scheme 3.1). This further extension of the dimedone core continued to allow for 
preservation of the main interactions of the ligand with the active site, and introduced 
the potential for additional binding interactions. 
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Berry ci al.'° reported the direct 4-alkylation of dimedone by alkyl bromides via the 
dianionic species 83, generated at -78 °C using lithium diisopropylamide and 
hexamethylphosphoric triamide (Scheme 3.2). 
Scheme 3.2 
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R= CH2CH=CH2, CH2CH2CH3, CH(CH3)2, cyclohexyl, benzyl 
Reaction of dimedone with benzyl bromide and allyl bromide under these conditions 
resulted in a complex mixture (>6 spots by TLC), which on purification by column 
chromatography, was found to be mainly dimedone starting material. Only a 
negligible yield of the desired 4-alkyl species could be recovered. 
Despite the literature precedence, none of the alkyl bromides studied could be 
coupled to the active dianionic dimedone with any great success. However, it was 
later discovered that treatment of dimedone with methyl iodide under the reported 
conditions resulted in formation of 4-methyldimedone in 55 % yield. The 
alkyldimedonc 85 was then coupled to N-benzyloxycarbonyl-L-valine 43 in the usual 
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86 87 
'H and '3C NMR of the crude reaction mixture indicated that a small amount of the 
diastereomeric mixture 86 might he present in addition to the expected diastereomers 
87. Separation of the two sets of regioisomers by column chromatography, isolated 
diastereorneric mixture 87, with recovery of only a trace amount of the more 
sterically hindered reaction products 86. The diastereomeric mixture 87 could not be 
purified further into the component diastereomers by chromatography or by chiral 
HPLC. 
Successful alkylation of dimedone by methyl iodide implied that cleaner reactions 
might be achieved by adapting the conditions reported by Berry et. al. Indeed, the 
results were much improved by addition of sodium iodide to the reaction in order to 
affect halogen exchange. Using the new conditions, analogues 88 and 89 were 
prepared from the corresponding bromides (Scheme 3.4). 
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The preparation and successful coupling of 4-alkyldimedones to protected amino 
acids could now be performed in reasonable yield. However, the alkyldimedone 
analogues were generated as a mixture of enantiomers, resulting in a diastereomeric 
mixture of ligands on coupling to the amino acid, as seen with the 4-methyldirnedone 
ligand 85 (Scheme 3.3). The possibility of separating the 4-alkyldimedone 
enantiomers prior to coupling therefore required to be investigated as the next step 
towards library generation. 
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3.3.1 Separation of 4-Alkyldimedone Enantiomers 
3.3.1.1 Chiral camphanic acid 
The first strategy studied was the resolution of enantiomers by coupling with a chiral 
camphanic acid species, followed by separation of the resulting diastereomers by 
column chromatography then cleavage of the chiral agent. (-)-Camphanic acid 
chloride 90 was coupled to 4-methyl dimedone 85 under basic conditions to produce 
the enol ester 91 as a 1:1 mixture of diastereomers, as shown in (Scheme 3.5). 
Attempted separation of the diastereorneric mixture 91 by column chromatography 
resulted in isolation of one diastereomer 91a (12 % yield of the most polar 
component by TLC, one peak by chiral HPLC) as a pure compound, and recovery of 
a quantity of the diastereomeric mixture. The camphanic acid group was cleaved 
using sodium methoxide in methanol. 
In genera!, successful separation of the diastereomers using the camphanic acid 
strategy was found to be very dependent on the alkyl group involved. Additionally, 
only the first diastereomer eluted from the column was ever recovered pure, with 
later fractions recovered as a mixture, indicating the difficulty of the separation. 
Scheme 3.5 
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3.3.1.2 Chiral alcohols 
Further investigation of the literature revealed that 4-alkylation of the enol ether 92 





LDA, THF, -78 °C, 2.5h 





It was proposed that this might be a cleaner method of generating the required 4-
alky1dimedones compared to the dianion chemistry, with the added advantage that it 
may be possible to use a chiral enol ether derivative to facilitate separation of the 
diastereomeric dimedone analogues. It would also be interesting to see if a chiral 
dimedone ether could direct the course of the reaction to alter the ratio of 
diastereomers obtained. 
Two chiral alcohols were tested using this strategy; [(IS)-endo]-(-)-borneol 96 and 
(IR)-endo-(+)-fenchol 93 (illustrated in Scheme 3.7). Although, as expected, cleaner 
dimedone alkylation reactions were observed in each case, the yields of 4-
alkyldimedones isolated were not improved, and separation of the mixtures 95 and 
98 into their component diastereomers, was again impossible by chromatography. It 
was also noted, by analysis of '3C NMIR spectra that an almost equal ratio of 
diastereomers was obtained in mixtures 95 and 98, indicating that no asymmetric 
induction of the alkylation by the chiral alcohol auxiliary occurred. This observation 
was confirmed by chiral HPLC of diastereomeric mixtures 95 and 98, in which both 
chromatographs showed two peaks of almost identical percentage area. The chiral 
alcohol group was successfully cleaved using aqueous acid to regenerate 4-benzyl 
dimedone 99. Although the separation of the chiral 4-alkyldimedone enol ether 
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scale required for generation of sufficient quantities for library synthesis. Separation 
of a racemic mixture of 4-benzyl dimedone 99 was not possible by chiral HPLC 
using the conditions investigated. 
Scheme 3.7 
93 OH 	 96 
Olz 
 TsOH 	 TsOH 
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3.3.1.3 Chiral ammonium salts 
Chiral resolution of the enantiorneric mixture was attempted by complexation of the 
dimedone 1,3-diketone system with a chiral ammonium salt. As described in 










The chiral ammonium fluoride salts 100-102 have been reported in the literature '2"3 
and appeared to be a reasonable starting point for complex formation. These 
fluorides can be prepared from the commercially available chloride or bromide salts. 
F 	 H 






100 R1 =H R2 =H R3 =OH 
101 R0Me,R2 = OH, R3 H 
Treatment of N-benzylcinchonidinium bromide 103 (Scheme 3.10) with CsF in 
FI20IMeCN, adapting conditions reported by Hayami et al. 
14  resulted in only a small 
percentage conversion to the fluoride. The fluoride salt 104 was instead formed by 
passing the bromide salt through Amberlite IRA 410 (01-f) ion exchange resin, 
previously treated with aqueous HF, as described by Pless. 
15 
 '9F NIVIR of the 
resulting white solid with 4-fluorophenol as internal standard, indicated complete 
conversion of the quaternary ammonium salt to the fluoride. The peak centred at 125 
ppm was in agreement with the reported chemical shifts of quaternary ammonium 
89 
\J<// C'-O-AO 105 
/ \ (2 equivalents) 
THF 
06 1 
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fluorides. 16  Comparison of the 'H NIvIR spectra of the salt 104 and the N-
benzylcinchonidinium bromide starting material 103 revealed that no decomposition 
of the N-benzylcinchonidinium moiety had taken place during the transformation. 
The 4-methylcyclohexyldimedone analogue 105, prepared by reaction of the 
dimedone dianion with bromornethylcyclohexane in the presence of NaT, was treated 
with 0.5 molar equivalents of the 1-alkylammonium fluoride 104, with the hope of 
achieving selective complexation of the salt with a single enantiomer of the 
dimedone analogue. 4-Methylcyclohexyldimedone was chosen as it was the only 
4-alkyldirnedone adduct isolated in crystalline form. Unfortunately, all signals in the 
'3C NvlIR spectra of the reaction mixture were found to correspond to those of the 
two starting materials 104 and 105 indicating that the desired salt complex 106 had 
not formed. Additionally, the '3C NMIR of the salt complex would be expected to 
show a peak at ca. 116 ppm corresponding to the enolic proton (H, Scheme 3.10) of 
the dimedone adduct, and no signals were present in this region of the spectrum. 
Scheme 3.10 
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At this point the emphasis of the project changed when the crystal structure of 
diastereomeric 87 bound to the CypA active site became available. This structure, 
obtained by crystal soaking and shown in Figure 3.5, indicated that binding of the 
diastereomeric 87 was very similar to that of the non-methylated ligand 42 described 
previously (Figure 3.3). 
Figure 3.5: Ligand 87 and CsA superimposed 
In Figure 3.5 the ligand 87 structure is shown in green and that of CsA is shown in 
white. The crystal structure of the CsA:CypA complex has been superimposed on 
that of the ligand 87:CypA complex. Again, the carboxybenzyloxy group is pointing 
up towards the Abu pocket, while the dimedone portion remains within the 
hydrophobic pocket. One slight difference observed is that the orientation of the 
dimedone dimethyl group is slightly altered so that one methyl group and the 
adjoining carbon-carbon bond of the dimedone ring form the shortest contacts with 
the hydrophobic binding pocket residues. It should be noted that although the CypA 
crystal was soaked in a solution of diastereomers 87, the crystal structure obtained 
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was bound within the active site. However, successful acquisition of a crystal 
structure using diastereomeric ligands, suggested that it would be possible to screen a 
library of ligand pairs existing as two diastereomers at the dimedone chiral centre. 
For this reason and partly due to time constraints, attempts to separate the 
enantiomeric 4-alkyldimedone building blocks were postponed at this stage in order 
to concentrate on library generation. 
3.4 	Introduction of Diversity to the Library Template 
In view of the type of structures exhibiting greatest binding affinity to CypA, the 
proposal was to generate a small diverse library of the form shown in Scheme 3.11. 
Study of the chemical routes developed thus far indicated three positions (X, Y, Z) 








X = amino protecting group 
Y = amino acid side chain 
Z = alkyl, aryl group 
3.4.1 Introduction of Diversity at Positions X and Y of Template 
3.4.1.1 Coupling/deprotection strategy 
The initial idea was to couple dimedone to a set of N-protected amino acids, followed 
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The use of N-tertbutyloxycarbonyl protected amino acids 81 proved problematic 
because treatment with trifluoroacetic acid in the deprotection step was found to 
cleave the enol ester, resulting in recovery of dimedone. TLC and mass spectrometry 
of the crude reaction mixture indicated the presence of the free amino acid L-valine 
(Scheme 3.13). Attempted cleavage using IM H2SO4 in EtOAc again resulted in 





+ HO 	NH 
81 	 (49%) 
The use of Fmoc protected amino acids was then investigated. In this case the idea 
was to cleave the Fmoc protecting group using piperidine. However, formation of the 
dimedone derivative 108 was only possible in low yield (12 %), rendering this route 
unsuitable for generation of library building blocks. 
In view of the instability of the dimedone enol ether linkage to the conditions 
investigated for the deprotection of amino acids, a new strategy was sought for the 
introduction of diversity at position x in the library template 107. It seemed sensible 
to change the order of synthetic steps in order to form the less-stable enol ester 
linkage in the final stage. 
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3.4.1.2 Protection/coupling strategies 
An alternative route for introduction of an amino acid N-protecting group has been 
achieved by reaction of the free amino acid with an acyl chloride using conditions 
reported by Hartwig et. al. 17  (Scheme 3.14). The amino acid 109 was refluxed with 
chiorotrimethylsilane in DCM for 2h before cooling to -15 °C. Treatment with 
benzoyl chloride and triethylamine at low temperature, followed by acidic work-up, 











/ I) (CF N)3 
pyridine 
/\ DCM 






cLIY1O LO  
111 
However, attempts to activate the carboxy terminus of the amino acid for further 
coupling, by acid fluoride formation and via the mixed anhydride were unsuccessful. 
This may be due to cyclisation of the activated N-acyl amino acid species 112 
resulting in oxazolone 113 formation (Scheme 3.15), evidence of which was 
observed by ESI MS (+ve) with a peak at 251 (ME[). Generation of the oxazolone 
would then prevent formation of the desired dimedone enol ester derivative 111. 
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Scheme 3.15 
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In order to avoid this problem, less reactive carbamates such as 115 (Scheme 3.16) 
were prepared by reaction of the chosen amino acid with a chloroformate 114 under 
identical conditions to those described previously. The N-methoxycarbonyl-L-valine 
115 shown in Scheme 3.16 was successfully coupled to dimedone forming the enol 
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Although the modified Hartwig route worked well for the formation of N-carbamoyl 
amino acids, the conditions were not ideal for library generation because of the 
heating and cooling steps involved. A search of the ISIS available chemicals 
database also raised concerns about the number and structural diversity of 
chioroformates that are commercially available. This would limit the diversity of 
95 
Scheme 3.17 
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library compounds that could potentially be prepared. In view of these drawbacks 
two new N-protection strategies were investigated. 
Kobayashi et al. 18  have reported that amino acid derivatives of kojic acid 117 can be 
prepared using DSC 118 and DMAP, as shown in Scheme 3.17. 
R = CH3  
CH(CH3)2 
CH2CH(CH3)2 
















The reaction proceeds by formation of the N-succinimidyl carbamate of kojic acid 
119, followed by succinimide displacement by the amino terminus of the amino acid 
to give the carbamate 120. The possibility of using different sets of nucleophiles for 
activation, such as alcohols or amines, forming carbamates 121 or ureas 122 
respectively, was investigated (Scheme 3.18). 
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Scheme 3.18 
R'OH 	 RNH2 
I 	I) DSC/DMAP 	 I i) DSC/DMAP 
ii) 	 ii) 
H2NJ..,,LL0 /NEt3 	 H2N,.JLOH  /NEt3 




OH 	 R''('OH 
0 R 	 0 R 
121 122 
The reaction conditions were tested in the coupling of two alcohols and two amines 
to L-valine (R=CH(CH3)2). The results are shown in Table 3.2. 
Table 3.2 
R"OH Result R!NH2 Result 
C)--OH 
40 % yield of 
O—NH2 
MS evidence 
desired carbamate of hydantoin 
O formation 
fl(i 	
OH ao O 
123 
)lOH 
51 % yield of No urea 





The alcohol protection reactions resulted in formation of the desired carbamate in 
reasonable yield. The advantage of using this strategy for carbamate formation, 
rather than the chloroformate sequence, is that there are a greater variety of available 
alcohols and the reaction conditions are milder and more amenable to automation. 
97 
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In the reactions of amines with L-valine, none of the desired urea product was 
observed but there was evidence of hydantoin formation in one case. The hydantoin 
126 results from cyclisation of the urea 125 as shown in Scheme 3.19. As this 
reaction would be even more likely on formation of the acyl fluoride 127 for 














Preparation of carbamate derivatives, such as 123 and 124, will be discussed further 
with regard to library preparation in Chapter 4. 
3.4.2 Introduction of Diversity at Position Z of Template 
A number of 4-alkyldimedone derivatives had now been prepared according to the 
procedure described in Scheme 3.4. Table 3.3 shows the binding data available on 
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Table 3.3 
Ligand Structure Interaction Resolution of 
with hCyp hCypA-Ligand 
Complex 
128 ND 2.70 A 
R:20.1 % 
EEEL Rfree:28.4 % 
116 70 M 1.8A 
.0 N IAO,6"0 
R:20.7% 
Rfree:26.8 % 
O /\  




89 45 jiM 1.90 A 
R:20.4% 
Rfree:26.0 % 

















130 ND 2.2 A 
R:19.7 % 1IIII Rfree:25.3 % 




* Kddetermined by PPIase assay 
ND not determined 
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3.5 Discussion 
In the following crystal structures of ligand:CypA complexes, the orientation of the 
CypA active site is the same in each case, so that some comparisons between 
different ligand binding conformations can be drawn (oxygen atoms are coloured red 
and nitrogen atoms blue). The ligand structures can be found in Table 3.3. 
3.5.1 Ligands 42, 128 and 116 
Figure 3.6: Ligand 128 
Determination of a dissociation constant of 70 j.tM for ligand 116, in the same 
micromolar range as that obtained for 42, reinforced the decision to focus on O-acyl 
dimedone derivatives. The crystal structures of ligands 128 and 116 complexed with 
CypA are shown in Figures 3.6 and 3.7 respectively. For comparison, the X-ray 
structure of the 42:CypA complex, viewing the active site in the same orientation as 
the other two ligand:CypA complexes, is shown in Figure 3.8. The dimedone groups 
in both ligand 42 and 116 appear to occupy a similar region of space within the 
binding site of CypA, as do the valine side chains of both ligands. The geminal 
dimethyl of dimedone in ligand 128 has a slightly different orientation, but 
100 
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positioning of the O-acyl side chain is similar to that of 42 and 116, as indicated by 
the superimposed crystal structures of all three complexes (Figure 3.9). 
Figure 3.7: Ligand 116 
Figure 3.8: Ligand 42 
101 
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Figure 3.9: Ligands 42, 116 and 128 superimposed 
3.5.2 Ligands 89 and 129 
Promising results were obtained from PPIase assay of the 4-alkyldimedone ligands 
85 (1(6= 134 .tM), 89 (Kd= 45 jiM), and 129 (1(6= 85 jtM). Although the dissociation 
constants are comparable, the crystal structures of the 89:CypA and 129:CypA 
complexes, Figures 3.10 and 3.11 respectively, reveal that the dimedone groups of 
these two ligands bind in quite different orientations. Superimposing the 89:CypA 
and 129:CypA complexes (Figure 3.12) does however indicate that the 4-alkyl side 
chains of both ligands are similarly positioned. 
The most surprising result is the 1(6= 134 tM measured for ligand 85 (compared with 
Kj= 22 mM for dimedone). Although the relative orientations of ligand 85 (Figure 
3.14) and dimedone within the binding site are different, the addition of a methyl 
group alone to the dimedone core, would not seem to account for such a large 
increase in binding affinity. However, observation of micromolar binding for the 
other 4-alkyldimedone ligands 89 and 129 may go some way towards authenticating 
this result. Future research should include a more detailed study on the binding of a 
combination of 4-, 5- and 6- mono-, di- and possibly even tn-methyl substituted 
102 
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cyclohexane 1,3-diones, along with repeated determination of the original dimedone 
dissociation constant under controlled conditions. 
Figure 3.10: Ligand 89 
Figure 3.11: Ligand 129 
103 
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Figure 3.12: Ligands 89 and 129 superimposed 
3.5.3 Ligands 85 and 87 
By comparison of the crystal structures of 87:CypA and 85:CypA complexes shown 
in Figures 3.13 and 3.14 respectively, it can be seen that 4-methyl dimedone is 
binding in an entirely different orientation when the O-acyl chain is present (ligand 
87). This observation is further clarified by superimposing the two complexes, as in 
Figure 3.15. This may reflect the relative importance of the interactions of the 
O-acyl chain and dimedone groups respectively, for binding to the protein. It is 
interesting to note that the O-acyl side chain of 87 appears to adopt a rather different 




Chapter 3 	 Results and Discussion II 
Figure 3.15: Ligands 85 and 87 superimposed 
3.5.4 Ligands 130 and 131 
The commercially available 4,4-dimethyl cyclohexane- 1 ,3-dione 130 was studied as 
a means of investigating the effect on CypA-binding of changing the position of the 
dimethyl group relative to the I ,3-dione in the cyclohexane ring. The isomer 130 
was found to complex with CypA in the orientation shown in Figure 3.16, in which 
the dimethyl group appears to be less closely associated with the hydrophobic 
binding pocket than in previous examples (Figure 3.8, ligand 42). Ligand 131 was 
prepared in the same way as ligand 42 but using 4,4-dimethyl cyclohexane-1,3-dione 
in place of dimedone, in order to further assess the importance of the O-acyl side 
chain on binding and its influence on cyclohexanedione orientation. Again the 
orientation of ligand 130 in the binding site is altered when the O-acyl chain is 
present, as in ligand 131, where the dimethyl group appears to point away from the 
hydrophobic pocket. The ligand 131:CypA complex is shown in Figure 3.17, and the 
two complexes superimposed are illustrated in Figure 3.18. Comparison of Figures 
3.8 and 3.17 reveal that the O-acyl chains of ligands 42 and 131 adopt similar 
conformations, despite attachment to different dimethylcyclohexane isomers. These 
Chapter 3 
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observations seem to suggest that the hydrophobic interaction of the ligand dimethyl 
group may not be the major protein-ligand interaction. 
Figure 3.16: Ligand 130 
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Figure 3.18: Ligands 130 and 131 superimposed 
3.6 	Initial Mass Spectrometry Results 
In experiments carried out by Sally Shirran at Edinburgh University, the binding of 
CsA to CypA was observed by electrospray mass spectrometry of a 1:1 mixture of 
CypA and CsA (20 jiM concentration of each) in 10 mM aqueous ammonium acetate 
solution, pH 6.9 (Figure 3.19). The experiment was repeated with the highest 
affinity dimedone-based ligand 42, and a mass corresponding to the CypA:42 
complex was observed, as shown in Figure 3.20. In this case, the ratio of 
CypA:ligand had to be increased to 1:50 in order to observe the complex, which is a 
reflection of the lower binding affinity of ligand 42 for CypA relative to that of CsA. 
However, some complications did arise. Firstly, the peak at m/z = 18247.3 in Figure 
3.20 corresponds to the mass expected for an acylated enzyme species which may be 
formed by cleavage of the weak enol ester bond in ligand 42 and acylation of CypA 
by the N-benzyloxycarbonyl-valinyl moiety. Secondly, the spectrum in Figure 3.20 
also shows peaks corresponding to complexation of two (m!z = 18763.5) and three 
(mlz = 19132.5) molecules of ligand 42 to CypA. Both of these observations suggest 




Results and Discussion II 
CypA at positions other than the active site may be occurring. The extent of 
denaturation of CypA under the ESI conditions has yet to be fully investigated and 
this study should be included in any future work on this screening method. 
Nevertheless, initial results indicated that it should be possible to screen a library of 
dimedone analogues by MS, since under identical experimental conditions to those 
used to observe the CypA:42 complex, any library members complexing to CypA 
with comparable or greater binding affinity to that of ligand 42, should be visible. 
For any ligands found to bind to CypA, the issues of specific active site binding, and 
enzyme acylation would require to be clarified at a later date. 
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Figure 3.19: Electrosnrav mass sDectrum of a 1:1 mixture of CypA and CsA. 
Figure 3.20: Electrospray mass spectrum of a 1:50 mixture of CypA and Ligand 42. 
CypA:ligand 42 1:5020 minutes 
550314K 1 (1,665) Sm (SG,x10.O0), Tr (15W:35000.13Mid) 
1B0123 
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3.7 Conclusion 
By examination of the data obtained from the various screening techniques 
employed, it can be seen that each technique provides rather different information on 
receptor-ligand binding. While X-ray crystallography is vital for information on the 
protein-ligand interactions and orientation of the ligand within the active site, 
quantitative measurement of binding dissociation constants was obtained from the 
PPIase assay. Although limited information on binding could be taken from the 
initial fluorescence assay results, the data from the first round of fluorescence 
screening altered the focus of ligand design towards producing O-acyl dimedone 
derivatives. From early crystallographic data it was initially proposed that the 
interaction between the geminal dimethyl group of dimedone and the CypA 
hydrophobic binding pocket was the major binding interaction. However, later 
crystal structures contradict this theory, since the binding of the geminal dimethyl 
group of dimedone analogues has been observed in various orientations depending 
on the 4-alkyl substituent and O-acyl side chain, in ligands exhibiting similar Kd's by 
PPIase assay. In conclusion, the ideal strategy is to employ a combination of all 
techniques in order to determine as much as possible about the binding of successive 
groups of ligands within the active site, in order to direct the focus of successive 
rounds of synthesis. In the meantime the decision was made to use mass 
spectrometry to screen the proposed dimedone-based library in the first instance, and 
then to study any promising ligands by PPIase assay and crystallography. The speed 
and ease of MS screening and the fact that minimal amounts of protein and ligand are 
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4 	Results and Discussion III 
4.1 	Library Synthesis 
4.1.1 Equipment 
Figure 4.1 is a representation of the robotic equipment recently purchased at 
Edinburgh University for parallel array preparation, synthesis, purification and analysis 
of combinatorial libraries. After the time-consuming installation had been completed, 
the aim was to prepare a small library of dimedone derivatives in order to become 
familiar with the operation of each system, and to illustrate the application of the full 
range of equipment to the synthesis of combinatorial libraries in the ligand design 
process. 
Figure 4.1 	Parallel Array Synthesis and Analysis 
Biotage 
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4.1.2 Proposed X-Y-Z Array 
The first step in library preparation was development of the synthetic route to the 
desired dimedone-based compounds of the form shown in Scheme 4.1. The decisions 
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4.2 	Automated Synthesis 
4.2.1 Step 1 
The next major challenge proved to be adaptation of the chosen synthetic route to 
make it suitable for automation. A test reaction for step 1 (Scheme 4.2) was carried 
out on the scale required for library synthesis, using various conditions. The reactions 
were monitored on the ZMD 4000 LCMS system, which was found to give a 
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reasonable indication of the reaction progress from the mass spectrum, including 








A number of difficulties were encountered at this stage: 
4.2.1.1 Dissolution of reagents in step 1 
It was anticipated that the Bodhan Neptune TM-MB Automated Workstation' would be 
suitable for the preparation and dispensing of reagents in step 1 of the library 
synthesis. This equipment is capable of tare weighing vials and dispensing solvent to 
prepare solutions of known concentration, when the compound molecular weights 
and required solution volumes have been entered. Thus, although the accurate 
weights and volumes are calculated by the computer, all solid reagents must be 
weighed out approximately by hand. In the automated synthesis of an array of 
compounds formed using common building blocks it is therefore important to be able 
to dispense all of the required reagents as solutions in an appropriate solvent, in order 
to minimize manual effort and time. 
Preparation of the carbamates in step 1 of the original synthetic route (Chapter 3, 
3.4.1.2) was initially carried out by dissolution of the appropriate alcohol, DSC and 
DMAP in DCM:MeCN (1:1) with stirring overnight at room temperature, followed 
by addition of solid amino acid and neat triethylaniine to the reaction mixture. This 
method was unsuitable for automation because all amino acids would have to be 
weighed out by hand, which, apart from proving time consuming, would not make full 
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use of the equipment available. It was therefore necessary to investigate different 
solvent systems for this reaction. 
In test reactions, the DSC and DMAP were weighed out into the reaction vessel and 
solvent added. Attempted preparation of separate stock solutions of DSC and DMAP 
in DCM:MeCN revealed that DSC is only soluble in this system when the base, 
DMA1P, is present. DSC did dissolve in DMSO, but the use of this solvent was 
avoided because of the high temperatures and longer periods required to remove it 
using the Christ system. A further difficulty was discovered in the selection of an 
appropriate solvent for amino acid dispensing. Valine was used in the test reaction. 
Of the numerous solvent systems investigated (MeCN, MeOH, DMF, ether, THF, 
dioxane, EtOAc, H2O and NaHCO3), 0.5 M NaFIC03 was found to be the most 
suitable, but only when triethylamine was added. Although an aqueous component 
proved necessary for amino acid dissolution, this caused problems on addition to the 
DCM:MeCN solution of DSC/DMAP, as the DCM and water are immiscible. 
Altering the solvent ratios did not solve this problem, but it was discovered that the 
DSC/DMAP could instead be dissolved in MeCN alone, which was compatible with 
the aqueous amino acid solution. There was some concern over using aqueous 
solvent with the DSC, as this reagent is easily hydrolysed, however experimental 
evidence (ZMD 4000 LCMS) indicated that formation of the activated succininiidyl 
carbonate alcohol species had occurred before addition of the aqueous amino acid 
solution. Also, sufficient reaction of this activated species with the amino acid took 
place before it was hydrolysed. All reagents could now be prepared as stock solutions 
of appropriate concentration, and remain in solution on mixing. Already, it became 
apparent that transferral of a seemingly facile reaction step for automation was not 
trivial. 
Stock solutions of each reagent were prepared in 20 ml reagent vials, the largest vials 
available on the Neptune, so several vials were required for some solutions. The 
reagents were dispensed into MiniBlocksTM 2  (the MiniBlock consists of 48 fitted 
tubes, each reversibly sealed at the narrow tube end by a pinching mechanism, and 
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encased in an insulated block which may be heated or cooled). The reactions were 
carried out on a 0.4 mmol scale in 1.8 ml total volume of solution. 
4.21.2 Aqueous work up of step 1 
It was anticipated that the Myriad® Allex liquid-liquid extraction system3 could be 
used for purification of the crude mixtures from step 1. The Allex is capable of 
separating a two phase system (aqueous and organic layers) by sensing the change in 
dielectric constant at the meniscus. It can then be programmed to transfer either the 
top or bottom layer to a different reaction vessel, with separation just above or just 
below the meniscus depending on the layer required. Two phase systems can also be 
mixed before separation. 
In the original preparation (Chapter 3 and Chapter 6, 6.2.5.21), the crude reaction 
mixture from step 1 was evaporated under reduced pressure to leave an oily residue, 
which was then dissolved in a saturated solution of NaHCO3 and washed with EtOAc. 
The aqueous layer was then acidified with 2 N HC1, before extracting with EtOAc and 
concentration under reduced pressure. 
The first problem in performing this protocol on the crude mixtures from step 1 was 
in transferral from the MiniBlock to the test tubes used on the Allex system. The 
difficulty lay in the limited compatibility of the volume and format of reagent vessels 
used in the MiniBlock, Allex and Christ systems. MiniBlock tubes can be drained into 
the commercially available 48 well polypropylene plates, which are compatible with 
the Christ and Allex. However, these plates have a well volume of 4 ml and the Allex 
requires at least 2 ml (possibly nearer 3 ml from experience) of solvent in each layer to 
facilitate accurate separation. This meant that the solutions would have to be 
transferred from the 48 well plate into larger test tubes on the Allex, following 
evaporation of the crude mixtures and redissolution in saturated NaHCO3 solution. 
Although this process can be automated, each transferal step does result in some loss 
of sample. Additionally, the concentrated crude samples from step 1 were fairly 
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insoluble in NaHCO3 solution, and would not dissolve without agitation, so it seemed 
that transferal would have to be done by hand. A further difficulty was that TLC of 
test reactions indicated some of the required carbamate product remained in the 
aqueous layer after EtOAc extraction. Repeated extractions and extraction with 
DCM were attempted, but always with a substantial loss of required product. The 
DCM also proved to be particularly difficult to work with on the Allex when 
performing small scale separations, because the high density caused it to drip out of 
the separation vessel during the settling time. Eventually it seemed more sensible to 
abandon purification on the Allex altogether. Step 2 of the reaction, involving 
activation of the amino acid C-terminus as the acyl fluoride, was attempted on the 
crude mixture. This involved evaporation of the MeCN:NaHCO3 solvent using the 
Christ, before attempted dissolution of the samples in DCM. Unfortunately, a white 
precipitate, insoluble in the DCM, resulted indicating that purification would be 
necessary at this stage. 
In the end, purification was achieved using the ZMD 4000 mass-directed LCMS 
system. This system is quoted to be capable of purif,ring a maximum of 50 mg/mi of 
crude sample (found to be less in practice), which meant that for library generation, 
four 15 minute runs per sample were required to yield enough of each carbamate for 
the next step. The step 1 samples were therefore prepared in four batches in the 
MiniBlocks and drained into four polypropylene 96 well plates for direct purification 
on the ZMD 4000. 96 well plates were used instead of 48 well as less of the sample is 
lost at the bottom of the smaller well during uptake by the ZMD. In the library 
synthesis samples were evaporated using the Christ system prior to storage, and then 
redissolved in MeCN:H20 (1:1) for purification. This avoided samples sitting around 
in solution for several days. Although this was a time consuming method of 
purification, more reasonable yields were obtained than from the Allex system, and all 
of the steps could be automated, with no need for manual transfer. 'H NMR of the 
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4.2.2 Steps 2 + 3 
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The original route developed for coupling of dimedone to the protected amino acid is 
shown in Scheme 4.3. The acyl fluoride 57 was prepared by treatment of Cbz-L-
valine with cyanuric fluoride in the presence of pyridine, with anhydrous DCM as 
solvent. The resulting crude mixture containing the required acyl fluoride 57, excess 
cyanuric fluoride, pyridine and cyanuric acid 132 by-product, was purified by aqueous 
work up. The organic layer was washed with ice-water before drying over MgSO4 
and evaporation under reduced pressure. The resulting acyl fluoride 57 was then 
coupled to dimedone in the presence of DIPEA, with DCM as solvent, as shown in 
step 3. 
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This route presented several problems for automation: 
Firstly, the cyanuric fluoride is very corrosive and consequently unsuitable for robotic 
dispensing. This reagent would therefore have to be added manually. Cyanuric 
fluoride is additionally a fairly unstable reagent, and formation of the acyl fluoride is 
very sensitive to the presence of water, which hinders this reaction. This is 
particularly problematic when we consider that the protected amino acids formed in 
step 1 are purified on the ZMD 4000 using an acetonitrile:water gradient. Even after 
Christ evaporation, it is likely that a small amount of water may remain in the sample. 
Another point to consider when designing chemistry for library preparation is that the 
samples will sit around in solution for much longer than when synthesizing an 
individual compound, because of the time taken to prepare and dispense the reagents 
to many vials. This is another reason for avoiding sensitive reagents. The aqueous 
wash presents similar difficulties to those discussed in step 1. Again, using DCM as 
solvent is not compatible with the Allex system on small volumes. 
Test reactions performed using Cbz-L-valine with cyanuric fluoride and pyridine in 
anhydrous ethyl acetate, indicated that this solvent could be used instead of DCM. 
However using the Allex to wash out the white cyanuric acid by-product from step 2 
was still impractical because of the time taken to transfer and wash larger (>10) 
numbers of samples: even when ice-water was used, the yields were greatly reduced. 
Formation of the acyl fluoride in step 2 was done in the MiniBlocks to allow cooling 
to —15 T. The MiniBlocks are fitted to enable samples to be filtered. It was thought 
that this facility could possibly be used to overcome the purification step, since the 
cyanuric acid by-product is relatively insoluble in the organic solvent used, forming a 
thick white suspension. Filtration of the MiniBlock samples into a 48 well plate did 
indeed remove much of this white precipitate, but problems were still encountered at 
the next stage. The amino acids from step 1 could be further dried by dissolution in 
ethyl acetate and transferal to MiniBlocks, followed by addition of a small quantity of 
MgSO4 and filtration, although this did require a couple of extra steps. Experiments 
were also performed with addition of a basic scavenger resin to the crude acyl fluoride 
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in order to remove the cyanuric acid. The tetramethylammonium polystyrene resin 






Attempts were made to proceed with the step 3 dimedone coupling without prior 
purification of the acyl fluoride. Progress of the reaction was again monitored by 
sampling of the crude reaction mixture and analysis on the ZMI) 4000. Although the 
required dimedone adduct was observed by mass spectrometry, and collected by the 
fraction collector, after evaporation of the solvent using the Christ, the sample was 
found to have decomposed. Removal of the solvent at lower temperatures still 
resulted in decomposition and was a longer procedure. Yields were found to improve 
by raising the temperature of each step. The cyanuric fluoride was added at 0 °C and 
the samples shaken at 10 °C for 40 mins before addition of dimedone and warming to 
room temperature. Alteration of the stoichiometry of reagents amino acid:cyanuric 
fluoride:pyridine was also investigated with no improvement in results. The use of 
NEt3 as an alternative base in steps 2 and 3 did not change the outcome of the 
reaction. Eventually, it was postulated that the impurities present from the acyl 
fluoride formation, consisting mainly of cyanuric acid, were somehow causing any 
dimedone adducts formed to decompose during the concentration step. 
In the end an alternative activation of the amino acid was required. In Chapter 2 the 
various activation methods originally investigated were described. Acyl fluoride 
formation produced the best yield, followed by formation of the mixed anhydride of 
the amino acid by treatment with chioroformate. The main disadvantage of the 
chioroformate reaction was that both carbonyl groups of the anhydride were attacked 
by dimedone, albeit not to the same extent, resulting in formation of the dimedone by-
product 51 (Scheme 4.4). The by-product 51 was impossible to remove fully by 
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library scale as shown in Scheme 4.4, and analysed on the ZMID 4000, the required 
product 42 was separated from by-product 51 under these conditions. 
Scheme 4.4 
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0OT OH NEtS 
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51 	 0 	42 
Full experimental details of the final automated synthetic route (Scheme 4.5) are 
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4.3 	Selection of Building Blocks 
4.3.1 Alcohols 
A total of 23 alcohols were tested as potential library components. The reactions 
were carried out on a 0.4 mmol scale, since a 50 % yield would then result in around 
50 mg carbamate product of average molecular weight 250 amu. The ZMD 4000 can 
purify a maximum of 50 mg/mi of crude sample, with a maximum injection of 2 ml. 
Alcohols were chosen from those available in the lab. A number of benzyl derivatives 
were chosen because the highest affinity ligand identified at this stage included an N-
Cbz-protecting group on the amino acid. The range was also weighted towards 
relatively hydrophobic alcohols, as crystallographic data thus far indicated a 
preference for hydrophobic groups in the region of the active site where the alcohol 
derived portion of the ligand would potentially bind. However, some hydrophilic 
structures were included as it would be premature to exclude these completely at this 
stage. The alcohols were reacted with a standard amino acid: L-valine was chosen, as 
again, this was the amino acid component in the highest affinity ligand. The 








X"° N~"A 0H 
The crude reaction mixture was then analysed using the ZMID 4000. The percentage 
yield of carbamate product obtained in each reaction was estimated from the total ion 
count trace of the mass spectrum using the ZMD 4000 software. The list of alcohols 
tested and yields estimated are shown Table 4.1. In cases where none of the required 
product was observed by MS, the alcohol has been marked as a fail. A couple of 
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those tested were found to be insoluble or precipitated out at some stage in the 
reaction. These are also unsuitable for library generation where all reagents are 
dispensed in solution. The hydroxybenzyl alcohols displayed solubility problems so 
these were discounted. 3-Methylbenzyl alcohol was selected as this alcohol gave a 
higher yield of carbamate than methoxy substituted or benzyl alcohol itself. Reaction 
with glycerol formyl resulted in the greatest yield of protected valine, but 
unfortunately this reagent was found to consist of a mixture of 3,5-dioxo and 4,6-
dioxocyclohexanol, which made it unsuitable for inclusion in the library. Allyl alcohol 
and 2-methyl prop-2-enol were selected on the basis of yield, along with cyclohexanol 
and tryptophol. Ethyl glycolate was selected as a more hydrophilic example. This 
gave six alcohols of varying size and functionality. The estimated yields were not 
particularly high (23-57 %), but attempts were made to further optimise the reaction 
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Table 4.1 
Alcohol Structure Y Comment Alcohol Structure V Comment 
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4.3.2 Amino Acids 
Selection of the amino acids for the library was a more straightforward process. Only 
those amino acids which do not require side chain protection were desirable, in order 
to avoid additional protection and deprotection steps in the synthesis. The acids 
shown in Table 4.2 were tested by reaction with 2-methyl prop-2-enol, one of the six 
alcohols selected previously, using the conditions shown in Scheme 4.7. Again, the 
reactions were monitored using the ZMD 4000. The hydroxy substituted amino 
acids, tyrosine and serine both exhibited solubility problems so were not selected. 
Glycine surprisingly did not form any of the carbamate with 2-methyl prop-2-enol. 
Two amino acid substitutes, 1-amino-i -cyclopentane carboxylic acid and 2-amino-
isobutyric acid, were also included and selected, bringing the total to six acids. The 
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Table 4.2 
Acid Structure Y Comment Acid Structure Y Comment 
glycine 0 0 fail serine 0 
H2N 
0 fail  
H 2N OH OH 
OH 












H2N .JI OH 









31 selected 2-amino- 0 








4.3.3 Dimedone Analogues 
Dimedone and three of the dimedone analogues that could be prepared in sufficient 
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Table 4.3 
Dimedone Analogue Structure Comments 
5,5-dimethyl-cyclohexane- I ,3-dione selected
(commercially 
0 available) 
4,5,5-trimethyl-cyclohexane- 1,3- insufficient yield 
dione (85) 
O'd 
(2,2-dimethyl-4,6-dioxo-cyclohexyl)- insufficient purity 
acetic acid methyl ester (89) 
OA---O—YO 
4-allyl-5,5-dimethyl-cyclohexane- selected 








5,5-dimethyl-4-(3-phenyl-aIIyl)- insufficient purity 
cyclohexane-I ,3-dione (129) 
4.4 	Proposed 144 Member Library 
A total of 6 alcohols (Table 4.1), 6 acids (Table 4.2) and 4 dimedone analogues 
(Table 4.3) were selected to generate the proposed 6 x 6 x 4 = 144 member library. 
Step 1 therefore involved the synthesis of 6 x 6 = 36 carbamates. The carbamate 
synthesis was done in four batches (as a consequence of the maximum purification 
capacity of the ZMD 4000 described previously) to produce four plates of 36 
carbamates. Each plate was then reacted with one of the four dimedone analogues, in 
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theory to yield a 144 member library, not accounting for any reaction failures. A 
rehearsal step was included prior to library synthesis. 
The ZMID 4000 system was very useful for investigating all components of the crude 
mixture in order to determine optimum reaction stoichiometries and times. The amino 
acid protection step (step 1) was studied using this method. In most cases the 
activated alcohol was observed by mass spectrometry, indicating that the reaction 
with DSC was occurring, although some alcohol starting material was seen in certain 
reactions where the coupling did not go to completion. Observation of the reaction 
intermediate also suggested that the coupling of the activated alcohol to the amino 
acid did not go to completion. The reaction stoichiometries, concentrations and times 
were altered resulting in a small improvement in the yields obtained. However, it 
became apparent that a lot of the reduction in yield was due to the method of 
purification on the ZMD 4000. The mass directed fraction collection begins only 
when detection of the required ion reaches a certain intensity threshold. This 
threshold can be reduced but not without compromising the purity of the sample 
obtained. 
4.5 	Rehearsal of Step 1 
In order to obtain a greater indication of the yields and purity of the protected amino 
acids to be synthesized in step 1 a rehearsal stage was included. This rehearsal 
involved reacting all 6 selected alcohols with a single amino acid (L-valine), then 
reacting all 6 selected acids with a single alcohol (2-methyl prop-2-enol), under the 
conditions established for library synthesis (detailed in Chapter 6, 6.2.7). Table 4.4 
shows the proposed set of 36 carbamates with the shaded boxes representing the 
rehearsal compounds. The percentage yield by mass recovered for each of the 
rehearsal compounds is shown in Table 4.4. 
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-. 
ally] alcohol 54 
cyclohexanol 45 
3-methyl 
benzyl alcohol 40 
2-methyl prop-2-enol 48 45 31 12 17 47 
tryptophol 20 
ethyl glycolate 10 
Average yield = 34 % 
The yields obtained were moderate to low, which was mainly attributed to the ZMD 
4000 purification step, but also to the different reactivities of the various components 
tested. However, 'H and '3C NMR analysis of the carbamates formed indicated that 
most were> 80 % pure, with DMAIP being the main impurity. The NMR data has 
been included in Chapter 6, 6.2.6. Due to time constraints, the decision was made to 
proceed with the library generation, since the recovery of lower yields of each 
compound than had been hoped should still produce sufficient quantities for CypA 
binding analysis by MS, especially if the purity was good. 
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Table 4.5: Carbamates 
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Table 4.5 continued. 
No. Structure No. Structure No. Structure 
154 ° 
Of><OH 
















4.6 	Results of Library Generation 
Of 144 possible compounds from the proposed library, 82 final library members were 
detected after step 2 of the synthesis and collected using the ZMD 4000. Some of the 
reactions failed in step 1, generation of the carbamates. In some cases the yields of 
carbamate were very low, and separate purification of each 36 carbamate plate meant 
that certain carbamates were not present in all four plates. Overall, only 126 of the 
possible 144 carbamates were detected by the ZIvID 4000 after step 1 of the synthesis. 
Graph 4.1 
Distribution of successful samples 
No. of 
samples 
valine 	leucine 	phenylalanine 	1-amino-1- 	2-amino 	alanirie 
cyclopentane isobutyric acid 
carboxylic acid 
UallyI alcohol •cyclohexanol D3-methyl benzyl alcohol 02-methyl prop-2-enol •tryptophol Dethyl glycolatej 
132 
Chapter 4 	 Results and Discussion III 
Graph 4.1 shows the distribution of carbamate samples synthesised across the four 
plates: for example, if a given carbamate is present in each plate then the graph shows 
a value of 4 samples. From Graph 4.1 it is obvious that carbamates containing ethyl 
glycolate were much less successful than those generated using the other alcohols. 
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carboxylic acid 
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Graph 4.2 indicates the mass distribution of the carbamates synthesised, taken as an 
average over the four plates. As indicated in Graph 4.1, the carbamates containing 
ethyl glycolate were shown to be present in very low yield. Additionally, carbamates 
synthesised from 1-amino-1-cyclopentane carboxylic acid or 2-amino isobutyric acid 
were generally less successful with lower yields recovered. 
For brevity the following sections only report the final library compounds generated in 
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4.6.1 Plate 1 - Reaction of Carbamates with Dimedone 
Table 4.6 shows the yields in mg from the reaction of the carbamates in plate 1 with 
dimedone. 25 final library members were synthesised from this plate. The shaded 
boxes represent failed reactions. Reaction of carbamates with dimedone on average 














allyl alcohol 8 9 8 9 
cyclohexanol 8 9 6 6 
3-methyl 
benzyl alcohol 7 8 8 12 9 12 
2-methyl prop-2-enol0
-0 6 8 5 7 
tryptophol 7 9 7 7 3 11 
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4.6.2 Plate 2 - Reaction of Carbamates with 4-Allyl-5,5-dimethyl-cyclohexane-
1,3-dione (88) 
Table 4.7 shows the yields in mg from the reaction of the carbamates in plate 2 with 
4-allyl-5,5-dimethyl-cyclohexane-1,3-dione 88. 	26 final library members were 










allyl alcohol 12 6 6 8 4 
cyclohexanol 7 2 3 3 
3-methyl 
benzyl alcohol 7 4 
2-methyl prop-2-enol 3 2 2 6 4 
tryptophol 33 6 5 
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4.6.3 Plate 3 - Reaction of Carbamates with 4-Benzyl-5,5-dimethyl-cyclo-
hexane-1,3-dione (99) 
Table 4.8 shows the yields in mg from the reaction of the carbamates in plate 3 with 
4-benzyl-5,5-dimethyl-cyclohexane-1,3-dione 99. 20 final library members were 










allyl alcohol 8 6 3 
cyclohexanol 4 3 3 3 
3-methyl 
benzyl alcohol 5 4 9 4 2 
2-methyl prop-2-enol 2 2 2 6 3 
tryptophol 3 6 5 
ethyl glycolate 
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4.6.4 Plate 4 - Reaction of Carbamates with 4-Cyclohexylmethyl-5,5-dimethyl-
cyclohexane-1,3-dione (105) 
Table 4.9 shows the yields in mg from the reaction of the carbamates in plate 4 with 
4-cyclohexy1methy1-5,5-dimethy1-cyc1ohexane 1,3 -dione 105. 	11 final library 
members were synthesised from this plate, with dimedone analogue 105 proving to be 






ally! alcohol 2 2 
cyclohexanol 8 2 
3-methyl 
benzyl alcohol 4 34 2 
2-methyl prop-2-enol 
tryptophol I 2 2 
ethyl glycolate 
Graph 4.3 shows the distribution of successful samples from step 2 with regard to the 
carbamate used. For each carbamate four products are possible from the reaction 
(step 2) with dimedone and its three derivatives. So, for example, the carbamate 
prepared from valine and allyl alcohol was found to react with only one of the 
dimedone analogues (the dimedone analogues have not been specifically identified in 
Graph 4.3). Interestingly, Graph 4.3 indicates that some of the ethyl glycolate 
containing carbamates have reacted in step 2 to form the desired library members 
despite the poor yields obtained in step 1. Additionally, the low yields of carbamates 
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building blocks, have not prevented these carbamates from reacting with the 
dimedone analogues in step 2. The alanine containing carbamates were less 
successful. 
Graph 4.3 
Distribution of successful library samples 
valine 	leucine 	phenylalanine 	1-amino-1- 	2-amino 	alanine 
cyclopentane isobutyric acid 
carboxylic acid 
allyl alcohol • cyclohexanol D 3-methyl benzyt alcohol D 2-methyl prop-2-enol •tryptophol 0 ethyl glycolate 
Overall, the final yields of the library were very low. This was partly due to 
insufficient optimisation of the chemical route with regard to automated synthesis, and 
also because of the inclusion of two ZMD 4000 purification steps, which were found 
to result in appreciable loss of material. The purity of the final library also required to 
be investigated. The initial indication of purity was obtained from the mass spectrum 
recorded during ZMD 4000 purification. In general the quantities of material 
recovered were too small to acquire reliable NMR data from the 200 MHz NMR. 
The mass spectrometry screening of the library for binding to CypA involved 
dissolution of the samples for dispensing to the assay. A second mass spectrum of 
each sample was run at this stage. From these spectra and the original ZMI) 4000 
LCMS data, the purity of each of the library samples was estimated and the results are 
shown in Table 4.10 along with the chemical structures of the final 82 library 
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Table 4.10 
Structure Yield Purity Structure Yield Purity 
(mg) (%) (mg) (%) 
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Estimated Purity 	% of library 
A=75-100% 	 15.9 
B=50-74% 	 15.9 
C = 25-49 % 	 25.6 
D = 0-24 % 	 42.7 
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4.7 	Mass Spectrometry Results 
Using identical conditions to those used to obtain the mass spectrum for the CypA:42 
complex described in Section 3.6, the 82 member library was screened for binding to 
CypA, with the aim of identifiing any compounds with equivalent or greater binding 
affinity for CypA than ligand 42. The screening experiments were carried out by Sally 
Shirran. The CypA (20 iM concentration) and ligand (1 mM, assuming 100 % 
purity) were dissolved in 10 mM ammonium acetate pIll 6.9. After standing at room 
temperature for 30 min the CypA/ligand mixture was infused into the mass 
spectrometer at 8[d/min using an infusion pump. The samples were analysed at 50 
CV in positive ion electrospray. One compound, ligand Eli was observed to form a 
complex with CypA (Figure 4.3). Again, a peak corresponding to the mass expected 
for an acylated CypA species was observed (mlz = 18250). 
Figure 4.2: Electrospray mass spectrum of Eli 
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Figure 4.3: Electrospray mass spectrum of a 1:50 mixture of CypA and Eli 
.10 
0010246 	3.063; SmOG. 2,115 00;, Tr (1674 3063.1 00L*) 
1001 	 112i CypA 
CypA:E1 I 
17000 	17200 	17400 	17600 	17800 	08703 	18230 	18400 	1 
Star 00* 
261n? 
A 	1l3.18±3 18 
143 
Chapter 4 	 Results and Discussion III 
4.8 Discussion 
Unfortunately it was difficult to draw many conclusions from the library screening. 
The assay is still in the development stage and requires further optimisation. 
Additionally, the purity of the final 82 member library was considerably lower than 
expected. The amounts of ligand used against the CypA assumed 100 % purity, so in 
some cases the ligand concentration was a factor of 5 lower than that expected, which 
obviously affects whether sufficient CypA:ligand complex was formed for detection 
by mass spectrometry. Future work will include repeating the assay with ligand 
concentrations taking into account the purity of the samples. Additionally, further 
work is required to determine the extent of denaturation of CypA under ESI 
experimental conditions and to investigate the extent to which specific active site 
binding has occurred. In conclusion, the exercise of preparing a library using the 
automated equipment and taking the final compounds through to screening was 
invaluable experience for designing and synthesising future arrays of small molecules. 
Also, it was promising to observe the CypA:ligand complex in the MS screening, 
confirming that the principle of using mass spectrometry as an initial screen was still 
viable, although further investigation would be required both to opthnise the 
chemistry for automation in order to increase the yields and purity of the final library, 
and to increase the reliability of the MS assay. Further studies should include 
resynthesis of the ligand Eli and analysis using the PPIase assay and crystal 
soaking/crystallography techniques. 
4.9 	Suggestions for Further Work 
Replacement of the enol ester linkage of the high affinity ligand 42 with an enol amide 
linkage, using the route shown in Scheme 4.8, would be an interesting method of 
altering the order of hydrogen bond donor/acceptor atoms along the ligand backbone. 
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5 	Results and Discussion IV 
5.1 	Backbone Amide Linkers 
Since the development of the first resin-bound peptide synthesis strategy by 
Merrifield in 19631,  numerous methods have been reported for the generation of 
peptide libraries on solid support, including conventional C-terminal peptide 
attachment and the less widely used N-terminal attachment to resin. A third and 
more recent strategy concerns attachment of the peptide to the support via the amide 
bond. Linkers of this type, known as backbone amide linkers (BAL), have been 
relatively unexplored in comparison to C- or N-terminal linkers. Examples include 
the strategy reported by Jensen et al.2 where the growing peptide chain is anchored 
through a backbone nitrogen (Scheme 5.1). The BAL was prepared by coupling 5-
(4-formyl-3,5-dimethoxyphenoxy)valeric acid 168 to amino polystyrene or amino 
PEG polystyrene resin, forming the supported aldehyde species 169. On-resin 
reductive amination with an amino acid residue (or an appropriately modified 
derivative) afforded the resin-bound amino acid 170. 	N-acylation by an 
appropriately protected second amino acid residue forms the dipeptidyl unit 171, 
linked to the support through the backbone amide nitrogen. The peptide can be 
cleaved from support by acidolysis using TFA. A number of linear peptides with C-
terminal modifications, including alcohols, aldehydes, esters and NN-dialkylamides, 
were prepared using this strategy, with incorporation of different amino acid 
derivatives. These linkers have the advantage that the peptide chain can be extended 
in either direction, allowing greater flexibility in modification of the termini, and an 
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5.2 	Applications of Dimedone Chemistry 
5.2.1 Amide Linker 
Development of routes for the incorporation of dimedone into a peptide chain 
described in Chapter 2, involved synthesis of ligands of the form 59 (Scheme 5.2). 
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Although initial screening results indicated that ligands of this type were unable to 
bind to CypA, study of the BAL strategy described above led to the exploration of 
other possible applications of this chemistry. More specifically, the idea was to 
investigate the use of the dimedone system for anchoring a peptide to solid support. 
Tethering the cyclohexane-1,3-dione system to resin using an additional ring 
functionality, as shown in 172, Scheme 5.2, results in a peptide linked to support 
effectively via the carbonyl of a backbone amide. Oxidative cleavage of the double 
bond connecting the dimedone linker to the peptide would be required to reveal the 
carbonyl and release the peptide 173 from support. Preliminary solution phase 
studies on the ligand 59, indicated that it was possible to oxidatively cleave the 
methylene double bond using sodium periodate, although yields of recovered 

















The first requirement for this strategy is generation of a resin-bound cyclohexane-
1,3-dione species. Once formed, it seemed acceptable to envisage incorporation of 
the dione system into a peptide using the chemistry previously developed, and shown 
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in Scheme 5.3. An additional advantage of this strategy is that the first amino acid 
attached to support is activated for further coupling by conjugation with the 
cyclohexanedione system, as in species 175. In this manner the cyclohexanedione 
functions as both a coupling agent and linker. It should be noted that racemisation of 
the amino acid initially coupled to dimedone (L-valine in 59) would be a limitation in 
the synthesis of peptides by this method. One solution would be to limit residues at 
this position to glycine or a,a-disubstituted amino acids. Alternatively, the route 
may be more applicable to the solid phase synthesis of low molecular weight, amide-
containing non-peptidic molecules. 
Scheme 5.3 
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a) (CFN)3, pyridine, DCM, -10 °C; b) i) NN-diisopropylethylamine, DCM, ii) acetone cyanohydrin, 
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5.2.2 Scavenger Resin 
Another useful exploitation of the reactivity of the 1,3-dicarbonyl functionality 
would be to employ this group as a universal resin-bound scavenger. Cyclohexane-
1 ,3-diones have previously been shown to react with amine nucleophiles at a 
carbonyl group to form enamines (Chapter 2, 2.2.7.1), and the enolic nature of the 
1 ,3-dione system means that it has potential to react with both hard and soft 
electrophiles, at the 0- and C- sites respectively. Scheme 5.4 illustrates potential 
scavenging reactions of an immobilised dione with primary amines, aldehydes and 
allyl cations (dimedone is commonly employed for the solution capture of allyl 
cations in palladium catalysed abc deprotection).3 If a method could be found for 
facile synthesis of cyclohexane- 1 ,3-dione on resin, this species will have huge scope 
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5.2.3 Aim 
The objectives of this work were two-fold. Firstly, a route to resin-bound 
cyclohexane-1,3-diones was required. Secondly, a reliable means of cleavage of the 
peptide from solid support was sought. 
5.3 	Route to Resin-Bound Cyclohexane-1,3-diones 
5.3.1 Background 
A few examples of cyclohexanedione-based linkers have been reported. Graf von 
Roedern4 used immobilised cyclohexanedione 176 in the demonstration of an HPLC-
based method for characterisation of chemical libraries. A small library of 20 
compounds was synthesised on solid support using four different aldehydes (R) and 
five different vinyl ethers (R), as shown in Scheme 5.5. A computer algorithm was 
then used to assign HPLC peaks to their corresponding library compounds by 
correlation of product retention times with the different substituents in variable 
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R1  = n-octyl, i-butyl, 2-thiophenyl, i-propyl 
R2 = 0-ethyl, O(CH2)40H, O-t-butyl, N(CH3)Ac, 0-cyclohexyl 
Bycroft et al.5 have described a primary amine linker based on their 1-(4,4-dimethyl-
2,6-dioxo-cyclohexylidene)ethyl (Dde) protecting group strategy (Scheme 5.6). 
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They first prepared a more base-stable Dde derivative 178, by acylation of dimedone 
with the mono-protected dicarboxylic acid 177. This provided a Dde unit with a 
terminal carboxylic acid on the side chain for coupling to the support, and an 
adjustable spacer arm which imparts base stability for the amino attachment. The 2-
acy1dimedone 178 was then masked with 2-aminopropane and deprotected to yield 
enamine 179, which was secured onto TG amino resin. Coupling in 2-aminopropane 
prevented unwanted amidation of the Dde centre by the support. The utility of the 
linker 180 was illustrated in the synthesis of pseudoargiopinine III 183, a 
pharmacologically active component of spider venom. Transamination of the linker 
180 with 1 ,5-pentanediamine resulted in enamine 181 which was coupled to Fmoc-L-
Asn(Trt)-OH using standard peptide chemistry. The Fmoc group was removed using 
piperidine and the product acylated with indole-3-acetic acid to form 182. 
Acidolysis removed the trityl side chain protection and the final product 183 was 










Results and Discussion IV 
Scheme 5.6 





















a) Fmoc-Asn(Trt)-OFI/TBTU/HOBt/DIPEA; b) 20 % v/v piperidine in DMF; c) indole-3-acetic 
acidITBTU/HOBt/DIPEA; d) 50 % v/v TFA in DCM/T[PS/H20; e) 5 % v/v N}17NH2 or 10 % v/v 
C3H7NT-12 in THF/H20 (1:1). 
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A variation of the cyclohexanedione linker 184 (Scheme 5.7) has also been applied 
to the synthesis of oligosaccharides.6 Aminosugars have been immobilised directly, 
via the formation of a vinylogous amide bond, as in the resin—bound sugar 185. 
Alternatively the linker 184 may be derivatised by reaction with p-aminobenzyl 
alcohol to enable the formation of 0-linkages to saccharides, as in species 186. After 
cleavage from the resin using NH3, the resulting p-aminobenzylglyco side is N-
acetylated to enable cleavage of the anomeric p-aminobenzyl group with DDQ to 
afford the glycosylated saccharide 187. The system is stable to a variety of 
carboydrate reaction conditions and cleavage of the fmal product is easily performed 
using ammonia. It is also possible to regenerate the immobilised linker 188 for 
further use by treatment with hydroxide. 
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A further Dde-based linker for the attachment of primary amines to solid support, 
illustrated in Figure 5. 1, has been described by Bannwarth et al.7 The linker is again 
stable towards acidic conditions (TFA) and basic conditions (piperidine, DBU) as 




i) combinatorial synthesis 




The synthesis of the linker molecule 194 is described in Scheme 5.8. Birch reduction 
of 3,5-dimethoxybenzoic acid 189, followed by methylation provided the bis enol 
ether as the methyl ester 190. Treatment with HCl resulted in the formation of the 
3,5-dioxo-1-methyl-cyclohexane carboxylic methyl ester 191 which was acylated to 
form the O-acyl derivative 192. DMAP-catalysed rearrangement of the O-acyl 
species 192 afforded the 4-acetyl-3,5-dioxo- 1 -methyl-cyclohexane carboxylic acid 
methyl ester 193. The methyl ester of 193 was converted to the free acid to form the 
4-acetyl-3,5-dioxo-1-methylcyclohexane carboxylic acid linker (AI)CC linker) 194. 
Application of the linker was demonstrated by coupling in phenylalanine methyl 
ester to form the linker 195, which was attached to amino polystyrene resin using 
TPTU to yield the resin-bound amino acid 196. 	Successful cleavage of 
L-phenylalanine methyl ester 198 was performed using 2 % hydrazine hydride 
solution, with formation of the resin-bound oxotetrahydro-1-H indazole derivative 
197. 
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The Bannwarth method of attachment of a cyclohexane- 1 ,3-dione species was 
particularly relevant to the proposed amide linker, since the cyclohexanedione is 
functionalised and immobilised via the 5-position, leaving the 1 ,3-dione system free 
for coupling to amino acids. However, the Bannwarth strategy involves coupling of 
the amine (phenylalanine in the example) to the acyl-dimedone linker 194 prior to 
immobilisation on resin. This was done by formation of the C-acyl-dimedone 193 by 
DMAP catalysed thermal rearrangement of the O-acyl species. Earlier work on 
dimedone reactions (Chapter 2) revealed that this rearrangement is not applicable 
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when the acylating agent is an amino acid. Additionally, a more general method for 
generation of resin-bound cyclohexanedione would be required for scavenger 
applications. Thus, the general principles of the Bannwarth linker strategy required 
to be adapted by alteration of the coupling events, in order to form an 
unfunctionalised cyclohexanedione system on resin. 
A number of routes, illustrated in Scheme 5.9, were considered for the attachment of 
diones to resin. 
Scheme 5.9 
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In a very general sense, one might employ a nucleophilic resin with a 
cyclohexanedione bearing electrophilic functionality (Routes 1 and 2), as in the 
Bannwarth example. Alternatively an electrophilic resin might be coupled to a 
cyclohexanedione with nucleophilic functionality (Route 3). This route could be 
immediately discounted because of the self-condensation problems associated with 
the unprotected amino functionality and carbonyl functionality of a 5-amino 
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cyclohexane- 1 ,3-dione 200. An amide linkage, as seen in Route 1 was deemed more 
favourable than the corresponding ester linkage (Route 2) for greater stability to a 
wider variety of reagents. 	The obvious problem with coupling 5- 
carboxycyclohexane-1,3-dione 199 to a nucleophilic amino resin is that attack of the 
carbonyl groups is likely in addition to the required amide formation. Indeed, this 
outcome was verified experimentally. The 5-carboxycyclohexen-1,3-dione 203 was 
prepared by Birch reduction of 3,4,5-trimethoxy benzoic acid 201 via hydrolysis of 
the intermediate bis-enol ether 202, according to the procedure reported by Kuehne 
et al.8 (Scheme 5.10). Attempted coupling of the acid 203 to aminomethyl 
polystyrene resin was performed using TPTU/DIPEA. Comparison of the JR of the 
reacted resin with that of aminomethyl resin starting material and that of acid 203, 
indicated that some coupling had occurred as peaks were observed in the carbonyl 
region. The absence of immobilised free primary amine was confirmed by the 
Kaiser resin test.9 However, gel '3C NIVIR of the reacted resin was incompatible with 
the desired product. Further investigation of this reaction by coupling the acid 203 to 
benzylamine in solution, revealed that di-addition of the amine to both the acid and 
one of the carbonyl groups was occurring to form the enamine 204. This problem 
did not occur in the Bannwarth linker synthesis because the cyclohexanedione 
species was acylated before attachment to the amino resin, which obviously alters the 
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Scheme 5.10 
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However, returning to the Birch reduction route to cyclohexanediones, it was 
postulated that the bis-enol ether species 202 could be regarded as a protected 
dicarbonyl compound, which might be attached to support and then hydrolysed to the 
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Unfortunately, the test reaction to couple benzylamine to the bis-enol ether 202 under 
the required conditions, resulted only in recovery of the benzyl amide 206 in 13 % 
yield (Scheme 5.12). It was thought that this result may be attributed to the presence 
of 3,5-dimethoxybenzoic acid remaining as an impurity from the partial reduction of 
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3,4,5-trimethoxybenzoic acid 201 in the Birch reduction step (Scheme 5.10). None 








Returning again to the Bannwarth linker, it was observed that this route used the 5-
methylated analogue 190 of the bis-enol ether system. The next step was to try 
forming the 5-methyl derivative of 202, for reaction with benzylamine. No detailed 
experimental details were given for formation of ester 190 in the Bannwarth 
synthesis, other than reporting that the Birch reduction was followed by quenching 
with methyl iodide. A search of the literature resulted in several reported methods 




The method reported by Liepa et al.'° introduced another important consideration: 
namely that if successful attachment of the dione linker to support was achieved via 
an amide linkage, then this linkage could interfere in later coupling of electrophilic 
species (eg activated acids) to the dione, with the possibility of amide N-acylation. 
The aim was therefore to attempt coupling of the bis-enol ether species 207 as the 
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The dihydrodimethoxy species 202 was again prepared from 3,4,5-trimethoxy 
benzoic acid 201, following the procedure reported by Kuehne et al., using sodium in 
liquid ammonia with ethanol as the proton source, followed by acidic work-up. 
Methylation at the 5-position was attempted using potassium amide and methyl 
iodide, followed by acidification, according to the route reported by Chapman et al." 
Unexpectedly, this resulted in partial hydrolysis of one of the methoxy groups to the 
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Direct formation of the desired compound 207 by reduction of 3,4,5-
trimethoxybenzoic acid using lithium in liquid ammonia with T1{F, and immediate 
quench with methyl iodide, followed by acidification, was also attempted with no 
success (Scheme 5.14). This procedure, reported by Liepa et al.,12 again resulted in 
the mono-ketone as the free acid 209. Even when acidification was carried out to a 
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Further investigation of the literature suggested that starting from 
3,5-dimethoxybenzoic acid 210 may result in cleaner Birch reduction products.13 
The reduction and methylation were repeated using dimethoxybenzoic acid, but all 
attempts to quench with methyl iodide resulted in products that were unstable in 
solution, usually decomposing to the partially hydrolysed mono-ketone species 209. 
However, the ethyl analogue 211 of the elusive bis-enol ether key intermediate 207, 
was finally successfully synthesised by simply quenching with ethyl bromide instead 
of methyl iodide in the Birch reduction of 3,5-dimethoxybenzoic acid 210 (Scheme 
5.15). 	The enol ether 211 was coupled to N-methyl benzylamine using 
TBTU/HOBT, and the amide 212 obtained successfully hydrolysed to the desired 
diketone system 213. 
Scheme 5.15 
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5.4 Oxidative Cleavage 
The second requirement in the development the proposed linker for the attachment of 
peptides and amides in general to solid support, was a means of performing oxidative 
cleavage of the alkene bond in order to release the amide into solution. 
There are several reported cases of the use of periodate and other strong oxidising 
agents on solid support. 14,15 Sodium periodate has been used in the oxidation of 
bicyclic pyrrole C=C bonds to form cyclic ketolactams.16 Initial studies in solution 
indicated partial periodate cleavage of the double bond of ligand 59 to release the 
dipeptide 174, but the yields recovered were very low. Alternative reagents were 
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TLC: unreacted 59 
Ozonolysis, also used previously on solid support, 17 did not result in any cleavage of 
the alkene bond of 59, and starting material was recovered unchanged. 
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Oxidative cleavage of hindered alkenes has been successfully achieved by treatment 
with periodate in the presence of a ruthenium (III) catalyst.'8 MS results indicated 
minimal cleavage of the dipeptide 174 under these conditions. 
Synthesis of a model system for the immobilised cyclohexane-1,3-dione amide linker 
was proposed in order to establish that selective cleavage of the alkene bond was 
possible in good yield, and to optimise reagents and conditions. The model was 
prepared as shown in Scheme 5.17. Propionic acid 214 was first coupled to 
dimedone using DCC/DMAP, to form the activated alcohol 215. Treatment with N-










214 	 215 	 216 
(60%) 	 (75%) 
Oxidative cleavage of the alkene of 216 in order to release amide 217 was attempted 
under several sets of conditions detailed in Scheme 5.18. Treatment of the alkene 
216 with sodium periodate afforded a 24 % yield of amide 217, but the presence of 
benzylamine (present in the mass spectrum of the crude reaction mixture), indicated 
that some cleavage of the amide bond of 217 had also occurred. Selenium dioxide 
catalysed oxidation, using conditions reported by Naota et al.' 9, resulted in recovery 
of starting material 216. Treatment of alkene 216 with chromium oxide, using 
conditions reported by Kalaus et al.20, was again unsuccessful. The most promising 
result was obtained by oxidative cleavage of alkene 216 using ammonium molybdate 




Results and Discussion IV 










cat.Se0 H202 	1) DCM/ AcO
/ H202 
 
DCM 	 7OoC 
2) Cr03! Ac20 
N
-60 	 H 
0 
217 	 0 217 
(24%) (35%) 
TLC: 	 TLC: 
unreacted 216 	unreacted 216 
1H NMR: amide 	 1H NMR: amide 
MS ESL amide MS ESI: amide 
evidence of BzNH2 	 evidence of BzNH2 
A second model system 218 (Scheme 5.19) was synthesised in a similar manner to 
216, but with N-butylamine in place of N-benzylamine. Treatment of alkene 218 
with molybdate catalysed hydrogen peroxide, resulted in release of amide 219. 
There was no evidence of N-benzylamine in the mass spectrum of the crude reaction 
mixture, indicating that the amide bond of 219 was not affected in this case. 
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Scheme 5.19 
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The molybdate/H202 cleavage conditions were then tried out on the linker system 
previously prepared (213, Scheme 5.15). Propionic acid was coupled to diketone 
213 using DCC/DMAP, to form the activated alcohol 220, which was then reacted 
with butylamine to form the cyclohexanedione-supported 'amide' 221 (Scheme 
5.20). This promising result verified that the N-methyl amide attachment of the 
cyclohexane to the resin did not interfere with reactions at the dione system. 
Cleavage of the amide 219 from the dione was again achieved using molybdate 
catalysed hydrogen peroxide, although some cleavage of the N-methyl amide bond, 
releasing 222, was also indicated by MS. However, the absence of N-methyl 
benzylamine in the 111  NMR spectrum reassuringly indicated that it was present only 
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5.5 Summary 
Successful solution phase development of a model resin-bound cyclohexane-1,3-
dione linker system was achieved. A combined synthesis and coupling of simple 
amides to the linker system, effectively via the amide carbonyl, to form an alkene 
bond to cyclohexanedione was demonstrated. Finally, oxidative cleavage of the 
resulting alkene bond to release the amide was illustrated. 
5.6 	Further Work - Solid Phase Chemistry 
Time constraints prevented any further investigation of the transferral of the 
successfully concluded solution phase model cyclohexanedione linker route, to solid 
support. However, some suggestions for future adaptation of the solution phase 
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5.6.1 Method A 
Coupling of the bis-enol ether 211 to solid support, using conditions identical to the 
solution phase chemistry previously tested, should afford the resin bound diketone 
224 (Scheme 5.21). The TBTU/HOBT coupling conditions were previously reported 
by Berteina et al .22  for the attachment of carboxylic acids to N-methyl polystyrene 
resin. Coupling of Fmoc-glycine to the resin-bound diketone 224 to form the 
carbamate species 225 in the final step, is proposed in order to obtain a loading from 
Fmoc cleavage and analysis. 
Scheme 5.21 
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5.6.2 Method B 
An alternative method for immobilisation of the cyclohexanedione on solid support 
would be to exploit the dianion chemistry used previously (Chapter 3) in the 
preparation of 4-alkyl dimedones. The 4-benzyl dimedone 99 has been prepared in 
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It was envisioned that these conditions might therefore be adapted for coupling 










Additional further work should include investigating the scope of employment of 
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6 Experimental 
6.1 	General Techniques 
6.1.1 Instrumentation 
'H and '3C NMR spectra were recorded on BrUker AC250, DPX-360 or Varian 
Gemini-200 instruments. The following abbreviations are used: 6, chemical shift; d, 
doublet; dd, doublet of doublets; dt, doublet of triplets; dq, doublet of quartets; J, 
coupling constant; m, multiplet; q, quartet; s, singlet; t, triplet. Chemical shifts (ö) 
are reported in parts per million (ppm) and coupling constants (J) in Hz. Residual 
protic solvent, CHC13 (H  7.26, s) was used as the internal standard in 'H NMR 
spectra, and '3C NIvIIR shifts were referenced using CDC13 (öc 77.0, t) with broad 
band decoupling. Electrospray (ESI) nominal mass spectra were recorded using a 
Micromass Platform II mass spectrometer (CV25). Fast Atom Bombardment 
(FAB) high resolution mass spectra were recorded on a Kratos MS50TC instrument. 
Infra-red absorption spectroscopy was performed on a Perkin-Elmer FT-JR Paragon 
1000 spectrometer, and Vmax values are quoted in cm 1 . High performance liquid 
chromatography (HPLC) was carried out using a Waters 486 tunable absorbance 
detector and Waters 600E controller and pump. A Chiralcel OD-H column with 
dimensions 25 x 0.46 cm was used. Samples were injected via a 20 p1 loop and a 
flow rate of 1 ml/min was employed for elution using an isocratic system of 
hexane/isopropyl alcohol (95:5). A wavelength of 215 nm was used for sample 
detection. Melting points were obtained on Gallenkamp melting point apparatus and 
are uncorrected. Optical rotations were performed on an AA1000 polarimeter from 
Optical Activity Ltd (measurements made at the sodium D-line). Concentrations are 
given in g/lOOml. Solid phase samples were shaken on a New Brunswick Scientific 
G76 gyrorotory water bath shaker. Resin samples were spun on a Stuart Scientific 
Blood Rotator SB1. 
173 
Chapter 6 	 Experimental 
6.1.2 Chromatography 
Analytical TLC was carried out on Merck aluminium-backed plates coated with 
silica gel 60 F254, 0.25 mm. Components were visualised using ultra-violet 
fluorescence (254 nm), and ammonium molybdate or permanganate dips. Flash 
chromatography was carried out using silica gel 6011 (Merck 9385, 0.04-0.063 mm, 
230-400 mesh). Alternatively, where stated, a Biotage FLASH 40i system using 
40 g (40S) or 90 g (40M) prepacked silica cartridge was employed for 
chromatographic separation. A Biotage Quad system, capable of separating 4 
samples in parallel on 4 prepacked slica cartridges, was used where stated. 
6.1.3 Solvents and Reagents 
All reagents and solvents were standard laboratory grade and were used as supplied 
unless otherwise stated. DMF refers to peptide synthesis grade. Wang resin was 
purchased from Novabiochem. 
6.1.4 Solid Phase Protocols 
6.1.4.1 Washing protocol: 2 x THF; 2 x DMF; 2 x DMF:MeOH (1:1); 2 x DMF; 2 x 
THF;2 xDCM. 
6.1.4.2 Protocol for photometric analysis of p-nitrophenol (from Novabiochem, 
modified by Dr A. Long) 
Standard: p-nitrophenol (4-6 mg) was dissolved in DMF (2 ml). A standard 20 % 
solution of piperidine in DMF (2 ml) was added and the resulting solution stirred for 
1 h before making up to 25 ml with methanol. An aliquot (250 jil) was removed and 
diluted to 10 ml with water. 
Sample: Resin (4-6 mg) was suspended in DMF (1 ml). The standard 20 % 
piperidine in DMF solution (1 ml) was added and the resulting solution stirred for 1 h 
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before making up to 10 ml with methanol. An aliquot (200 t1) was removed and 
diluted to 5 ml with water. 
Blank: DMF (1 ml) and standard 20 % piperidine in DMF solution (1 ml) were 
stirred for 1 h before making up to 10 ml with methanol. An aliquot (200 t1) was 
removed and diluted to 5 ml with water. 
Measurement: The absorbance of the sample and standard were measured against 
the blank at 400 nm. The loading was then calculated as follows: 
mmol/g = [Abs(sample) x weight of standard x 1000] / 
[weight of sample x Abs(standard) x 4 x 139.11 
6.1.4.3 Protocol for photometric analysis of dibenzofulvene piperidine adduct 
Two samples of dry resin (4-10 mg) were accurately weighed directly into 10 ml 
volumetric flasks. The volume was made up with 20 % piperidine in DMF and the 
flasks sonicated at room temperature for 10 min. The remaining 20 % piperidine in 
DMF solution was used as a blank, and the absorbance of each sample measured at 
301 nm. The loading was calculated using following relationship: 
mmollg = (A x v) / (c x 10-3  x wt) 
A = absorbance @ 301 nm (k-max) 
v = volume/ ml 
wt = weight of resin sample / mg 
= extinction coefficient of N-(9-fluorenylmethyl)piperidine25  
6310nm= 7800 M'cm 1 
Cleavage MS samples: Resin (3-5 mg) was suspended in TFA/DCMIH20 (9:10:1) 
and spun at room temperature for 1 h. The resin was filtered off, washed with DCM, 
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and the filtrate concentrated under reduced pressure. Acetonitrile/water (1:1) (1 ml) 
was added and the solution sonicated for 10 mm. An aliquot (100 l) was removed 
and made up to 1 ml. The resulting solution was then filtered before analysis. 
Gel '3C NMR : Only signals which appear on the peak list are quoted. Some 
additional signals are present but are barely distinguishable from the baseline noise. 
6.2 	Experimental Procedures 




To a stirred solution of N-benzyloxycarbonylglycine (1.50 g, 7.17 mmol) in DMF 
(50 ml), dimedone (1.10 g, 7.89 mmol), DCC (1.48 g, 7.17 mmol) and DMAP 
(0.88 g, 7.17 mmol) were added and the mixture stirred at room temperature for 40 h. 
The resulting yellow solution was filtered to remove the white DCU precipitate and 
concentrated under reduced pressure to an orange residue (4.60 g) which was then 
dissolved in EtOAc (120 ml) and further DCU precipitate removed by filtration. The 
EtOAc solution was washed with 1M KHSO4 (40 ml) and the product extracted with 
NaHCO3  (2 x 200 ml). The aqueous solution was acidified using 2N HC1 and 
extracted with DCM (3 x 100 ml). The solution was concentrated under reduced 
pressure to afford a yellow oil (1.02 g) which solidified on standing. The residue 
was recrystallised twice from methanol/water (1:1) and dried in a desiccator 
overnight to yield a white solid (0.32 g, 13 %): mp 109 °C; R1 041 
cyclohexane/EtOAc (1:3); vmax(polyethylene card) 338 lbr (0-H & N-H), 1716 
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(urethane C=O), 1661 (a,13-unsaturated ketone), 1567 (amide II); SH (200 MHz, 
CDC13) 1.08 (611, s, C(CH3)2), 2.35 (2H, s, CH2C(CH3)2), 2.56 (2H, s, CH2C(CH3)2), 
4.66 (2H, d, J 5.5, CH2NH), 5.14 (211, s, OCH2Ph), 5.43 (111, br s, Nil), 7.26-7.36 
(5H, m, Ar-I]), 16.92 (1H, s, OR); 3c (63 MHz, DEPT, CDC13) 28.0 (C(CH3)2), 30.9 
(C(CH3)2), 45.2 (CH2C(CH3)2), 49.8 (NHCH2), 51.7 (CFT2C(CH3)2), 66.7 (OCH2Ph), 
111.1 (COCCOH), [127.9 (CU), 128.3 (CH), 5C, Ar-H], 136.2 (OCH2Ph), 156.2 
(CONU), 194.9 (COC=CCO), 200.4 (COC=COH); MS ESI (-ye) found mlz 329.9 
([M-H], 100 %); HRIVIS FAB (+ve) found m/z 332.14966 (MIFfl, C181122N05  
requires 332.14980. 
6.2.1.2 	N-[]-(4,4-dimethyl-2, 6_dioxocyclohexylidene)-2-benzyloxy- 
carbonylaminoethylJbutylamine (41) 
1 (4,4dimethyl2,6-dioxocyclohexylidene)-2-beflzylOXYCarbOflYlafl1ifl0ethafl0l 	40 
(0.10 g, 0.30 mmol) and N-butylamine (30 tl, 0.30 mmol) in DMF (4 ml) were 
stirred at room temperature for 26 h. The reaction mixture was concentrated under 
reduced pressure to yield a yellow oil. Flash column chromatography on silica gel 
using cyclohexane/EtOAc (1:3) as eluent afforded a yellow oil (combined yield 
0.19 g, 84 %); R=0. 58 cyclohexane/EtOAc (1:3); v ax(polyethylene card) 3421 (N-
U), 1717 (urethane C=O), 1634 (a43-unsaturated ketone), 1580 (amide II); 6H (200 
MHz, CDC13) 0.94 (311, t, J7.0, C112CH3), 1.01 (6H, s, C(CH3)2), 1.43 (211, tq, J7.0, 
7.0, CH2CH3), 1.57-1.68 (2H, m, CH2CH2CU3), 2.33 (211, s, CH2C(CH3)2), 2.38 (211, 
S. CH2C(C113)2), 3.78 (211, dt, J 12.5, 7.0, NHCH2CH2), 4.35 (2H, d, J 7.0, 
CONHCH2), 5.06 (2H, s,OCH2Ph), 6.37 (1H, t, J 7.0, CONR), 7.31 (5H, s, Ar-fl), 
13.44 (1H, br s, NHCH2CH2); 8C (63 MHz, DEPT, CDC13) 13.5 (CH2CH3), 19.8 
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(C112CH3), 28.1 (C(CH3)2), 30.1 (C(CH3)2), 31.4 (CH2CH2CH3), 38.8 (NHCH2CH2), 
43.7 (CH2C(CH3)2), 52.0 (CH2C(CH3)2), 53.0 (CON}ICH2), 66.7 (OCH2Ph), 106.8 
(C=CNH), [127.8 (CH), 128.0 (CH), 128.3 (CH), SC, Ar-H], 136.2 (OC142Ph), 156.2 
(OCONH), 169.9 (C=CNH), 197.0 (CH2CO), 199.9 (CH2CO); MS ESI (+ve) found 
mlz 386.9 (M1{, 18 %), 409.1 (MNa, 100), 432.1 (22), 450.2 (26); I{RMS FAB 
(+ve) found m!z 387.22828 (MIEf), C22H31N204 requires 387.22838. 




45 	 46 
Triethylamine (0.35 ml, 2.5 mmol) and ethyl chloroformate were added to a solution 
of Cbz-L-valine (0.63 g, 2.5 mmol) in THF (5 ml) at —10 T. The resulting mixture 
was stirred for 15 min at —10 °C, before warming to 0 °C and addition of a 2M 
aqueous solution of sodium azide (2.5 ml, 5.0 mmol). After stirring for 30 min at 
0 °C, the reaction was diluted with cold EtOAc (20 ml) and washed with cold brine 
(3x5 ml). The EtOAc layer was separated, dried (MgSO4) and concentrated under 
reduced pressure to yield a colourless oil (0.07 g, 10 %): vmax(crude oil) 331 9br (N-
H), 2966 (acid C=O, from Cbz-L-valine), 2252 (isocyanate —NC0), 2140 (azide 
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6.2.1.4.1 	Method A 
To a cold (-10 °C) solution of N-benzyloxycarbonyl-L-leucine (0.73 g, 2.74 mmol) in 
EtOH (5 ml), were added triethylamine (0.38 ml, 2.74 mmol), and ethyl 
chioroformate (0.26 ml, 2.74 mmol). The mixture was stirred for 15 min at -5 °C, 
and dimedone (0.38 g, 2.74 mmol) added. After stirring for 1 h 20 min at 0 °C, TLC 
hexane/EtOAc (1:1) indicated formation of products. The reaction was allowed to 
warm to room temperature and stirred for 1 h before concentration under reduced 
pressure to give a colourless oil (1.66 g). Flash column chromatography on silica gel 
using hexane/EtOAc (4:1—*2:1) yielded a colourless oil (0.34 g, 32 %); [CID -18.0 (c 
2.2, CHC13); R=0.33 cyclohexane/diethyl ether (1:1); vm (polyethylene card) 3322 
(N-H), 1770 (vinyl ester), 1715 (urethane C=O), 1674 (a,-unsaturated ketone), 
1532 (amide II); ö (250 MHz, CDC13) 0.96 (6H, d, J 6.0, CH(CH3)2), 1.06 (6H, s, 
C(CH3)2), 1.58-1.76 (311, m, CH2CH(CH3)2), 2.25 (2H, s, CH2C(CH3)2), 2.38 (211, s, 
CH2C(CH3)2), 4.42-4.46 (1 H, m, CHNIU), 5.11 (2H, s, CH2Ph), 5.21 (1H, d, J 8.0, 
NIT), 5.90 (111, s, COCHCO), 7.33 (511, s, Ar-H); öc (63 MI-Tz, DEPT, CDC13) 21.5 
(CH(CH3C'31-13)), 22.7 (CH(CAH3CBH3)), 24.7 (CH(CH3)2), 27.9 (C(C4H3CBH3)), 
28.0 (C(C"H3C'H3)), 33.0 (C(CH3)2), 40.9 (CH2CH(CH3)2), 41.7 (CH2C(CH3)2), 
50.6 (CH2C(CH3)2), 52.6 (NHCH), 67.1 (OCH2Ph), 116.1 (COCH=COCH2), [127.9 
(CH), 128.2 (CH), 128.4 (CH), 5C, Ar-HI, 135.9 (OCH2Ph), 155.8 (OCONH), 167.8 
(COOC=CH), 170.0 (NHCHCO), 199.2 (COCH=COCO); MS ESI (+ve) found m/z 
410.2 (MNa, 100 %), 426.0 (MK, 17), 433.3 (17), 451.2 (48); HRMS FAB (+ve) 
found m/z 388.21214 (MW), C221130N05 requires 388.21240. 
The by-product carbonic acid 5,5-dimethyl-3-oxo-cyclohex-1-enyl ester ethyl ester 
(51) was also isolated. 
io  
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Colourless oil: Rf=0.47 Hexane/EtOAc (2:1); 8H (200 MHz, CDC13) 1.11 (6H, s, 
C(CH3)2), 1.37 (3H, t, J 7.0, CH2CH3), 2.28 (2H, s, CH2C(CH3)2), 2.45 (2H, s, 
CH2C(CH3)2), 4.29 (2H, q, J7.0, CH2CH3), 6.04 (1H, s, COCHCO). 








14 t ONLLF y  
° 1 
To a stirred solution of N-benzyloxycarbonyl-L-leucine (0.50 g, 1.87 mmol) and 
pyridine (0.15 ml, 1.88 mmol) in anhydrous DCM (5 ml) kept under a N2 atmosphere 
was added cyanuric fluoride (0.51 ml, 5.64 mmol) at -15 to -10 T. A white 
precipitate formed. After stirring for 1 h at -5 °C, JR of the crude reaction mixture 
indicated formation of the acyl fluoride. After 2 h crushed ice was added along with 
DCM (10 ml). The organic layer was separated and the aqueous layer extracted with 
DCM (5 ml). The combined DCM layers were washed with ice-cold water (10 ml), 
dried (MgSO4) and concentrated under reduced pressure to afford a colourless oil 
(0.36 g, 73 %) which was used in subsequent reactions without further purification: 
vmax(polyethylene card) 3317 (N-H), 1843 (acid fluoride); 6H (200 MHz, CDC13) 
0.97 (6H, d, J6.0, CH(CH3)2), 1.62-1.78 (3H, in, CH(CH3)2 & CH2CH(CH3)2), 4.54-
4.61 (111, in, NIHCJI), 5.02 (IH, in, NH), 5.14 (2H, s, CH2Ph), 7.36 (511, s, Ar-H). 
N-Benzyloxycarbonyl-L-leucinylfluoride 54 (0.36 g, 1.36 mmol) in DCM (15 ml) 
was stirred at room temperature with dimedone (0.19 g, 1.36 mmol) and DIPEA 
(0.47 ml, 2.72 mmol). The solution changed colour from pale yellow to blue/purple. 
After 20 min JR (crude mixture; polyethylene disc) indicated disappearance of the 
acyl fluoride. The solution was washed with 2N HC1 (2 x 5 ml), saturated NaHCO3 
solution (2 x 5 ml), water (2 x 5 ml), dried (MgSO4) and concentrated under reduced 
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pressure to yield a blue/purple oil (0.42 g). Flash column chromatography on silica 
gel using cyclohexane/diethyl ether (1:1) as eluent afforded a colourless oil (0.16 g, 
29 %). Analysis identical to 50 obtained by 6.2.1.4.1 Method A. 
6.2.1.5 	3(Nbenzyloxycarbony1 L-pheflYla1aniflY1OXY)-5,5-dimethYl-2 
cyclohexen-1 -one (52) 
0 Y N "~Oz~o 
o c 
The general procedure outlined above (6.2.1.4, Method A) was followed using Cbz-
L-phenylalanine (0.10 g, 0.37 mmol) and methyl chloroformate (45 p1, 0.37 mmol). 
Flash column chromatography on silica gel using Pet.Ether/EtOAc (4:3) as eluent 
gave a colourless oil (0.12 g, 77 %): [U]D —10.3 (c 1.2, CHC13); R0.66 
hexane/EtOAc (1:1); vmax(crude oil) 3319br (N-H), 1761 (vinyl ester), 1720 
(urethane C=O), 1669 (a,13-unsaturated ketone), 1528 (amide II); 6H (250 MHz, 
CDC13) 1.04 (3H, d, J 7.0, C(CAH3CBH3)), 1.12 (3H, d, J 7.0, C(CAH3CBH3)), 2.19-
2.25 (1H, m, CH(CH3)2), 2.24 (211, s, CH2C(CH3)2), 2.29 (211, s, CH2C(CH3)2), 3.08-
3.19 (2H, m, CHCH2Ph), 4.60-4.82 (114, m, NHCII), 5.10 (2H, s, OCH2Ph), 5.45 
(111, d, J8.0, NI]), 5.81 (1H, s, COCH=CO), 7.12-7.38 (1011, m, Ar-H); 8c (63 MHz, 
DEPT, CDCI3) 27.9 (C(C4H3CBH3)), 28.0 (C(C"H3C8H3)), 33.0 (C(CH3)2), 37.9 
(CHCH2Ph), 41.6 (CH2C(CH3)2), 50.6 (CH2C(CH3)2), 54.9 (NHCH), 67.2 
(OCH2Ph), 116.6 (COCH=CO), [128.0 (CH), 128.5 (CH), 128.8 (CH), 129.1 (CH), 
IOC, Ar-HI, 134.8 (OCH2Ph), 135.6 (CHCH2Ph), 155.5 (CON}T), 167.6 
(COOC=CH), 168.6 (NHCHCO), 199.2 (COCHCOCO); MS ESI (+ve) found m/z 
444.3 (MNa, 100 %); fiRMS FAB (+ve) found m/z 422.19795 (MFf), C25H28N05 
requires 422.19675. 
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The by-product carbonic acid 5,5-dimethyl-3-oxo-cyclohex-1-enyl ester methyl 
ester (53) was also isolated. 
°°io  
Colourless oil: R1=0.42 Hexane/EtOAc (3:2); 8H (200 MHz, CDC13) 1.10 (6H, s, 
C(CH3)2), 2.27 (2H, s, CH2C(CH3)2), 2.44 (211, s, CH2C(CH3)2), 3.83 (311, s, OCH3), 
6.03 (1H, s,COCHCO). 
	
6.2.1.6 	carbonic acid 5,5-dimethyl-3-oxo-cyciohex-1-enyl ester isobutyl 
ester (128) 
OOyO 
128 was formed as a by-product in the general procedure outlined above (6.2.1.4, 
Method A) as a colourless oil: R1=0.39 Pet.Ether/EtOAc (4:1); vmax(crude oil) 1769, 
1705 (anhydride), 1673 (a,-unsaturated ketone); 6H (250 MHz, CDC13) 0.97 (611, d, 
J7.0, CH(CH3)2), 1.10 (6H, s, C(CH3)2), 1.43-2.08 (1H, m, CH(CH3)2), 2.26 (211, s, 
CH2C(CH3)2), 2.44 (211, S. CH2C(CH3)2), 3.99 (2H, d, J 7.0, CH2CH(CH3)2), 6.02 
(1H, s, COCHCO); 8c (63 MHz, DEPT, CDC13) 19.2 (CH(CH3)2), 28.1 
(CH(CH3)2), 28.5 (C(CH3)2), 33.5 (C(CH3)2), 42.1 (GH2C(CH3)2), 51.0 
(CH2C(CH3)2), 75.6 (OCH2CH(CH3)2), 115.7 (COCH=CO), 151.6 (OCOO), 168.3 
(COOCCH), 200.3 (COCHCOCO); HRMS FAB (+ve) found m/z 241.14392 
(MW), C13H2104 requires 241.14398. 
6.2.1.7 	N-benzyloxycarbonyl-L-valinylfluoride (57) 
0 
H 	II - 
0 
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To a stirred solution of N-benzyloxycarbonyl-L-valine (0.50 g, 2.00 mmol) and 
pyridine (0.16 ml, 2.00 mmol) in anhydrous DCM (5 ml) kept under a N2 atmosphere 
was added cyanuric fluoride (0.90 ml, 10.00 mmol) at -15 to -10 T. A white 
precipitate formed. The reaction was followed by TLC CHC13/MeOH/AcOH 
(9:1:0.1) on a small amount of reaction mixture quenched in MeOfl. After lh 40 
mm, crushed ice was added along with DCM (10 ml). The organic layer was 
separated and the aqueous layer extracted with DCM (5 ml). The combined DCM 
layers were washed with ice-cold water (10 ml), dried (MgSO4) and concentrated 
under reduced pressure to afford a colourless oil (0.60 g, 119 %) which was used in 
subsequent reactions without further purification: R0.78 CHC13/MeOH/AcOH 
(9:1:0.1); v x(polyethylene card) 3320 (N-H), 1843 (acid fluoride), 1738 (urethane 
C=O), 1538 (amide II); oH (200 MHz, CDC13) 1.01 (3H, d, J7.0, CH(CH3CB113)), 
1.05 (3H, d, J 7.0, CH(CAH3CH3)), 2.26 (111, m, CH(CH3)2), 4.49 (111, m, NECk!), 
5.14 (3H, m, OCH2Ph & NH (masked)), 7.37 (5H, s, Ar-H); MS ESI (+ve) found mlz 
233.8 (C6H5CH2CONHCH(CH(CH3)2)CO-, 41 %), 251.8 (N-Cbz-Val, 58), 268.9 (N-
Cbz-VaNH4 , 64), 273.8 (N-Cbz-VaNa, 33), 289.9 (N-Cbz-ValK, 22), 341.9 




To a stirred room temperature solution of N-benzyloxycarbonyl-L-valinylfluoride 57 
(0.48 g, 1.89 mmol) in DCM (20 ml) was added dimedone (0.27 g, 1.89 mmol) and 
DIPEA (0.66 ml, 3.78 mmol). On addition of DIPEA there was an immediate colour 
change from colourless to green/brown then blue/purple. JR (crude solution; 
polyethylene disc) indicated disappearance of the acyl fluoride peak @ 1842 cm'. 
After stirring for 1/2 h the solution was washed with IN HC1 (2 x 5 ml), saturated 
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NaHCO3 solution (2 x 5 ml), water (2 x 5 ml), dried (MgSO4) and concentrated 
under reduced pressure to a blue/purple oil (0.62 g). Flash column chromatography 
on silica gel using CHC13/MeOH (9:1) as eluent afforded a pale yellow oil (0.58 g, 
82 %); [a]D -15.6 (c 1.4, CHC13); R=0.75 CHC13/MeOH (9:1); vmax(NaC1) 3326br 
(N-H), 1769 (vinyl ester), 1715 (urethane C0), 1668 (u,13-unsaturated ketone), 
1532 (amide II); 6H (250 MHz, CDC13) 0.95 (3H, d, J 7.0, CH(CAH3CBHA, 1.02 
(3H, d, J 7. 0, CH(CAH3CBH3)), 1.10 (6H, s, C(CH3)2), 2.20-2.27 (111, m, CH(CH3)2), 
2.27 (21-1, s, CH2C(CH3)2), 2.39 (21-1, s, CH2C(CH3)2), 4.39 (11-1, dd, J 9.0, 5.0, 
N}ICII), 5.12 (211, s, OCH2Ph), 5.19 (11-1, d, J 9.0, NI]), 5.89 (11-1, s, COCH=CO), 
7.35 (SH, s, Ar-I]); 6c  (63 MHz, DEPT, CDCI3) 17.5 (CH(C
4H3CB1-13)), 18.9 
(CH(CAH3CRH3)), 27.9 (C(dH3CBH3)), 28.0 (C(CAH3CBH3)), 30.9 (CH(CH3)2), 33.1 
(C(CH3)2), 41.8 (CH2C(CH3)2), 50.7 (CH2C(C113)2), 59.1 (NHCH), 67.2 (OCH2Ph), 
116.8 (COCH=CO), [128.0 (CH), 128.2 (CH), 128.5 (CH), SC, Ar-H], 135.9 
(OCH2Ph), 156.1 (CONH), 167.7 (COOC=CH), 169.1 (NHCHCO), 199.0 
(COCH=COCO); MS ESI (+ve) found m!z 396.0 (MNa, 100 %), 437.1 (22); HRMS 
FAB (+ve) found m/z 374.19741 (MIt), C211128N05 requires 374.19675. 
6.2.1.9 	Attempted rearrangement of 3-(NbenzyIoxycarbony1-L-va1inyloxy)- 




42 (0.23 g, 0.62 mmol) was stirred in anhydrous DCM (2 ml). Anhydrous 
aluminium chloride (0.17 g, 1.26 mmol) was added and the reaction stirred at —5 °C 
for 2 h, before pouring into a mixture of ice water (1 ml) and 2 M HC1 (1 ml). The 
organic phase was separated and the aqueous phase extracted with C}{C13 (2 x 2 ml). 
The combined organic extracts were washed with H20 (2 ml), dried (MgSO4) and 
concentrated under reduced pressure. The resulting residue was dissolved in the 
minimum quantity of ether and treated with 2 M NaOH (3 ml). The solution was 
acidified with 2M HCI to pHi and extracted with ether (3 x 2 ml). The combined 
ii:i 
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ether extracts were dried (MgSO4) and concentrated under reduced pressure to give a 
colourless oil (0.13 g, 58 %): 6H  (250 MHz, CDC13) as 42. Heating the reaction to 
45 °C for 2.5 h after addition of the aluminium chloride, with identical work-up again 
resulted in recovery of starting material 42. 
6.2.1.10 	1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-2-benzyloxycarbonyl- 
amino-3-methylbutanol (58) 
The enol ester 42 (0.56 g, 1.50 mmol) was dissolved in MeCN (8 ml) containing 
triethylamine (0.84 ml, 6.00 ml) and acetone cyanohydrin (14 j.xl, 0.15 mmol). After 
2.5 h, TLC hexane/EtOAc (1:1) indicated remaining enol ester 42. The solution was 
stirred at room temperature overnight then partitioned between hexane (8 ml) and 
cold IN HC1 (8 ml). The hexane phase was washed with water (2 ml), dried 
(MgSO4) and concentrated under reduced pressure to yield an off-white solid (0.26 g, 
66 %): mp 72 °C; [am +12.4 (c 2.1, CUd 3); R=0.41 hexane/EtOAc (1:1); Vmax 
(KBr) 3424 (0-H & N-H), 1722 (urethane C=O), 1667 (a,13-unsaturated ketone), 
1513 (amide II); 6H (200 MFIz, CDC13) 0.75 (3H, d, J 7.0, CH(CAH3CBH3)),  0.86-
1.27 (911, m, CH(CAH3CBH3) & C(CH3)2), 2.07-2.13 (1H, m, CH(CH3)2), 2.28-2.35 
(2H, m, CH2C(CH3)2), 2.54 (2H, s, CH2C(CH3)2), 5.08 (2H, s, CH2Ph), 5.49 (1 H, d, J 
9.5, NH), 5.60 (1H, dd, J 9.5, 3.0, CHCH(CH3)2), 7.34 (511, s, Ar-H), 17.54 (111, s, 
Oil); 6c  (63 MHz, DEPT, CDC13) 15.6 (CH(CIH3CBH3)),  20.3 (CH(C'H3C8H3)), 
27.7 (C(C4H3CBH3)),  28.3  (C(CAH3CBH3)),  30.6 (CH(CH3)2), 45.9 (CH2C(CH3)2), 
52.2 (CH2C(CH3)2), 60.9 (CHCH(CH3)2), 66.8 (CH2Ph), 110.8 (C=COH), [128.0 
(CH), 128.4 (CH), 5C, Ar-H], 136.3 (OCH2Ph), 156.2 (OCONH), [194.4 (C), 196.7 
(C), 203.5 (C), COCC(OH)CO]; MS ESI (+ve) found m/z 373.9 (MW, 90 %), 
185 
Chapter 6 	 Experimental 
396.0 (MNa, 100); FIRMS FAB (+ve) found m/z 374.19769 (MK), C21H28N05  
requires 374.19675. 
6.2.1.11 	N-[]-(4,4-dimethyl-2,6-dioxocyclohexylidene)-2-benzyloxy- 
carbonylamino-3-methylbutylJphenylalanine methyl ester (59) 
(diastereomers in ratio 60:40, X:Y) 
1 -(4,4-dimethyl-2,6-dioxocyclohexylidene)-2-benzyloxycarbonylamino-3-methyl 
butanol 58 (0.11 g, 0.29 mmol) was dissolved in DMF (1 nil). L-phenylalanine 
methyl ester HC1 salt (0.06 g, 0.29 mmol) was added followed by DIPEA (0.05 ml, 
0.29 mmol) and the mixture stirred at room temperature overnight after which time 
TLC hexane/EtOAc (1:1) indicated remaining 58. The reaction was heated at 50 °C 
for 7 h before removal of the solvent under reduced pressure to yield a yellow oil 
(0.19 g). Flash column chromatography using hexane/EtOAc (1:1) as eluent 
afforded a colourless oil (0.05 g, 34 %); [UID -30.5 (c 2.5, CHC13); R0.64 
hexane/EtOAc (1:1); vmax(polyethylene card) 3352 (N-H), 1748 (ester), 1713 
(urethane 0=0), 1634 (a3-unsaturated ketone), 1565 (amide II); 6H (360 MHz, 
COSY, CDCI3) 0.33 (3H, d, J 7.0, CH(CAH3CI3H3),  Y), 0.76 (3H, d, J 7.0, 
CH(CAH3 CB H3), X), 0.92 (3H, d, J 6.5, CH(CH3CBH3),  Y), 1.01 (3H, d, J 6.5, 
CH(CAH3CBH3),  X), 1.04-1.07 (12H, m, C(CH3)2, X & Y), 2.02-2.11 (1H, m, 
CH(CH3)2, Y), 2.19-2.26 (1H, m, CH(CH3)2, X), 2.30-2.52 (8H, m, CH2C(CH3)2CH2, 
X & Y), 3.17 (1H, dd, J 14.0, 9.0, CHCHAHBPh, Y), 3.29 (2H, d, J 7.0, CHCH2Ph, 
X), 3.40 (1H, dd, J 14.0, 4.5, CHCHAHBPh, Y), 3.69 (3H, s, OCH3, Y), 3.72 (3H, s, 
OCH3, X), 4.30 (111, dd, J 10.5, 10.5, CHCH(CH3)2, Y), 4.48 (1H, dd, J 10.5, 10.5, 
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CHCH(CH3)2, X), 5.05-5.19 (5H, m, OCH2Ph. X & Y, CHCH2Ph, Y), 5.37 (1H, dt, J 
8.0, 7.0, CHCH2Ph, X), 7.22-7.39 (2011, m, Ar-H, X & Y), 7.69 (111, d, J 12.5, 
CONH, Y), 7.72 (1H, d, J 10.5, CONH, X), 14.61 (1H, d, J 8.0, COCHNH, Y), 
14.71 (1H, d, J 8.0, COCHNH, X); 6c (63 MHz, DEPT, CDCI3) 19.2 
(CH(C4H3CBH3),  Y), 19.3 (2C, CH(CAH3CBH3),  X & Y), 19.9 (CH(C4H3CBH3),  X), 
27.4 (C(C4H3CB1-13),  Y), 27.5 (C(C4H3C8H3), X), 28.5 (C(CAH3CI9H3),  X), 28.6 
(C(C'H3C8H3), Y), 29.1 (CH(CH3)2, Y), 29.4 (CH(CH3)2, X), 29.8 (2C, C(CH3)2, X 
& Y), 39.3 (CHCH2Ph, Y), 39.8 (CHCH2Ph, X), 52.0 (CH2C(CH3)2, X), 52.1 
(CH2C(CH3)2, Y), 52.4 (OCH3, X), 52.7 (OCH3, Y), 53.4 (2C, CH2C(CH3)2, X & Y), 
55.8 (CHCH(CH3)2, Y), 56.1 (CHCH(CH3)2, X), 59.1 (CHCH2Ph, X), 59.7 
(C1-TCH2Ph, Y), 66.5 (OCH2Ph, Y), 66.6 (OCH2Ph, X), 107.0 (COCCNH, X), 107.2 
(COC=CNH, Y), [127.2 (CH), 127.3 (CH), 127.6 (CH), 127.7 (CH), 127.9 (CH), 
128.0 (CH), 128.2 (CH), 128.3 (CH), 128.4 (CH), 128.6 (CH), 129.2 (CH), 129.3 
(CH), 20C, Ar-H, X & Y), 134.5 (CHCH2Ph, X), 135.2 (CHCH2Ph, Y), 136.4 
(OCH2Ph, X), 136.5 (OCH2Ph, Y), 156.4 (2C, OCONH, X & Y), 169.8 
(COC=CNH, Y), 169.9 (COC=CNH, X), 173.0 (COOCH3, X), 173.6 (COOCH3, Y), 
197.2 (2C, COC=CNH, X & Y), 200.3 (2C, COC=CNH, X & Y); MS ESI (+ve) 
found m/z 535.2 (MH, 29 %), 557.1 (MNa, 100); FIRMS FAB (+ve) found mlz 
535.28083 (MIff), C311-139N206 requires 535.28081. 
6.2.1.12 	(N-benzyloxycarbonyl-L-valinyl)-L-phenylalanine methyl ester (60) 
"AN 0 
o_-..._ 	0 
3 -(N-benzyloxycarbonyl-L-valinyloxy)-5,5-dimethyl-2-cyclohexen- 1-one 42 (0.12 g, 
0.33 mmol) was dissolved in DMF (2 ml). L-phenylalanine methyl ester. HC1 salt 
(0.07 g, 0.33 mmol) was added along with DIPEA (0.12 ml, 0.66 mmol) and the 
reaction stirred at room temperature overnight. TLC DCMIMeOH (9:1) indicated 42 
remaining so the reaction was heated at 60 °C for 6 h. The solution was then 
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concentrated under reduced pressure to yield a pale yellow oil (0.25 g). Flash 
column chromatography on silica gel using CHC13/diethyl ether (1:2) as eluent 
afforded a white solid (0.10 g, 70 %): mp 131 °C; [aID +40.2 (c 1.8, CHC13); R0.50 
CHC13/diethyl ether (1:2); vinax(polyethylene card) 330 lbr (N-H), 1738 (ester) 1693 
(urethane C0), 1651 (amide 1)1538 (amide TI); 61, (250 MHz, CDC13) 0.86 (3H, d, 
J 7.0, CH(C'H30143)), 0.92 (311, d, J 7.0, CH(CAH3CBH3)),  1.98-2.11 (1H, m, 
CH(CH3)2), 3.07-3.10(211, m, CHCH2Ph), 3.69 (31-1, s, OCH3), 4.03 (114, dd, J9.0, 
6.0, CHCH(CH02), 4.87 (111, dt, J 8.0, 6.0, CHCH2Ph), 5.04 (1H, d, J 12.0, 
OCH4HBPh), 5.12 (1H, d, J 12.0, OCHAHBPh), 5.40 (111, d, J 9.0, OCONH), 6.45 
(1H, d, J8.0, CONH), 7.05-7.33 (1 OH, m, Ar-I]); 8c (63 M}Iz, DEPT, CDC13) 17.5 
(CH(CAH3CB113)), 19.0  (CH(CH3CBH3)),  31.0  (CIT(CAH3CBH3)),  37.8 (CHCH2Ph), 
52.2 (OCH3), 52.9 (CHCH2Ph), 60.0 (CHCH(C113)2), 66.9 (OCH2Ph), [127.0 (CH), 
127.9 (CH), 128.0 (CH), 128.4 (CH), 128.5 (CH), 129.1 (CH), 10C, Ar-H], 135.4 
(CHCH2Ph), 136.1 (OCH2Ph), 156.1 (OCONH), [170.7 (C), 171.5 (C), CHCONI-T & 
COO]; MS ESI (+ve) found m/z 435.1 (MNa, 100 %), 458.2 (16); HRMS FAB 
(+ve) found m/z 413.20883 (MW),  C231129N205 requires 413.20765. 
6.2.2 Results and Discussion I - Solid Phase Synthesis 
6.2.2.1 	p-nitrophenol carbonate Wang resin (65) 
NO 2 
Q('0 j:r 
Novabiochem Wang resin (100-200 mesh, loading 0.76 mmol/g) was washed 
according to protocol and dried under vacuum overnight. 
Dry resin (1.00 g, 0.76 mmol) was swollen in anhydrous DCM (5 ml) under argon. 
An anhydrous solution ofp-nitrophenol chioroformate (0.46 g, 2.28 mmol) in DCM 
(10 ml) was added followed by pyridine (0.18 ml, 2.28 mmol). The reaction was 
shaken overnight at room temperature. The resin was then filtered, washed 
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according to protocol and dried under vacuum overnight to yield yellow resin (p-
nitrophenol loading 0.68 mmol/g, 100 %); Vmax(CH2C12) 1765 (carbonate), 
1526,1348 (NO2); 6c  (63 MHz, Gel, CD202) 70.1 (CH2OAr), 71.0 (OCH2Ar), 115.0 
(2C, o-OCH2Ar-H), 122.0 (2C, o-OCOAr-H), 125.4 (2C, o-NO2Ar-H). 
6.2.2.2 	L-valinefluorenyl methyl ester. p-toluene sulfonic acid salt (66) 
S03  
Boc-L-Val (2.50 g, 11.5 mmol), 9-fluorenemethanol (4.52 g, 23.0 mmol) and DMAP 
(12.0 mg, cat.) in distilled DCM (40 ml) were cooled in an ice bath under argon for 
10 mm. DIC (2.90 g, 23.0 mmol) was added dropwise and the reaction stirred 
overnight. A white precipitate formed. The precipitate was filtered off and washed 
with DCM. The combined DCM layers were washed with water (2 x 50 ml), 
saturated NaHCO3 (2 x 50 ml) then citric acid (10 %, 2 x 50 ml) alternately, followed 
by water (2 x 50 ml) then saturated brine (2 x 50 ml) alternately. The organic layers 
were dried (Na2SO4) and concentrated under reduced pressure to a colourless oil 
which later solidified to an off-white solid (5.60 g). The residue was dissolved in 
TFA (25 ml) causing effervescence and a green solution resulted. After 15 mm p-
toluene sulfonic acid (3.07 g, 16.15 mmol) was added and a pink colour observed. 
The TFA was removed under reduced pressure and the resultant yellow oil triturated 
with diethyl ether to afford a white substance which, after drying in a desiccator over 
P2O5 , yielded a white powder (3.23 g, 60 %): mp 157 °C; R=0.57 DCMIMeOH 
(9:1); vmax(KBr) 2965br (-NH3, & Ar-H & -CH2, -CH3), 1751 (ester), 1618, 1534, 
1498 (Ar-H); 6H  (200 MHz, CD30D) 0.71 (3H, d, J 7.0, CH(CAH3CBH3)),  0.81 (3H, 
d, J 7.0, CH(CAH3CBH3)),  1.94-2.03 (1H, in, CH(CH3)2), 2.42 (3H, s, ArCH3), 3.79 
(1H, d, J 4.0, CHCH(CH3)2), 4.32 (1H, dd, J 4.5, 4.5, OCH2CII), 4.75 (111, dd, J 
11.0, 4.5, OCH4HBCH), 4.99 (1H, OCHAHBCH (masked by HDO)), 7.26-7.90(1211, 
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m, Ar-H); öc (63 MHz, DEPT, CD30D) 15.8 (CH(dH3CBH3)),  16.1 
(CH(C1H3CBH3),  19.4 (Ar-CH3), 28.8 (CH(CH3)2), 46.1 (OCH2CHAr), 57.2 
(NHCH), 66.0 (OCH2CHAr), 119.1 (2C, (CH), Ar-H), 123.8 ((CH), Ar-H), 123.9 
((CH), Ar-H), 125.0 (2C, (CH), o-CH3Ar-H), 126.4 (2C, (CH), Ar-H), 127.0 ((CH), 
Ar-H), 127.1 ((CH), Ar-H), 127.9 (2C, (CH), o-SO3 Ar-H), 139.8 ((C), Ar-CH3), 
140.8 ((C), Ar-Ar), 141.0 ((C), Ar-Ar), 141.5 ((C), ArS03), 142.7 ((C), Ar-CHCH2), 
142.9 ((C), Ar-CHCH2), 168.2 ((C), COO); HRMS FAB (+ve) found m/z 468.18403 
(MIFf), C26H30N05S requires 468.18447. 
6.2.2.3 fluorenyl methyl ester-protected L-valine-N-carboxy Wang resin (67) 
/\ 
o o10  
p-Nitrophenol carbonate Wang resin 65 (0.60 g, loading 0.68 mmol/g, 0.41 mmol) 
was swollen in DMF (10 ml) containing DMAP (0.18 g, 1.43 mmol) and L-valine 
fluorenyl methyl ester. p-toluene sulfonic acid salt 66 (0.57 g, 1.23 mmol). The 
reaction was spun at room temperature overnight. The resin was then filtered, 
washed according to protocol and dried under vacuum overnight. The resin changed 
colour from yellow to white (Fm loading 0.27 mmol/g, 44 %); Vmax(CH202) 1713br 
(ester & urethane G=O); 6c (63 MIHz, Gel, CD2C12) 17.4 (CH(C4H3C'3H3)), 19.1 
(CII(CAH3CH3)), 31.2 (CH(043)2), 47.0 (OCH2CH), 59.3 (NIETCH), 66.9 (2C, 
OCH2Ar & OCH2CH), 70.1 (GET2OAr), 114.8 (2C, o-OCH2Ar-H), 120.2 (2C, 
OFmAr-H); Cleavage MS ESI (+ve) found m/z 117.4 (Val, 18 %),295.8 (MW, 100), 
336.9 (14); C19H21NO2 requires 295.4; Cleavage LCMS R=19.4 mm, 118.4 (VaI}f, 
20 %), 296.5 (MW, 100). 
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6.2.2.4 	L-valine N-carboxy Wang resin (68) 
AN OH H 
ooc_ 
Fluorenyl methyl ester-protected L-valine-N-carboxy Wang resin 67 (loading 0.27 
mmol/g) was swollen in 20 % piperidinelDMF (10 ml) and the reaction spun at room 
temperature for 2 h. The resin was then filtered, washed according to protocol and 
dried under vacuum overnight: Vmax(CH2C12) 1713 (urethane C=O & carboxylic acid 
C=O); öc (63 MHz, Gel, CD2C12) 17.7 (CH(C4H3CBH3)), 19.5 (CH(C"H3C8H3)), 
31.4 (CH(CH3)2), 60.8 (NHCH), 66.4 (OCH2Ar), 70.0 (CH20Ar), 114.7 (2C, o-
OCH2Ar-H), 156.8 (CONH), 158.9 (CH20Ar), 177.0 (COOH); Cleavage MS ESI 
(+ve) found mlz 71.4 (18 %), 85.4 (100), 117.4 (M, 45), 158.6 (20), C5H10NO2 
requires 117.2. 
6c (63 MHz, Gel, CD2C12); 3 unassigned peaks 6c 22.8, 34.2, 44.4 




L-valine-N-carboxy Wang resin 68 (0.34 g, loading 0.27 mmol/g, 0.09 mmol) was 
swollen in DCM (3 ml) containing pyridine (7.5 tl, 0.09 mmol). Cyanuric fluoride 
(8.3 tl, 0.09 mmol) in DCM (2 ml) was added dropwise and the reaction mixture 
shaken at room temperature for 1 h 40 mm. A white precipitate formed. The resin 
was filtered and washed with 3 x DMF/water (1:1) to remove the cyanuric acid 
precipitate. The resin was then washed according to protocol and dried under 
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vacuum overnight: Vmax(CH2C12) 1844 (acid fluoride), 1723 (urethane CO); 6c (63 
MiHz, Gel, CD2C12) 17.6 (CH(dH3C'3H3)), 18.8 (CH(CAH3CBH3)), 30.3 (cFJ(CH3)2), 
59.0 (NHCH), 67.4 (OCH2Ar), 70.1 (CH20Ar), 114.9 (2C, o-OCH2Ar-H); 6F (250 
MFIz, Gel, CD2C12) 28.1; Cleavage MS ESI (+ve) found mlz 72.2 (18 %), 91.1 (13), 
118.1 (ValIr, 13), 120.1 (MW, 62), 130.2 ((C(OH)N)3, 22), 180.1 (100), C5H10FNO 
requires 119.1. 






L-valinylfluoride-N-carboxy Wang resin 69 (0.14 g, assume max. loading 0.27 
mmol/g, 0.04 mmol) was swollen in DCM (2 ml) containing dimedone (0.02 g, 0. 12 
mmol) and DIPEA (0.02 g, 0.12 mmol) and the reaction mixture spun at room 
temperature. A blue/purple colour was observed after 30 mm. After 7 h the resin 
was filtered and washed according to protocol, then dried under vacuum overnight: 
Vmax(CH2Cl2) 1763 (vinyl ester), 1718 (urethane CO), 1671 (a, 13-unsaturated 
ketone); 8c (63 MHz, Gel, CD2C12) 17.6 (CH(C4H3CBH3)), 19.0 (CH(C"H3C8H3)), 
28.0 (C(C113)2), 3 1. 0 (CH(CH3)2), 33.1 (C(CH3)2), 42.0 (GH2C(CH3)2), 50.8 
(CH2C(CH3)2), 59.5 (NHCH), 67.0 (OCH2Ar), 70.1 (CH2OAr), 114.8 (2C, o-
OCH2Ar-H), 116.9 (COCH=CO), 156.4 (CONH), 159.1 (CH20Ar), 168.0 
(COOC=CH), 169.4 (NETCHCO), 198.9 (COCH=COCO); Cleavage MS ESI (+ve) 
found m/z 181.6 (16 %), 239.8 (MW, 100), C13H21NO3 requires 239.3; Cleavage 







fluoride salt (72) 
O 
IZ 
 OH ---- FNBu4 
Dimedone (0.25 g, 1.78 mmol) was dissolved in DMF and tert-butyl ammonium 
fluoride (0.56 g, 1.78 mmol) added. Molecular sieves (3 A) were added and the 
solution decanted and concentrated under reduced pressure to yield an orange solid 
(0.71 g, 99%): 6H (200 MHz, CDC13) 0.99 (1211, t, J7.0, 4xCH2CH3), 1.03 (6H, s, 
C(CH3)2), 1.41 (8H, tq, J7.0, 4xCH2CH3), 1.63 (8H, U, J 7.0, 4xCH2CH2CH3), 2.16 
(4H, S. CH2C(CH3)2CH2), 3.19-3.27 (811, m, 4xCH2CH2CH2CH3), 5.22 (1H, br s, 
CHCOH); 3c  (63 MHz, DEPT, CDCI3) 13.4 (CH2CH2GH3), 19.5 (CH2GH2CH3), 
23.7 (CH2CH2CH3), 28.6 (C(C113)2), 32.2 (C(CH3)2), 48.3 (CH2C(C113)2), 58.4 
(FNCH2), 101.2 (COCH=COH), 162.4 (COCH=COH), 192.1 (COCH=COH). 
6.2.3 Results and Discussion I - Additional Ligands 




To a solution of dimedone (1.00 g, 7.13 mmol) in CHC13 (20 ml) was added L-valine 
methyl ester HC1 salt (1.20 g, 7.13 mmol) and the suspension neutralised by the 
addition of triethylamine (1.00 ml, 7.13 mmol). The resulting solution was stirred at 
room temperature overnight. The solution was then concentrated under reduced 
pressure to a yellow residue, which was triturated with hot ether, filtered and washed 
with ether to yield a white solid (1.66 g). The solid was dissolved in CHC13, washed 
with 2N HC1 and dried (MgSO4) before concentration under reduced pressure to a 
white solid (1.02 g, 57 %): rap 123 °C; [aI D —61.8 (c 1.0, CHC13); R0.44 
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DCMIMeOH (9:1); Vmax(flUjOl) 3268 (N-H), 1756 (ester), 1735 (cL43-unsaturated 
ketone), 1604 (enamine C=C), 1574, 1537 (amide II); 6H  (200 MHz, CDC13) 0.92 
(3H, d, J 7.0, CH(C1H3CBH3)),  0.94 (3H, d, J 7.0, CH(C'H3C'3H3)), 1.06 (61-1, s, 
C(C113)2), 1.82-1.95 (111, m, CH(CH3)2), 2.17 (211, s, CH2C(CH3)2), 2.23 (211, s, 
CH2C(CH3)2), 3.91 (1H, dd, J 8.0, 5.0, NHCII), 4.88 (111, d, J 8.0, NI]), 5.06 (1H, s, 
COCH=CO); 6c (63 MHz, DEPT, CDC13) 18.9 (CH(C4H3CB1-13)),  19.0 
(CH(CAH3CBH3)), 28.5  (C(( 41-13CBH3)), 28.7  (C(CAH3d3H3)),  31.4 (CH(CH3)2), 33.2 
(C(CH3)2), 44.0 (CH2C(CH3)2), 50.7 (CH2C(CH3)2), 52.7 (00113), 60.8 (NHCH), 
97.0 (COCH=CNH), 162.3 (COCH=CNH), 172.4 (COOCH3), 197.6 (COCH=CNH); 
MS ESI (+ve) found m/z 253.9 (M}[1 , 100 %), 276.1 (MNa, 16) 317.0 (64); FIRMS 
FAB (+ve) found m/z 254.17486 (MH), C141-124NO3 requires 254.17562. 
6.2.3.2 	N-benzyloxycarbonyl-L-valine methyl ester (79) 
H 	II I 0 
0 
The HC1 salt of L-valine methyl ester (1.00 g, 5.97 mmol) was dissolved in DCM (10 
MI) and DIPEA (1.04 ml, 5.97 mmol) added. N-(benzyloxycarbonyloxy)-
succinimide (1.49 g, 5.97 mmol) was added and the reaction stirred overnight at 
room temperature. The reaction mixture was then washed with water, dried over 
MgSO4 and concentrated under reduced pressure to a colourless liquid (1.45 g). 
Flash column chromatography on silica gel using DCM/MeOH (9.5:0.5) as eluent 
yielded a white solid (1.40g, 88 %): mp 63 °C, Lit .2  57-58 °C; [U]D -10.5 (c 1.0, 
C11C13), Lit .3  —21.3 (c 1.0, MeOH); R1=0.66 DCMJMeOH (9.5:0.5); Vmax(flUjOl) 
3351br (N-H), 1749 (ester), 1694 (urethane C=O), 1538 (amide II); 6H  (250 MIFIz, 
CDC13) 0.89 (3H, d, J 7.0, CH(CAH3CB113)),  0.96 (3H, d, J 7.0, CH(CH3CBH3)), 
2.11-2.20(IH, m, CH(CH3)2), 3.73 (3H, s, OCH3), 4.30(111, dd,J9.0, 5.0, NIHCI]), 
5.11 (2H, s, OCH2Ph), 5.26 (1H, d, J 9.0, NH); 8C (63 MHz, DEPT, CDC13) 17.3 
(CH(C4H3CBH3)), 18.7 (CH(C'H3C'FT3)), 31.0 (CH(CH3)2), 51.9 (OCH3), 58.8 
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(NHCH), 66.8 (OCH2Ph), [127.9 (CH), 128.3 (CH), 5C, Ar-H], 136.1 (OCH2Ph), 
156.0 (CONEI), 172.3 (COOCH3); FIRMS FAB (+ve) found m/z 266.13928 (MT{), 
C14H20N04 requires 266.13923. 





The general procedure outlined above (6.2.1.4, Method B) was followed using Cbz-
D-valine (0.20 g, 0.80 mmol) to yield a blue/pink oil. Flash column chromatography 
on silica gel using Pet.Ether/EtOAc (4:3) as eluent gave a colourless oil (0.19 g, 64 
%): [U]D +20.5 (c 0.5, CHC13); R=0.54 Pet.Ether/EtOAc (4:3); vmax(cnide oil) 
3326br (N-H), 1767 (vinyl ester), 1720 (urethane CO), 1672 (a,-unsaturated 
ketone), 1527 (amide II); 8H (250 MHz, CDC13) 0.94 (3H, d, J 7.0, CH(C"H3C'1-13)), 
1.02 (311, d, J 7.0, CH(C"H3C'3H3)), 1.09 (6H, s, C(CH3)2), 2.19-2.25 (111, m, 
CH(CH02), 2.25 (2H, s, CH2C(CH3)2), 2.38 (211, s, CH2C(CH3)2), 4.38 (1H, dd, J 
9.0, 5.0, NHCH), 5.11 (2H, s, OCH2Ph), 5.29 (1H, d, J 9.0, NI]), 5.89 (IH, s, 
COCH=CO), 7.34 (511, s, Ar-H); 8c (63 MHz, DEPT, CDC13) 18.0 
(CH(CIH3CBH3)), 19.4 (CH(C'H3C8H3)), 28.5 (C(dH3CBH3)), 28.6 
(C(CAH3CBH3)), 31.4 (C}I(CH02), 33.6 (C(CH3)2), 42.4 (CH2C(CH3)2), 51.2 
(CFI2C(CH3)2), 59.7 (NHCH), 67.7 (OCH2Ph), 117.3 (COCH=CO), [128.6 (CH), 
128.8 (CH), 129.0 (CH), SC, Ar-H], 136.4 (OC112Ph), 156.7 (CON}I), 168.2 
(COOC=CH), 169.6 (NIHCHCO), 199.7 (COCH=COCO); HRMS FAB (+ve) found 
mlz 374.19672 (MW), C211128N05 requires 374.19675. 
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6.2.4.2 	3-(N-tertbutyloxycarbonyl-L-valinyloxy)-5,5-dimethyl-2-cyclo- 
hexen-1 -one (81) 
To a cold (-10 °C) solution of tert-butyloxycarbonyl-L-valine (5.0 g, 23.0 mmol) in 
THF (50 ml), were added triethylamine (3.21 ml, 23.0 mmol), and methyl 
chioroformate (1.96 ml, 25.0 mmol). A white precipitate formed and further THF 
(30 ml) was added. The mixture was stirred for 5 min at -5 °C, and dimedone (3.22 g, 
23.0 mmol) added. The reaction was allowed to warm to room temperature and 
stirring continued overnight. The reaction mixture was diluted with EtOAc (100 ml), 
washed with brine (3 x 50 ml), dried over MgSO4 and concentrated under reduced 
pressure to a colourless oil (4.48 g). Flash column chromatography on silica gel 
using hexane/EtOAc (3:2) yielded a colourless oil (0.29 g, 37 %): [aID —12.0 (c 1.0, 
CHC13); R1=0.49 hexane/EtOAc (3:2); vmax(crude oil) 3329br (N-H), 1767 (vinyl 
ester), 1712 (urethane C=O), 1674 (a,3-unsaturated ketone), 1514 (amide TI); 6H 
(250 MHz, CDC13) 0.92 (3H, d, J 7.0, CH(C"H3C'3H3)), 0.99 (3H, d, J 7.0, 
CH(C/H3CBH3)),  1.07 (6H, s, C(CH3)2), 1.41 (9H, s, C(CH3)3), 2.16-2.21 (111, m, 
CH(CH02), 2.24 (21-1, s, CH2C(CH3)2), 2.38 (211, s, CH2C(CH3)2), 4.26 (114, dd, J 
9.0, 5.0, NIHCH), 4.99 (111, d, J 9.0, NH), 5.87 (1H, s, COCHCO); 8c (63 MHz, 
DEPT, CDC13) 17.5 (CH(CIH3CBH3)),  18.9 (CH(C'H3C8H3)), 28.0 (C(C113)2), 28.1 
(C(CH3)3), 30.8 (CH(CH3)2), 33.0 (C(CH3)2), 41.8 (CH2C(CH3)2), 50.6 
(CH2C(CH3)2), 58.7 (NHCH), 80.1 (C(CH3)3), 116.6 (COCH=CO), 155.5 (CONE), 
167.8 (COOC=CH), 169.3 (NHCHCO), 199.1 (COCH=COCO); MS ESI (+ve) 
found m/z 141.0 (dimedone, 72 %), 362.0 (MNa, 100); HRMS FAB (+ve) found 
m/z 340.21247 (MW),  C18H30N05 requires 340.21240. 
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6.2.5 4-Alkyl Dimedone Derivatives 
6.2.5.1 	4,5,5-trimethyl-cyclohexane-1,3-dione (85) 
N-Butyllithium (1.6 M solution in hexane, 9.8 ml, 15.7 mmol) was added dropwise 
to a solution of dry diisopropylamine (2.2 ml, 15.7 mmol) in anhydrous TI-IF (12.5 
ml) with stirring at 0 T. After 30 mm, the mixture was cooled to —78 °C and a 
solution of dimedone (1.0 g, 7.1 mmol) and hexamethylphosphoric triamide (4.0 ml, 
24.2 mmol) in anhydrous THF (8 ml) was added over 5 mm. After stirring for 1 h at 
-78 °C, methyl iodide (0.5 ml, 7.8 mmol) was added and the mixture allowed to reach 
room temperature overnight. The reaction was quenched with water (5 ml), diluted 
with ether (50 ml), washed with 2N HC1 (3 x 50 ml), then water (50 ml). The 
combined aqueous phased were extracted with ether (2 x 50 ml) and the total organic 
phase washed with brine (50 ml), dried (MgSO4) and concentrated under reduced 
pressure to an orange solid (1.2 g). Flash colunm chromatography using 
Pet.Ether/EtOAc (1:1) yielded an off-white solid (0.6 g, 55%): mp 113 °C, Lit .4  100-
102 °C; [aID 0 (c 1.0, CHCI3) racemate; Rf=0.27 Pet.Ether/EtOAc (1:1); vmax(nujol) 
1737 (ketone), 1708 (a-branched ketone); 8H  (250 MIHz, CDC13) 0.75 (311, s, 
C(CAH3CI3H3)), 1.12 (3H, s, C(CAH3CI3H3)),  1.13 (3H, d, J7.0, CHCH3), 2.50 (1 H, 
dd, J 15.0, 2.0, COCH11BC(CH3)2),  2.58 (111, q, J7.0, CHCH3), 2.62 (1H, d, J 15.0, 
COCHAHIC(CH3)2), 3.31 (1H, dd, J 17.0, 2.0, COCH4CH8CO), 3.41 (1H, d, J 17. 0, 
COCHACHBCO); 6c (63 MHz, DEPT, CDC13) 8.7 (C(C4H3C8113)), 21.3 
(C(CAH3CH3)), 28.5 (CHCH3), 33.7 (C(CH3)2), 54.0 (CHCH3), 55.2 
(COCH2C(C113)2), 57.4 (COC11CO), 203.4 (CO), 205.2 (CO); MS ESI (+ve) found 
m/z 154.7 (MW, 100 %), 309.0 (dimer, 57); HRMS FAB (+ve) found m/z 
155.10715 (Iv1IH), C9H1502 requires 155.10720. 
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6.2.5.2 	3-(N-tertbutyloxycarbonyl-L-valinyloxy)-5,5-dimethyl-6-methyl-2- 
cyclohexen-1 -one (87) 
0
HJZC 1'~OYio 
diastereomeric mixture (X & Y) 
The general procedure outlined above (6.2.1.4, Method B) was followed using Cbz-
L-valine (0.20 g, 0.80 mmol) and 85 (0.09 g, 0.57 mmol), to yield a blue/pink oil. 
Flash column chromatography on silica gel using DCMIMeOH (9.5:0.5) as eluent 
gave a colourless oil (0.17 g, 78%): chiral HPLC, single peak 4.6 mm; [a]D —11.8 (c 
1.3, CHC13); Rf=0.83 DCMIMeOH (9:1); vmax(crude oil) 3329br (N-H), 1767 (vinyl 
ester), 1712 (urethane C=O), 1674 (a,13-unsaturated ketone), 1514 (amide II); 
ö (250 MHz, CDC13) 0.92 (3H, d, J 7.0, CH(CAH3CI3H3)), 0.93-1.11 (15H, m, 
CH(CH3)2, C(CH3)2CH(CH3)), 2.19-2.58 (4H, m, CH(CH3)2, CH2C(CH3)2CH(CH3)), 
4.38 (IH, dd, J9.0,5.0, NHCII), 5.11(2H, s, OCH2Ph), 5.25 (1H, d, J9.0, NH), 5.85 
(1H, s, COCH=CO), 7.35 (51-1, s, Ar-H); Oc (63 MHz, DEPT, CDC13) 9.3 
(COCHCH3, X), 9.4 (COCHCH3, Y), 17.4 (CH(C4H3C'3H3), X & Y), 18.9 
(CH(C1H3CBH3), X & Y), 22.0 (C(dH30113), X), 22.1 (C(C4H3CBH3), Y), 28.4 
(C(CAH3CBH3), X & Y), 31.0 (CH(CH3)2, X & Y), 35.8 (C(CH3)2, X), 35.9 
(C(CH3)2, Y), 41.8 (CH2C(CH3)2, X), 41.9 (CII2C(CH3)2, Y), 51.3 (COCHCH3, X & 
Y), 59.0 (NHCH, X & Y), 67.1 (OGEI2Ph, X & Y), 116.3 (COCH=CO, X & Y), 
[128.0 (CH), 128.2 (CH), 128.5 (CH), IOC, Ar-H, X & Y], 135.9 (OCH2Ph, X & Y), 
156.1 (CONH, X & Y), 166.2 (COOC=CH, X & Y), 169.1 (NHCHCO, X & Y), 
201.7 (COCHCOCO, X & Y); MS ESI (+ve) found m/z 387.9 (MW, 20 %), 404.9 
(MNH4 , 51), 410.04 (MNa, 100); HRMS FAB (+ve) found m!z 388.21228 (MF[), 
C22H29N05 requires 388.21240. 
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6.2.5.3 	4-allyl-5,5-dimethyl-cyclohexane-1,3-dione (88) 
N-Butyllithium (1.6 M solution in hexane, 9.8 ml, 15.7 mmol) was added dropwise 
to a solution of dry diisopropylamine (2.2 ml, 15.7 mmol) in anhydrous THF (12.5 
ml) with stirring at 0 T. After 30 mm, the mixture was cooled to —78 °C and a 
solution of dimedone (1.0 g, 7.1 mmol) and hexamethylphosphoric triamide (4.0 ml, 
24.2 mmol) in anhydrous THF (8 ml) was added over 5 mm. After stirring for 1 h at 
-78 °C, a suspension of allyl bromide (0.7 ml, 7.8 mmol) and sodium iodide (1.2 g, 
7.8 mmol) in anhydrous THF (2 ml) was added and the mixture allowed to reach 
room temperature overnight. The reaction was quenched with water (5 ml), diluted 
with ether (50 ml), washed with 2N HC1 (3 x 50 ml), then water (50 ml). The 
combined aqueous phased were extracted with ether (2 x 50 ml) and the total organic 
phase washed with brine (50 ml), dried (MgSO4) and concentrated under reduced 
pressure to an orange solid (1.2 g). Flash column chromatography using 
Pet.Ether/EtOAc (2:1) yielded a colourless oil (0.52 g, 41 %): R0. 16 
Pet.Ether/EtOAc (2:1); vmax(crude oil) 1739 (ketone), 1709 (a-branched ketone); 6H 
(250 IVIFIz, CDC13) 0.83 (3H, s, C(C'H3C5H3)), 1.11 (3H, s, C(CAH3CBH3)),  2.24-
2.35 (1H, m, CHCH4HBCH=CH2),  2.43-2.55 (4H, m, CHCFI2CHCH2, 
COCH2C(CH3)2, CHCHAHICH=CH2),  3.32 (1H, dd, J 16.5, 1.5, COCHAHBCO), 
3.41 (1H, d, J 16.5, COCHAHBCO),  4.98-5.12 (2H, m, CHCFT2CHCH2), 5.74-5.90 
(1H, m, CHCH2CH=CH2); 6c (63 MHz, DEPT, CDCI3) 22.8 (C(dH3C'3H3)), 28.7 
(C(CAH3CBII3)), 28.8 (CHCH2CH=CH2), 33.6 (C(CH3)2), 54.4 (COCH2C(CH3)2), 
57.9 (COCH2CO), 60.0 (CHCH2CH=CH2), 116.3 (CHCH2CH=CH2), 136.3 
(CHCH2CH=CH2), 203.0 (CO), 203.9 (CO); HRMS FAB (+ve) found m/z 
181.12279 (MH), C11H1702 requires 181.12285. 
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6.2.5.4 	(2,2-Dimethyl-4, 6-dioxo-cyclohexyl) -acetic acid methyl ester (89) 
o;oi o____ 
The procedure outlined above (6.2.4.5) was followed using methyl bromoacetate 
(0.74 ml, 7.84 mmol) to yield a brown liquid (0.95 g). 	Flash column 
chromatography on silica gel using Pet.Ether/EtOAc (1:1) as eluent yielded a yellow 
oil (0.32 g, 21 %): R1=0.16 Pet.Ether/EtOAc (1:1); vmax(cmde oil); 6H  (250 MHz, 
CDC13); 8C  (63 MHz, DEPT, CDC13) 21.5 (C(C4H3CBH3)),  28.3  (C(CAH3CBH3)), 
28.4 (CH2C(0)OCH3), 33.4 (C(CH), 51.9 (CHCH2C(0)0CH3), 55.6 (OC1713), 56.0 
(CH2C(CH3)2), 58.1 (COC112CO), 173.1 (C(0)OCH3), 202.5 (COCH2CO), 202.7 
(COCH2CO); MS ESI (+ve) found m/z 212.6 (MIr, 100 %), 234.7 (MNa, 57); 
HRMS FAB (+ve) found m!z 213.11243 (MW), C, 1H1704 requires 213.11268. 
6.2.5.5 	4,7, 7-Trimethyl-3-oxo-2-oxa-bicyclo[2.2. lJheptane-1-carboxylic 
acid 4,5,5-trimethyl-3-oxo-cyclohex-1-enyl ester (91) 
85 (0.17 g, 1.07 mmol) was dissolved in anhydrous DCM (4 ml). Pyridine (0.13 ml, 
1.60 mmol) was added, followed by (-)-camphanic acid chloride (0.26 g, 1.18 mmol) 
and the solution stirred at room temperature for lh. DCM (6 ml) was added and the 
reaction mixture washed with saturated NaHCO3 solution, dried (MgSO4) and 
concentrated under reduced pressure to yield an orange oil (0.36 g). Flash column 
chromatography on silica gel using Pet.Ether/EtOAc (2:1) as eluent afforded a pale 
yellow solid 91a (43 mg, 12 %): chiral HPLC, single peak 4.5 mm; mp 103 °C; [a]D 
—15.4 (c 1.1, CHC13); Rf=0.37 Pet.Ether/EtOAc (2:1); Vmax(flUjOl) 3020-2877 (C-H), 
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1790br (ester C=O), 1677 (C=O); 6H (250 MHz, CDC13) 0.95 (31-1, s, 
CH2C(CAH3CH3)),  1.00 (31-1, s, CH2C(CH3)C(CH3)2), 1.06 (31-1, s, 
CH2C(CAH3CH3)),  1.06 (311, d, J 7.0, CHCH3), 1.10 (31-1, s, 
CH2C(CH3)C(CAH3CBH3)), 1.11 (311, s, CH2C(C113)C(CAH3CI3H3)), 1.65-1.76 (IH, 
m, CHAHBCH2),  1.89-2.14 (21-1, in, CHAH/CH2  & CH2CH4H'3), 2.23 (1H, q, J 7.0, 
CHCH3), 2.30-2.55 (3H, in, CH2CHAJIB & CH2C(CH3)2), 5.88 (11-1, s, OC=CH); 
6c (63 MHz, DEPT, CDC13) 9.3 (CH2C(CH3)C(C4H3C'3H3)), 9.5 
(CH2C(CH3)C(CA1-1301-13)),  16.6 (CH2C(CH3)C(CH3)2), 22.0 (CH2C(C4H3CBH3)), 
28.4 (CH2C(CAH3CBH3)),  28.7 (CH2CH2), 30.5 (CH2CH2), 35.9 (CH2C(CH3)2), 41.9 
(CH2C(CH3)2), 51.2 (CHCH3), 54.6 (CH2C(CH3)C(CH3)2), 54.7 
(CH2C(CH3)C(CH3)2), 90.3 (CH2CC(0)0), 116.6 (OC=CH), 164.5 (OC(0)C(CH3)), 
165.7 (OC=CH), 177.3 (C(0)OC=CH), 201.4 (OC=CHC(0)); MS ES! (+ve) found 
m!z 335.0 (MH, 100 %); FIRMS FAB (+ve) found m!z 335.18551 (MW), C19H2705  
requires 335.18585. 
A second fraction was isolated from the column as a pale yellow solid (79 mg, 22 
%), corresponding to a mixture of the two diastereomers 91 by TLC R0.35, 0.37 
Pet.Ether/EtOAc (2:1). 
6.2.5.6 	Cleavage of camphanic ester (91) 
91(0.20 g, 0.60 mmol) was dissolved in 0.5 M NaOMe solution in MeOH (1.2 ml, 
0.6 mmol) and the solution stirred at room temperature for 5 mm. The reaction 
mixture was diluted with DCM (4 ml) and acidified to pHi using 2M HC1. The 
organic layer was separated, dried (MgSO4), and concentrated under reduced 
pressure to an off-white solid (0.20 g). Flash column chromatography on silica gel 
using DCMIMeOH (9.5:0.5) as eluent afforded a white solid (0.08 g, 87 %); R0.42 
DCMIMeOH (9.5:0.5); analysis identical to 85, 6.2.4.3. 
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6.2.5.7 	5,5-Dimethyl-3-(1,3,3.-trimethyl-bicyclof2.2. lJhept-2-yloxy)- 
cyclohex-2-enone (94) 
Dimedone (1.00 g, 7.03 mmol) was dissolved in DCM (10 ml) with TsOH (1.35 g, 
7.84 mmol) and fenchol (1.21 g, 7.84 mmol). The solution was stirred at room 
temperature overnight, before concentration under reduced pressure to give a yellow 
oil (4.06 g). Flash column chromatography on the Biotage system (40M column) 
using hexane/EtOAc (4:1) as eluent afforded a colourless oil (0.27 g, 14 %): [a]D 
+154.3 (c 1.0, CHC13); R=0.22 hexane/EtOAc (4:1); vmax(cnide oil) 2960-2872br 
(C-H), 1639 (ketone C=O), 1601 (a43-unsaturated ketone); 6H (250 MIHz, CDC13) 
0.78 (3H, s, C(CH3)C112CH2), 1.01 (3H, s, C(0)HC(CAH3CH3)),  1.04 (611, s, 
CH2C(CH3)2), 1.11 (3H, s, C(0)HC(CAH3CBH3)),  0.98-1.86 (7H, m, 
C(C113)CH2CH2CHCH2), 2.17 (2H, s, CH2C(CH3)2CH2), 2.27 (211, d, J 4.5, 
CH2C(CH3)CH2), 3.77 (1H, d, J 1.5, C(0)H), 5.34 (IH, d, J 0.5, OC=CH); 8c  (63 
MHz, DEPT, CDC13) 19.4 (C(0)HC(dH3CBH3)),  19.5 (C(0)HC(C"113C8F13)), 25.4 
(C(CH3)C1712CH2), 26.3 (C(CH3)GH2CH2), 27.6 (CH2C(dH3CBHA,  28.5 
(C112C(CAH3CH3)), 30.0 (C(CH3)CH2CH2), 32.2 (CH2C(CH3)2), 39.7 
(C(CH3)CH2CH2), 41.1 (CH2C(CH3)CH2), 43.1 (C(CH3)CH2CHC(CH3)2), 48.8 
(C(C113)CH2CIIC(CH3)2), 49.0 (C(0)HC(C113)2), 50.5 (CH2C(CH3)2CH2), 89.8 
(C(0)H), 102.0 (OC=CH), 177.2 (OC=CH), 199.6 (C=O); MS ESI (+ve) found m/z 
277.1 (MW, 14 %), 300.1 (MNa, 100); FIRMS FAB (+ve) found m/z 277.21709 
(MIfl, C18112902 requires 277.21676. 
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6.2.5.8 	6-Benzyl-5,5-dimethyl-3-(1,3,3-trimethyl-bicyclof2.2. 11hept-2- 
y1oxy)-cyclohex-2-enone (95) 
k ?< 
(diastereomers X ;Y) 
N-Butyllithium (1.6 M solution in hexane, 0.90 ml, 1.43 mmol) was added dropwise 
to a solution of dry diisopropylamine (0.20 ml, 1.43 mmol) in anhydrous TIIF (1 ml) 
with stirring at 0 T. After 30 mm, the mixture was cooled to —78 °C and a solution 
of 94 (0.18 g, 0.65 mmol) in anhydrous TIIF (0.5 ml) was added over 5 mm. After 
stirring for 1 h at -78 °C, benzyl bromide (0.09 ml, 0.72 mmol) was added and the 
mixture allowed to reach room temperature overnight. The reaction was quenched 
with water (1 ml), diluted with ether (5 ml) and washed with 2N HCI (3 x 5 ml). The 
combined aqueous phased were extracted with ether (2 x 5 ml) and the total organic 
phase washed with brine (10 ml), dried (MgSO4) and concentrated under reduced 
pressure to a yellow liquid (0.31 g). Flash column chromatography on the Biotage 
system (20M column) using DCM as eluent yielded a colourless oil (0.05 g, 22 %): 
chiral IIPLC, 2 peaks, 4.4 mm (48.0 Area %), 5.8 mm (50.1 Area %); [a]D +64.9 (c 
1.0, CHC13); R0.58 DCM; vmax(cflide oil) 3084-2872 (C-H), 1653 (ketone C0), 
1609 (a,13-unsaturated  ketone); 8H  (250 MHz, CDC13) 0.78 (31-1, s, C(CH3)CH2CH2, 
X), 0.83 (3H, s, C(CH3)CH2CH2, Y), 1.01-1.15 (24H, m, C(0)HC(CH3)2, 
CH2C(CH3)2, X & Y), 1.18-1.82 (14H, m, C(CH3)CH2CH2CHCH2, X & Y), 2.32-
2.39 (61-1, m, CH2C(CH3)CHCH2Ph, X & Y), 2.65-2.75 (211, m, CHHBPh.,  X & Y), 
2.98-3.12 (2H, m, CHAIJBPh,  X & Y), 3.78 (211, d, J6.5, C(0)H, X & Y), 5.32 (2H, 
s, 0CCH, X & Y), 7.12-7.28 (1 OH, m, Ar-H, X & Y); öc  (63 MHz, DEPT, CDC13) 
19.4 (C(0)HC(C4H3C'3113), X & Y), 19.6 (C(0)HC(C'H3C8H3), X & Y), 22.9 
(CH2C(C4H3CBH3),  X), 23.3 (CH2C(C4H3CBH3),  Y), 25.5 (C(CH3)CH2CH2, X & Y), 
26.2 (C(CH3)CH2CT-12, X & Y), 28.8 (CH2C(C1H3CBH3),  X), 28.9 
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(CH2C(CA143CaH3),  Y), 3 0. 0 (C(U13)CH2CH2, X & Y), 31.4 (CH2Ph, X), 31.7 
(CH2Ph, Y), 35.6 (CH2C(CH3)2, X & Y), 39.7 (C(CH3)CH2CH2, X), 39.8 
(C(CH3)CH2C112, Y), 41.2 (C(CH3)CH2CH2CHCH2, X & Y), 42.8 (CH2C(CH3)2, X), 
43.2 (CH2C(CH3)2, Y), 48.8 (CHC(CH3)2CO3 X & Y), 49.0 (C(0)HC(CH3)2, X & 
Y), 59.0 (CHCH2Ph, X & Y), 89.5 (C(0)H, X), 89.7 (C(0)H, Y), 101.6 (OC=CH, 
X), 101.7 (OC=CH, Y), [125.5 (CH), 128.0 (CH), 128.8 (CH), 128.9 (CH), Ar-H], 
141.7 (CH2Ph, X), 141.9 (CH2Ph, Y), 174.9 (OC=CH, X & Y), 200.2 (C=O, X & 
Y); MS ESI (+ve) found m/z 367.3 (MH, 47 %), 389.3 (MNa, 100); FIRMS FAB 
(+ve) found m/z 367.26396 (Ml{1 ), C25H3502 requires 367.26371. 
6.2.5.9 	5,5-Dimethyl-3-(1, 7, 7-trimethyl-bicyclo[2.2. lJhept-2-yloxy)- 
cyclohex-2-enone (97) 
Dimedone (1.0 g, 7.13 mmol) was suspended in DCM (10 ml) with TsOH (1.2 g, 
7.80 mmol) and borneol (1.21 g, 7.85 mmol). The resulting mixture was stirred at 
room temperature overnight. The solution was then washed with saturated NaHCO3  
solution (5 ml), dried (Mg504) and concentrated under reduced pressure to a pale 
yellow oil. Flash column chromatography on silica gel using hexane/EtOAc (1:1) as 
eluent afforded a colourless oil (1.49 g, 76 %): [aID —234.3 (c 0.9, dC13); R0.52 
hexane/EtOAc (1:1); vmax(crude oil) 2952-2875br (C-H), 1639 (ketone C0), 1602 
((x,13-unsaturated ketone); 8H  (250 MHz, CDC13) 0.81 (611, s, C(CH3)C(CH3)2), 0.82 
(3H, s, C(CH3)C(CH3)2), 0.83 (3H, s, CH2C(CAH3CBHA,  0.87-0.96 (1H, m, 
CHCHAHBCH4'HB'),  1.04 (3H, s, CH2C(CAH3CH3)),  1.13-1.29 (2H, m, 
CHCH4HBCHA'If),  1.56-2.02 (411, m, CH2CHCHAH),  2.17-2.29 (411, m, 
CH2C(C113)2CH2), 3.94-4.00 (111, m, CHO), 5.20 (111, s, OC=CH); 8C (63 MHz, 
DEPT, CDCI3) 13.4 (C(CH3)C(CH3)2), 18.6 (C(CH3)C(dH3C'3H3)), 19.4 
(C(CH3)C(CAH3CIH3)),  26.6 (CHCH2CH2), 27.6 (CHGH2CH2), 27.9 
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(CH2C(C4H3CB1-13)), 28.3  (CH2C(CAH30H3)),  32.3 (CH2C(CH3)2), 36.5 
(CH(0)CH2), 42.8 (CH2C(C113)2CH2), 44.7 (CHCH2CH2), 47.5 (C(CH3)C(CH3)2), 
49.0 (C(CH3)C(CH3)2), 50.5 (CH2C(CH3)2C1-12), 83.9 (CHO), 102.3 (OC=cH), 176.2 
(OC=CH), 199.7 (C=O); MS ESI (+ve) found mlz 276.9 (MH, 100 %); FIRMS FAB 
(+ve) found mlz 277.21650 (MIE[), C18112902 requires 277.21676. 





N-Butyllithium (1.6 M solution in hexane, 6.88 ml, 11 mmol) was added dropwise to 
a solution of dry diisopropylamine (1.54 ml, 11 mmol) in anhydrous THF (9 ml) with 
stirring at 0 °C. After 30 mm, the mixture was cooled to -78 °C and a solution of 97 
(1.38 g, 5 mmol) and hexamethyiphosphoric triamide (2.81 ml, 17 mmol) in 
anhydrous THF (5.5 ml) was added over 5 mm. After stirring for 1 h at -78 °C, a 
suspension of benzyl bromide (0.65 ml, 5.5 mmol) and sodium iodide (0.82 g, 
5.5 mmol) in anhydrous THF (2 ml) was added and the mixture allowed to reach 
room temperature overnight. The reaction was quenched with water (5 ml), diluted 
with ether (50 ml) and washed with 2N HC1 (3 x 50 ml). The combined aqueous 
phased were extracted with ether (2 x 50 ml) and the total organic phase washed with 
brine (50 ml), dried (MgSO4) and concentrated under reduced pressure to an orange 
oil (2.72 g). Flash column chromatography on the Biotage system (40M column) 
using hexane/EtOAc (4:1) yielded a colourless oil (0.27 g, 15 %): chiral HPLC, 
2 peaks, 5.1 mm (45.4 Area %), 6.6 mm (51.8 Area %); [U]D -69.5 (c 1.5, CHCI3); 
Rf=0.61 hexane/EtOAc (4:1); vmax(crude oil) 3084-2873br (C-I-I), 1654 (ketone 
C0), 1614 (a43-unsaturated ketone); oH (250 MHz, CDC13) 0.85-0.89 (18H, m, 
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C(CH3)C(CH3)2, X& Y), 0.85-1.35 (611, m, CHCH4HBCH2,  X & Y), 1.02 (311, s, 
CH2C(C1H3CB113),  X), 1.03 (3H, s, CH2C(CAH3CBH3),  Y), 1.10 (311, s, 
CH2C(C1H3CBH3),  X), 1.12 (31-1, s, CH2C(CAH3CI3H3),  Y), 1.68-1.76 (4H, m, 
CHCHAHBCH2 & CH(0)CH4HB,  X & Y), 1.96-2.06(211, m, CH(0)CHAHB,  X & Y), 
2.24-2.39 (811, m, CHCH2CH2 & CH2C(CH3)2CHCH2Ph, X & Y), 2.67-2.76 (2H, m, 
CH4HBPh, X & Y), 2.98-3.12 (2H, m CH"II8Ph, X & Y), 4.16-4.21 (211, m, CHO, 
X & Y), 5.17 (111, s, OC=CH, X), 5.19 (1H, s, OCCH, Y); 8c (63 MHz, DEPT, 
CDC13) 13.5 (C(CI-13)C(CH3)2, X & Y), 18.6 (C(CH3)C(dH3CBH3),  X & Y), 19.5 
(C(CH3)C(C1H3CBH3),  X & Y), 23.2 (CH2C(C4H3CB1-13),  X), 23.5 
(CH2C(CH3CBH3),  Y), 26.6 (CHCH2CH2, X& Y), 27.7 (CHCH2CH2, X& Y), 28.9 
(CH2C(C"H3C8H3), X), 29.6 (CH2C(C"H3C8H3), Y), 31.6 (CH2Ph, X), 31.7 (CH2Ph, 
Y), 35.7 (CH(0)CH2, X& Y), 36.5 (CH2C(CH3)2, X), 36.6 (CH2C(CH3)2, Y), 42.6 
(CH2C(CH3)2, X), 42.8 (CJ-12C(CH3)2, Y), 44.7 (CHCH2CH2, X & Y), 47.5 
(C(CH3)C(CH3)2, X & Y), 49.0 (C(CH3)C(CH3)2, X & Y), 58.9 (CHCH2Ph, X), 59.0 
(CHCH2Ph, Y), 83.6 (CEO, X), 83.8 (CHO, Y), 101.8 (OC=CH, X), 101.9 (OC=CH, 
Y), [125.5 (CH), 125.6 (CH), 128.1 (CH), 128.8 (CH), Ar-H, X & Y], 141.7 (CH2Ph, 
X), 141.8 (CH2Ph, Y), 173.8 (OC=CH, X), 173.9 (OC=CH, Y), 200.7 (C=O, X), 
200.8 (C=O, Y); MS ESI (+ve) found mlz 389.3 (MNa, 100 %); HRMS FAB (+ve) 
found m/z 367.26360 (MiFf), C25113502  requires 367.26371. 
Attempts to separate the diastereomeric mixture by TLC using numerous different 
solvent systems were unsuccessful. 
6.2.5.11 	Cleavage of borneo! from (98) 
98 (0.25 g, 0.68 mmol) was dissolved in THF (5 ml) containing 12N HCl (1.67 ml, 
20 mmol). The solution was stirred at room temperature overnight. The mixture was 
diluted with DCM (20 ml), washed with saturated NaHCO3 solution (10 ml), dried 
(MgSO4) and concentrated under reduced pressure to a colourless oil. Flash column 
chromatography on silica gel using hexane/EtOAc (3:1) as eluent afforded a 
colourless oil 99 (0.13 g, 82 %): chiral J{PLC, single peak 6.4 mm; R0.35 
hexane/EtOAc (1:1); analysis identical to 99, 6.2.5.12. 
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6.2.5.12 	4-benzyl-5,5-dimethyl-cycioherane-1,3-dione (99) 
Oj 0 
N-Butyllithium (1.6 M solution in hexane, 39.2 ml, 62.8 mmol) was added dropwise 
to a solution of dry diisopropylamine (8.8 ml, 62.8 mmol) in anhydrous THF (40 ml) 
with stirring at 0 T. After 30 mm, the mixture was cooled to —78 °C and a solution 
of dimedone (4.0 g, 28.5 mmol) and hexamethylphosphoric triamide (16.0 ml, 97.0 
mmol) in anhydrous THF (20 ml) was added over 5 mm. After stirring for 1 h at -78 
a suspension of benzyl bromide (3.7 ml, 31.4 mmol) and sodium iodide (4.7 g, 
31.4 mmol) in anhydrous TI-IF (5 ml) was added and the mixture allowed to reach 
room temperature overnight. The reaction was quenched with water (15 ml), diluted 
with ether (150 ml) and washed with 2N HC1 (3 x 150 ml). The combined aqueous 
phased were extracted with ether (2 x 150 ml) and the total organic phase washed 
with brine (150 ml), dried (MgSO4) and concentrated under reduced pressure to an 
orange liquid (27.12 g). Flash column chromatography on the Biotage Quad system 
(40M column, several loadings) using hexane/EtOAc (2.5:1) yielded a yellow oil 
(2.08 g, 32 %): Rf=0.35 hexanefEtOAc (1:1); vmax(crude oil) 1640 (ketone), 1612 
(ketone); 6H  (250 MIHz, CDCI3) 0.85 (3H, s, C(C1 H3CBH3)),  1.25 (3H, s, 
C(CAH3CBH3)),  2.53 (1H, dd, J 15.0, 2.0, COCH4HBC(CH3)2,),  2.65 (111, d, J 15.0, 
COCHAHBC(CH3)2),  2.78 (1H, dd, J 14.5, 1.5, CHAHBPh),  2.80 (111, dd, J 10.0, 1.5, 
COCHCH2Ph), 3.13 (1H, dd, J 14.5, 10.0, CHAHBPh),  3.31 (1H, dd, J 16.0, 2.0, 
COCHACHBCO),  3.41 (1H, d, J 16.0, COCHACIIBCO),  7.17-7.30 (511, m, Ar-H); 8c 
(63 MHz, DEPT, CDC13) 22.2 (C(C4H3CBH3)),  29.0  (C(CAH3CBH3)),  29.7 (CH2Ph), 
34.1 (C(CH3)2), 55.2 (COCH2C(CH3)2), 58.6 (COCH2CO), 62.3 (CHCH2Ph), [126.1 
(CU), 128.3 (CH), 128.8 (CH), 5C, Ar-H], 140.5 (CH2Ph), 202.8 (CO), 203.0 (CO); 
MS ESI (+ve) found m/z 230.7 (ME[, 70 %), 247.8 (MN}I4 , 21), 252.8 (MNa, 
100), 293.8 (59); HRMS FAB (+ve) found m/z 23 1.13862 (MH), C15H1902 requires 
231. 1385 1. 
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6.2.5.13 	1benzyI-2(hydroxyquino1in-4-yI-methyI)-5-vinyl-1-azonia- 
bicyclof2.2.2]octane;fluoride (104) 
Amberlite IRA 410 (OH) ion exchange resin (10 ml) was loaded onto a glass column 
using 1120. The resin was washed through with 1120, then MeOH. 1M aqueous I-IF 
(100 ml) was passed through the column, followed by several column volumes of 
MeOH. Finally benzyl cinchonidinium bromide (0.95 g, 2.04 mmol) in MeOH 
(2 ml) was passed through the column followed by several more column volumes of 
MeOH. The combined MeOH washings were concentrated under reduced pressure 
to yield an off-white solid, which was dried in a vacuum desiccator over P205, 
affording a white solid (0.67 g, 81 %): mp 165 °C; [a]D —155.9 (c 1.0, CHC13); 8H 
(250 MHz, CDC13) and öc (63 MHz, DEPT, CDC13), signals identical to 1-benzyl-2- 
(hydroxy-quino lin-4-yl-methyl)- 5 -vinyl- 1 -azonia-bicyclo [2.2.2]octane; 	bromide 
(103) starting material; 6F  (CDC13) -126.6 (4-fluorophenol), -125.4 (fluoride 104). 
6.2.5.14 	4-cyclohexylmethyl-5,5-dimethyl-cyclohexane-1,3-dione (105) 
The general procedure outlined above (6.2.5.12) was followed using 
methylcyclohexyl bromide (4.38 ml, 31.38 mmol) to yield a dark orange liquid 
(11.86 g). Flash column chromatography on the Biotage Quad system (40M column, 
several loadings) using hexane/EtOAc (3.5:1) yielded a white solid (3.46 g, 51 %): 
mp 122 °C; Rj=0.50 hexane/EtOAc (1:1); vmax(nujol) 1616 (ketone); 6H (250 MHz, 
CDC13) 0.84 (311, s, C(CAH3CBH3)),  1.07 (311, s, C(CAH3CBH3)),  0.89-1.34 (711, m, 
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COCHCHA11BCH(CH2)5,  COCHCH2CHCH2(CH2)3CH2), 1.68-1.86 (6H, m, 
COCHCHAHBCH(CH2)5, COCHCH2CH(CH2)5, COCHCH2CHCH2(CH2)3CH2), 2.49 
(111, dd, J 10.5, 2.0 CHCH2CH(CH2)5), 2.55 (211, s, COCH2C(CH3)2), 3.39 (2H, s, 
COCH2CO); 8c (63 MFIz, DEPT, CDC13) 23.7 (C(C4H3CBHA,  [26.5 (CH2), 26.7 
(CH2), 26.9 (CH2), 3C, COCHCH2CHCH2(CH2)3CH2)] 29.2 (C(CAH3CBH3)),  [32.4 
(CH2), 32.8 (CH2), 2C, COCHCH2CHCH2(CH2)3CH2)], 34.0 (C(CH3)2), 34.8 
(CH2CH(CH2)5), 36.7 (CH2CH(CH2)5), 54.3 (COCIT2C(CH3)2), 57.7 
(COCHCH2CH(CH2)5), 58.0 (COCH2CO), 203.9 (CO), 205.5 (CO); H1RMS FAB 
(+ve) found m!z 237.18539 (M1{), C15H2502 requires 237.18546. 
6.2.5.15 	Attempted preparation of 6-cyclohexylmethyl-3-hydroxy-5,5- 
dimethyl-cyclohex-2-enone benzyl cinchonidinium fluoride salt 
(106) 
OH F / 
HO 	N 
105 (0.23 g, 1 mmol) was dissolved in THF (2 ml) and 104 (0.20 g, 0.5 mmol) 
added. The reaction mixture was heated until all of the suspended solid had 
dissolved. On cooling to room temperature a white solid precipitated out and was 
filtered off and dried in a vacuum desiccator to yield an off-white powder (0.07 g): 
81 (250 MHz, CDC13) and & (63 MHz, DEPT, CDC13) indicated a 1:1 mixture of 
104 and 105 starting materials. 
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6.2.5.16 	Attempted cleavage of Boc group of (81) 
OONH 
6.2.5.1 6.1 	MethodA 
81(0.76 g, 2.43 mmol) was dissolved in DCM (5 ml) and TFA (0.22 ml, 2.92 mmol) 
added. The solution was stirred at room temperature for 1.5 h, after which time TLC 
DCM/MeOH (9:1) indicated disappearance of 81. The solution was concentrated 
under reduced pressure to a pale yellow liquid (0.87 g). 	Flash column 
chromatography on silica gel using DCMIMeOH (9.5:0.5) as eluent afforded a 
yellow solid (0.17 g, 49 %): oF! (250 MHz, CDC13) analysis indicated recovery of 
dimedone starting material. 
6.2.5.16.2 	Method B 
81 (0.13 g, 0.38 mmol) was dissolved in 10 % H2SO4 in EtOAc. TLC DCMIMeOH 
(9:1) indicated immediate disappearance of 81. The solution was diluted with further 
EtOAc, washed (1-120), dried (MgSO4), and evaporated to a white solid (32 mg, 
61 %) 0H  (250 MHz, CDC13) analysis indicated recovery of dimedone starting 
material. 
6.2.5.17 	3-(N-fluorenylmethoxycarbonyl-L-valinyloxy)-5,5-dimethyl-2- 
cyclohexen-1 -one (108) 
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The general procedure outlined above (6.2.1.4, Method B) was followed using Fmoc-
L-valine (0.25 g, 0.74 mmol) to yield a pale yellow oil. Flash column 
chromatography on silica gel using Pet.Ether/EtOAc (1:1) as eluent gave a pale 
yellow oil (41 mg, 12 %): R0.76 Pet.Ether/EtOAc (1:1); vmax(crude oil) 3325br (N-
II), 1762 (vinyl ester), 1718 (urethane C0), 1673 (a,3-unsaturated ketone), 1525 
(amide II); 6H  (250 MHz, CDC13) 0.93-1.04 (6H, m, CH(CH3)2), 1.10 (6H, s, 
C(CH3)2), 2.13-2.37 (1H, m CH(CH3)2), 2.27 (2H, s, CH2C(CH3)2), 2.41 (2H, s, 
CH2C(CH3)2), 4.23 (1H, t, J 7.0, CHCH20), 4.34 (III, dd, J 9.0, 4.5, NHCR), 4.40 
(1H, dd, J 12.0, 6.5, CHCHAHBO), 4.42 (1H, dd, J 12.0, 6.5, CHCHAHBO), 5.26 (111, 
t, J 9. 0, NH), 5.92 (111, s, COCH=CO), 7.25-7.42 (4H, m, Ar-H), 7.59 (2H, d, J 7. 0, 
Ar-I]), 7.76 (2H, d, J 7.5, Ar-H); öc (63 MHz, DEPT, CDC13) 17.3 
(CH(C4H3CBH3)), 18.9  (CH(CAH3CBH3)), 28.0 (C(C4H3C'3H3)), 28.1 
(C(CAH3CBH3)),  30.9 (CH(CH3)2), 33.1 (C(CH3)2), 41.9 (CH2C(CH3)2), 47.1 
(OCH2CH), 50.6 (CH2C(CH3)2), 58.7 (NEIGH), 67.0 (OCH2CH), 116.8 
(COCH=CO), [119.9, (CH), 124.9 (CH), 127.0 (CH), 127.6 (CH), 8C, OFmAr-H], 
141.2 (2C, Ar-Ar), 143.6 (2C, Ar-CHCH2), 156.2 (CONE), 167.6 (COOCCH), 
168.9 (NHCHCO), 199.2 (COCH=COCO); MS ESI (+ve) found m/z 484.3 (MNa, 
100 %); HRMS FAB (+ve) found m!z 462.22833 (MW), C28H32N05 requires 
462.22805. 
6.2.5.18 	N-benzoyl-L-valine (110) 
To a stirred solution of L-phenylalanine (1.82 g, 11 mmol) in anhydrous DCM (20 
ml) was added chiorotrimethylsilane (1.4 ml, 11 mmol). The mixture was refluxed 
for 2 h before cooling to —15 T. Benzoyl chloride (1.2 ml, 10 mmol) was added 
dropwise, followed by triethylamine (3.1 ml, 22 mmol) with the temperature kept 
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below 5 T. The solution was stirred at -10 °C for 1.5 h, then stirring continued for a 
further 0.5 h at 0 °C. 0.5N HC1 (2 x 10 ml) was added and the phases separated. The 
combined aqueous phase was washed with DCM (2 x 10 ml), dried (MgSO4) and 
concentrated under reduced pressure to a yellow solid (3.07 g) which was triturated 
with ether yielding a pale yellow solid (1.72 g, 64 %): rap 179 °C, Lit.' 184-185 °C; 
[aID -8.2 (c 1.0, MeOH), Lit .6  -3.6 (c 0.7, MeOH); R0.19 DCMIMeOH (9:1); 
Vmax(flUjOl) 3324br (0-Fl), 1718 (acid C=0), 1613 (amide C0), 1536 (amide II); 6H 
(250 MIHz, DMSO) 3.05-3.25 (2H, m, CH2Ph), 4.59-4.68 (IH, in, NHCH), 7.14-7.35 
(511, in, Ar-H), 7.41-7.55 (3H, in, Ar-H), 7.78-7.83 (21-1, in, Ar-H), 8.74 (1H, d,J8.0, 
Nil); öc (63 MHz, DEPT, DMSO) 36.4 (CH2Ph), 54.4 (NHCH), [126.5 (CH), 127.5 
(CH), 128.3 (CH), 128.4 (CH), 129.2 (CH), 131.5 (CH), 10C, Ar-HI, 134.1 (CH2Ph), 
138.4 (CON), 166.6 (CONH), 173.4 (COOH); MS ES! (-ye) found m/z 267.8 ([M-
H]-, 100 %); FIRMS FAB (+ve) found m/z 270.11304 (MH), C16H16NO3 requires 
270.11302. 




To a stirred solution of L-valine (1.29 g, 11 mmol) in anhydrous DCM (20 ml) was 
added chlorotrimethylsilane (1.4 ml, 11 mmol). The mixture was refluxed for 2 h 
before cooling to -20 T. Methyl chioroformate (0.77 ml, 10 mmol) was added 
dropwise, followed by triethylamine (3.1 ml, 22 mmol) with the temperature kept 
below -20 T. The solution was stirred for 2 h at -20 to -40 °C, then stirring 
continued for a further 1 h at 0 °C. 0.5 N HC1 (2 x 10 ml) was added and the phases 
separated. The combined aqueous phase was washed with DCM (2 x 10 ml), dried 
(MgSO4) and concentrated under reduced pressure to a pale yellow oil which 
solidified on cooling. The oil was triturated with ether to yield a white solid (1.79 g, 
93%): 110 °C, Lit .7 109-110 °C; [ct]n -6.6 (c 1. 1, MeOH), Lit 
.8  -8.4 (c 1.2, MeOH); 
vmax(nujol) 3397br (0-H), 1749 (acid C=0), 1733 (urethane C=0), 1666 (C=0), 
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1552 (amide II) H (250 MHz, DMSO) 0.86 (311, d, J 6.5, CH(CiH3CB113)), 0.88 
(3H, d, J 6.5, CH(CAH3CBH3)),  1.96-2.07 (1H, m, CH(CH3)2), 3.53 (3H, s, OCH3), 
3.83 (1H, dd, J 8.5, 6.0, NHCH'), 7.33 (114, d, J 8.5, NH); 8c (63 MEk, DEPT, 
DMSO) 18.1 (CH(C4H3CB143)), 19.3 (CH(C1H3CBH3)),  29.7 (C1-T(CH3)2), 51.6 
(OCH3), 59.7 (N}ICH), 157.2 (CONH), 173.5 (COOH); MS ESI (-ye) found m/z 




The general procedure outlined above (6.2.1.4, Method B) was followed using 115 
(0.15 g, 0.86 mmol) to yield a blue/pink oil. Flash column chromatography on silica 
gel using Pet.Ether/EtOAc (4:3) as eluent to give a colourless oil (0.12 g, 46 %): [a]D 
—2.4 (c 1.6, CHC13); R1=0.59 Pet.EthertEtOAc (4:3); vmax(crude oil) 3325br (N-H), 
1767 (vinyl ester), 1717 (urethane C=O), 1674 (a,13-unsaturated ketone), 1534 
(amide II); 6H (250 MHz, CDC13) 0.90 (3H, d, J7.0, CH(C1\H3CBH3)),  1.07 (311, d, J 
7. 0, CH(CAH3CI3H3)), 1.54 (6H, s, C(CH3)2), 2.18-2.25 (1H, m, CH(CH02), 2.28 
(211, s, CH2C(CH3)2), 2.41 (211, s, CH2C(CH3)2), 3.71 (311, s, OCH3), 4.38 (1H, dd, J 
9.0, 5.0, NHCH), 5.12 (1H, d, J 9.0, NH), 5.90 (111, s, COCHCO); 8c (63 MHz, 
DEPT, CDC13) 17.8 (CH(C4H3CBH3)),  19.5  (CH(CAH3CBH3)),  28.6 (C(C4H3CBH3)), 
28.7 (C(C"H3C'H3)), 31.4 (CH(CH3)2), 33.7 (C(CH3)), 42.5 (CH2C(CH3)2), 51.1 
(CH2C(CH3)2), 53.0 (OCH3), 59.3 (NUCH), 117.3 (COCH=CO), 157.6 (CONH), 
168.5 (COOC=CH), 169.8 (NHCHCO), 200.1 (COCH=COCO); HRMS FAB (+ve) 
found m/z 298.16539 (MIT), C151124N05 requires 298.16545. 
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6.2.5.21 	Attempted preparation of N-cyclohexylaminocarbonyl-L-valine 




To a solution of cyclohexylamine (0.24 ml, 2.13 mmol) in DCM (5 ml) and MeCN 
(5 ml) were added DSC (0.55 g, 2.13 mmol) and DMAP (0.13 g, 1.07 mmol). The 
mixture was stirred at room temperature overnight resulting in a cloudy white 
solution. L-valine (0.25 g, 2.13 mmol) was added followed by triethylamine (0.15 
ml, 1.07 mmol) and the reaction again stirred overnight. The mixture was 
concentrated under reduced pressure to a white residue which was dissolved in 
saturated NaHCO3 solution (20 ml). The reaction mixture was acidified to pHi with 
2M HC1 and extracted with EtOAc (2 x 20 ml). The combined extracts were washed 
with 2M HCI (5 ml), dried (MgSO4) and concentrated under reduced pressure to a 
white solid (0.32 g):MS ESI (+ve) found mlz 225.0 (hydantoin, 100 %), 248.0 
(hydantoinNa, 42). 
6.2.5.22 	Attempted preparation of N-butylaminocarbonyl-L-vaiine 
0 
H JOH 
0 /k\  
The general procedure outlined above (6.2.5.21) was followed using N-butylamine 
(0.21 ml, 2.13 mmol) to yield a white solid (0.18 g): analysis indicated recovery of 
L-valine starting material. 
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6.2.5.23 	N-cyclolzexyloxycarbonyl-L-valine (123) 
0 
0 
Y  N ",:AOH 
> O ,/\  
To a solution of cyclohexanol (0.23 ml, 2.13 mmol) in DCM (5 ml) and MeCN (5 
ml) were added DSC (0.55 g, 2.13 mmol) and DMAP (0.13 g, 1.07 mmol). The 
mixture was stirred at room temperature overnight resulting in a cloudy white 
solution. L-valine (0.25 g, 2.13 mmol) was added followed by triethylamine (0.15 
ml, 1.07 mmol) and the reaction again stirred overnight. The mixture was 
concentrated under reduced pressure to a white residue which was dissolved in 
saturated NaHCO3  solution (20 ml). The reaction mixture was acidified to pHi with 
2M HC1 and extracted with EtOAc (2 x 20 ml). The combined extracts were washed 
with 2M HC1 (5 ml), dried (MgSO4) and concentrated under reduced pressure to 
yield a colourless oil (0.47 g). Flash column chromatography on the Biotage system 
(column 40S) using DCM!MeOH (9.5:0.5) as eluent afforded a colourless oil (0.21 g, 
40 %): [cL]D —1.4 (c 1.2, CHC13); R=0.40 DCMIMeOH (9.5:0.5); vmax(crnde oil) 
3468br (0-H), 1779 (acid C=0), 1706 (urethane C=0); oH (200 MFIz, CDC13) 0.92 
(311, d, J7.0, CH(C1H3CB1-13)),  0.99 (311, d, J7.0, CH(C1H3CBH3)),  1.26-1.56 (6H, 
m, OCHCH2(CH2)3CH2), 1.71-1.88 (41-1, m, OCHCH2(CH2)3CH2), 2.20-2.24 (1H, m, 
CH(CH3)2), 4.20 (11-1, dd, J 8.5, 4.0, NHCII), 4.55-4.70 (1H, m, CHOCO), 5.48 (1H, 
d, J 8.5, NJ]), 8.31 (1H, br s, C00If); oc (63 MHz, DEPT, CDC13) 17.9 
(CH(dH3CBH3)), 19.8  (CH(CAH3CBH3)),  [24.3, (CH2), 25.9, (Cl2), 3C, 
OCHCH2(CH2)3CH2)], 32.0 (CH(C113)2), [32.4, (CH2), 2C, OCHGH2(CH2)3CH2)], 
60.5 (NIHCH), 73.3 (CHOCO), 157.3 (CONE), 176.7 (COOl); MS ESI (+ve) found 
m/z 244.0 (MT{, 45 %), 265.9 (MNa, 100); HRMS FAB (+ve) found mlz 
244.15473 (Ml), C121122N04 requires 244.15488. 
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6.2.5.24 	N-(2-methyl-allyloxycarbonyl)-L-valine (124) 
OyJOH 
The general procedure outlined above (6.2.5.23) was followed using 2-methyl-prop-
2-enol (0.18 ml, 2.13 mmol) to yield a colourless oil (0.23 g, 51 %): [aID —3.1 (c 1.3, 
CHC13); R1=0.41 DCMIMeOH (9:1); vmax(crude oil) 3328br (0-H), 1716br (acid 
C=0 & urethane C=0), 1530 (amide II); 8H (200 M}Iz, CDC13) 0.92 (314, d, J 7.0, 
CH(CAH3CBH3)), 0.98 (3H, d, J 7.0, CH(C1H3CBH3)),  1.75 (3H, s, CH2=CCH3), 
2.20-2.25 (111, m, CH(CH3)2), 4.13 (111, dd, J8.0, 4.0, NI4CII), 4.42 (1H, d, J 13.5, 
CH4HBOCO),  4.52 (1H, d, .1 13.5, CHAHI0C0),  4.93 (2H, d, J24.0, CH2=CCH3), 
5.80 (1H, d, J8.0, NH), 8.13 (111, br s, COOl]); 6c (63 MHz, DEPT, CDC13) 18.0 
(CH(CH3)2), 19.8 (CH2=CCH3), 31.9 (CH(CH3)2), 61.2 (NT{CH), 68.2 (CH2000), 
112.3 (CH2=CCH3), 141.3 (CH2=CCH3), 157.0 (CONH), 177.5 (COOH); MS ESI 
(+ve) found m!z 215.7 (MW, 35 %), 232.9 (MNH4 23), 237.8 (MNa, 100); HRMS 
FAB (+ve) found m!z 216.123 13 (M1{), C10H18N04 requires 216.12358. 
6.2.5.25 	carbonic acid 5,5-dimethyl-3-oxo-cyclohex-1-enyl ester isobutyl 
ester (128) 
ooTo 
128 was isolated as a by-product of 6.2.1.4, Method A, using isobutyl chloroformate; 
Rç=0.39 Pet.Ether/EtOAc (4:1); vmax(crude oil) 1769, 1705 (anhydride), 1673 (a43-
unsaturated ketone); 8H (250 MHz, CDC13) 0.97 (611, d, J 7.0, CH(CH3)2), 1.10 (6H, 
s, C(CH3)2), 1.43-2.08 (1H, m, CH(CH3)2), 2.26 (2H, s, CH2C(CH3)2), 2.44 (214, s, 
CH2C(C113)2), 3.99 (2H, d, J 7.0, CH2CH(CH3)2), 6.02 (111, s, COCH=C0); 8c (63 
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MHz, DEPT, CDC13) 19.2 (CH(CH3)2), 28.1 (C11(CH3)2), 28.5 (C(C113)2), 33.5 
(C(CH3)2), 42.1 (CH2C(CH3)2), 51.0 (CH2C(CH3)2), 75.6 (OCH2CH(CH3)2), 115.7 
(COCH=CO), 151.6 (OCOO), 168.3 (COOC=CH), 200.3 (COCH=COCO); HRMS 
FAB (+ve) found mlz 241.14392 (MM), C13H2104 requires 241.14398. 
	
6.2.5.26 	5,5-dimethyl-4-(3-phenyl-aIlyI)-cyclohexane-1,3-dione (129) 
o 
The general procedure outlined above (6.2.5.12) was followed using cinnamyl 
bromide (6.18 g, 31.38 mmol) to yield a dark orange liquid (29.07 g). Flash column 
chromatography on the Biotage Quad system (40M column, several loadings) using 
hexane/EtOAc (2.5:1) yielded a yellow oil (2.05 g, 28 %): R0.31 hexane/EtOAc 
(1:1); vmax(cmde oil) 1705 (a-branched ketone); oH (250 MHz, CDC13) 0.84 (3H, s, 
C(CAH3CB1-13)),  1.16 (3H, s, C(CAH3CBH3)),  2.15-2.74 (511, m, COCH2C(CH3)2, 
CHCH2CH=CHPh, CHCH2CH=CHPh), 3.33 (1H, d, J 16.5, COCH4HBCO),  3.44 
(111, d, J 16.5, COCHAHICO),  6.15-6.29 (111, m, CHCH2CH=CHPh), 6.45 (111, d, J 
16.0, CHCH2CH=CHPh) 7.16-7.34 (5H, m, Ar-H); MS ESI (+ve) 257.0 (MH, 22 
%), 278.9 (MNa, 100), 319.9 (19); HRMS FAB (+ve) found mlz 257.15414 (MITt), 
C17112102 requires 257.15416. 
6.2.5.27 	3-(N-benzyloxycarbonyl-L-valinyloxy)-6, 6-dimethyl-2-cyclohexen-1- 
one (131) 
oy 0 00  
O/\  
The general procedure outlined above (6.2.1.4, Method B) was followed using 4,4-
dimethylcyclohexane-1,3-dione (0.12 g, 0.82 mmol) to yield a colourless oil (0.14 g, 
45 %): Rf=0.52 Pet.Ether/EtOAc (4:3); [aID —5.7 (c 1.4, CHC13); vmax(cnide oil) 
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3330br (N-H), 1766 (vinyl ester), 1719 (urethane C0), 1673 (a,13-unsaturated 
ketone), 1525 (amide II); 8H (250 MHz, CDC13) 0.96 (3H, d, J7.0, CH(C"H3C'3H3)), 
1.03 (311, d, J 7.0, CH(CAH3CBH3)),  1.13 (6H, s, C(CH3)2), 1.86 (211, t, J 6.0, 
CH2C(CH3)2), 2.19-2.28 (11-1, m, CH(CH02), 2.54 (2H, t, J 6.0, CH2CH2C(CH3)2), 
4.39 (1H, dd, J9.0, 5. 0, NHCH), 5.12 (21-1, s, OCH2Ph), 5.22 (1H, d, J9.0, NH), 5.79 
(11-1, s, COCH=CO), 7.36 (511, s, Ar-H); 6c (63 MFIz, DEPT, CDC13) 18.0 
(CH(C1H3C'1-13)), 19.4 (CH(CAH30113)),  24.4 (C(CH3)2), 26.1 (CH2C(CH3)2), 31.5 
(CH(C113)2), 35.2 (CH2CII2C(CH3)2), 41.1 (C(CH3)2), 59.6 (N}TCH), 67.7 (OCI-I2Ph), 
116.7 (COCH=CO), [128.6 (CH), 128.8 (CH), 129.0 (CH), SC, Ar-H], 136.4 
(OCH2Ph), 156.6 (CONII), 167.8 (COOC=CH), 169.6 (N}TCHCO), 204.3 
(COCHCOCO); MS ESI (+ve) 396.3 (MNa, 100 %), 459.5 (23); HRMS FAB 
(+ve) found m/z 374.19673 (ME[), C21H28N05 requires 374.19675. 
6.2.6 Results and Discussion III - Library Rehearsal 
For experimental conditions refer to Library Synthesis 6.2.7. 
Table 6.1 
No. Structure 'H &'-3C NMR 
134 H0 8H (3 60 MHz, CDC13) 0.92 (3H, d, J 7.0, CH(CAH3CBH3)),  0.99 
OyN.oH 
(3H, d, J 7. 0, CH( CAH3CBH3)),  2.19-2.29 (IH, m, CH(CH3)2), 
4.21 (1H, dd, J 9.0, 4.0, NHCII), 4.56 (1H, dd, J 5.5, 4.5, 
CH4HBOCO),  4.58 (In, dd, J5.5, 4.5, CHAHBOCO),  5.17-5.36 
(2H, m, CH2=CH), 5.65 (1H, d, J 9.0, NI]), 5.85-6.01 (I H, m, 
CH2=CH), 8.68 (1H, br s, COOl]); O (63 MHz, DEPT, CDC13) 
17.9 	(CH(CAH3CBH3)), 	19.8 	(CH(CAH3C)H3)), 	31.8 
(CH(CH3)2), 60.6 (NI-ICR), 65.8 (CH2000), 117.7 (CH2=CH), 








H (360 M1-Iz, CDC13) 0.92 (3H, d, J 7.0, CH(CAH3CBH3)),  0.99 
(3H, 	d, 	J 	7.0, 	CH(CAH3CBH3)), 	1.26-1.56 	(6H, 	m, 
OCHCH2(CH2)3CH2), 1.71-1.88 (4H, m, OCHCH2(CH2)3CH2), 
2.20-2.24 (1H, m, CH(CH3)2), 4.20 (1H, dd, J 8.5, 4.0, NHCH), 
4.55-4.70 (IH, m, CHOCO), 5.48 (11-1, d, J8.5, NIl), 8.31 (1H, 
br 	s, 	COOH); 	& 	(63 	MHz, 	DEPT, 	CDC13) 	17.9 
(CH(C4H3C8H3)), 19.8 (CH(CAH3CI3H3)),  [24.3, (CH2), 25.9, 
(CH2), 3C, OCHCH2(CH2)3CH2)], 32.0 (CH(CH3)2), 	[32.4, 
(CH2), 	2C, 	OCHCH2(CH2)3CH2)], 	60.5 	(NHCH), 	73.3 
(CI-IOCO), 157.3 (CONH), 176.7 (COOH). DMAP present 
145 (360 	MHz, 	CDC13) 	0.92 	(3H, 	d, 	J 	7.0, 
ft 	 OH CH(CAH3CBH3)),  1.00 (3H, d, J 7.0, CH(CAH3CBH3)), 
2.11-2.30 (1 H, m, CH(CH3)2), 3.19 (3H, s, CH3Ph), 4.15- 
4.30 (1H, m, NHCH), 5.08 (2H, s, CH2000), 5.65 (1 H, d, 
J 7.0, NH), 7.11-7.34 (4H, m, Ar-H), 7.61 	(IH, br s, 
COOH); 	öc 	(63 	MHz, 	DEFT, 	CDC13) 	17.9 
(CH(ClH3CBH3)), 19.7  (CH(CAH3CBH3)),  21.8 (PhCH3), 
31.8 (CH(CH3)2), 60.5 (NHCH), 67.1 (CH2000), [125.4 
(CH), 	128.8 	(CH), 	129.1 	(CH), 	4C, 	Ar-H], 	136.9 
(OCH2Ph), 	138.5 	(CH3Ph), 	157.5 	(CONH), 	176.0 
(COOH). DMAP present 
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)j H (360 	MHz, 	CDC13) 	0.92 	
(3H, 	d, 	J 	7.0, 
01N 
OHCH(CAH3CBH3)), 0.98 (3H, d, J 7.0, CH(CAH3CBH3)), 
1.75 (3H, s, CH2=CCH3), 2.20-2.25 (IH, m, CH(CH3)2), 
4.13 (1H, dd, J 8.0, 4.0, NHCH), 4.42 (1H, d, J 13.5, 
CHAHBOCO),  4.52 (IH, d, J 13.5, CHAHBOCO),  4.93 
(2H, d, J 24.0, CH2=CCH3), 	5.80 (1H, d, J 8.0, NH), 
8.13 (1 H, br s, COOH); 8c (63 MHz, DEPT, CDC13) 18.0 
(CH(CH3)2), 19.8 (CH2=CCH3), 31.9 (CH(CH3)2), 61.2 
(NHCH), 68.2 (CH2000), 	112.3 (CH2=CCH3), 	141.3 





156 0 (360 	MHz, 	CDCI3) 	0.89 	(3H, 	d, 	J 	7.0, r 
CH(CAH3CBH3)),  0.97 (3H, d, J 7.0, CH(CAH3CBH3)), 
2.14-2.26 	(IH, 	m, 	CH(CH3)2), 	3.07 	(2H, 	t, J 
6.5,CH2CH20), 4.14-4.24 (IH, m, NHCH), 4.31-4.42 (2H, 
m, CH2CH20), 5.42 (IH, d, J 8.5, NH), 7.03 (IH, s, 
NHCH=C), 7.06-7.19 (2H, m, Ar-H), 7.33 (IH, d, J 8.0, 
Ar-H), 7.59 (IH, d, J, 7.0, Ar-H), 8.27 (IH, br s, COOl]); 
c (63 MHz, DEPT, CDCI3) 17.3 (CH(CAH30H3)),  19.1 
(CH(CAH3CBH3)), 29.6 	(CH2C1-120), 	30.9 (CH(CH3)2), 
59.5 (NHCH), 65.0 (CH2CH2O), 111.1 (NHCH=C), 111.1 
(NHCH=C), [118.5 (CH), 119.2 (CH), 121.8 (CH), 122.2 
(CH), 	4C, Ar-H], 	127.3 	(Ar-C), 	136.0 	(Ar-C), 	156.7 
(CONH), 176.0 (COOH). 
0 
Y'OH 
6H 	(360 	MHz, 	CDCI3) 	0.98 	(3H, 	d, 	J 	7.0, 
T CH(CAH3CBH3)),  1.05 (3H, d, J 7.0, CH 	H3  
1.32 	(3H, 	t, J 7.0, 	OCH2CH3), 	2.21-2.28 	(IH, 	m, 
CH(CH3)2), 4.15-4.17 (1H, m, NHCH), 4.26 (2H, q, J7.0, 
OCH2CH3), 4.60 (IH, d, J 16.0, C(0)CHAHBO),  4.67 (IH, 
d, J 16.0, C(0)CHAHBO),  5.61 (1H, d, J 8.5, NI]); öc (63 
MHz, 	DEPT, 	CDC13) 	14.5 	(OCH2CH3), 	17.7 
(CH(ClH3CBH3)), 19.4 	(CH(CH3CBH3)), 31.5 
(CH(CH3)2), 	60.5 	(NHCH), 	61.9 	OCH2CH3), 	77.6 






151 N H 	(360 	MHz, 	CDC13) 	0.95 	(3H, 	d, 	J 	7.0, 
O1NOH 
CH(CAH3CBH3)),  0.97 (3H, d, J 7.0, CH(CAH3CBH3)), 
1.50-1.65 	(1H, 	m, 	CH(CH3)2), 	1.65-1.81 	(2H, 	m, 
CH2CH(CH3)2), 1.75 (3H, s, CH2=CCH3), 4.30-4.42 (1H, 
m, NHCH), 4.48 (2H, s, CH2000), 4.93 (2H, d, J 23.0, 
CH2=CCH3), 5.61 (IH, d, J 8.0, NH), 8.30 (1H, br s, 
COOH); 6c (63 MHz, DEPT, CDC13)  19.8 (CH2=CCH3), 
22.4 	(CH(ClH3CBH3)), 	23.6 	(CH(CAH3CBH3)), 	25.3 
(CH(CH3)2), 43.1 (CH2CH(CH3)2), 54.2 (NHCH), 68.2 
(CH2000), 	112.3 	(CH2=CCH3), 	141.2 	(CH2=CCH3), 
157.3 (CONH), 178.1 (COOH). DMAP present 
_IL_ H (250 MHz, CDC13) 1.74 (3H, s, CH2=CCH3), 3.12 (1 H, INJ 
 dd, J 14.0, 6.0, CHAHBPh),  3.26 (IH, dd, J 14.0, 5.0, 
CHH8Ph), 4.37 (111, d, J 13.5, CHAHBOCO),  4.45-4.61 
(IH, m, NHCH), 4.52 (IH, d, J 13.5, CHAHBOCO),  4.92 
(2H, d, J 15.0, CH2=CCH3), 5.58 (1H, d, J7.5, NB), 7.70 
(IH, br s, COOH); öc (63 MHz, DEPT, CDC13) 19.8 
(CH2=CCH3), 	38.6 	(CH2Ph), 	56.2 	(NHCH), 	68.3 
(CH2000), 112.4 (CH2=CCH3), [126.9 (CH), 128.7 (CH), 
130.1 	(CH), 	SC, 	Ar-H], 	137.6 	(CH2Ph), 	141.1 




8H (360 MHz, CDC13)  1.76 (3H, s, CH2 CCH3), 1.77-1.85 
(4H, 	m, 	CCH2(CH2)2CH2), 	2.08-2.37 	(411, 	m, 
CCH2(CH2)2CH2), 4.48 (2H, s, CH2000), 4.96 (211, d, J 
23.0, CH2=CCH3), 5.88 (IH, s, NB); 6c (63 MHz, DEPT, 
CDC13) 19.8 (CH2=CCH3), [26.0 (CH2), 30.1 (CH2), 38.0 
(CH2), 4C, (C(CH2)4)], 68.0 (C(CH2)4), 69.1 (CH2000), 
113.3 (CH2=CCH3), 141.3 (CH2=CCH3), 159.0 (CONH), 






(360 MHz, CDCI3) 1.59 (6H, s, C(CH3)2), 1.73 (3H, s, 
I CH2=CCH3), 4.43 (2H, s, CH2000), 
4.89 (2H, d, J 23.0, 
CH2=CCH3), 5.56 (IH, s, NH); 8c (63 MHz, DEPT, 
CDC13) 	19.3 	(CH2=CCH3), 	24.7 	(C(CH3)2), 	57.5 
(C(CH3)2), 68.7 (CH2000), 112.8 (CH2=CCH3), 141.7 




ö 	(360 MHz, CDCI3) 1.47 (3H, d, J 7.0, CHCH3), 1.75 
1 (3H, s, CH2=CCH3), 4.24 (1H, dq, J 7.0, 7.0, NHCH), 
4.48 (2H, s, CH2000), 4.93 (2H, d, J 23.0, CH2=CCH3), 
5.86 (1 H, d, J 7.0, NH), 8.71 (1 H, br s, COOH); 6c (63 
MHz, DEPT, CDCI3) 19.8 (CH2=CCH3), 40.2 (CHCH3), 
51.4 	(NHCH), 	68.1 	(CH2000), 	112.3 	(CH2=CCH3), 
141.3 (CH2=CCH3), 157.2 (CONH), 178.2 (COOH). 
DMAP present 
6.2.7 Results and Discussion III - Library Synthesis 
6.2.7.1 Synthesis step 1 










DSC 0.63 0.44 0.70 MeCN 
DMAP 0.27 0.20 
Alcohol 2.00 0.40 0.20 MeCN 
NEt3 0.44 0.40 0.90 0.5M 
NaRC03  Acid 0.44 0.40 
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Alcohols 	 Acids 
allyl alcohol 	 L-valine 
cyclohexanol 	 L-leucine 
3-methyl benzylalcohol 	 L-phenylalanine 
2-methyl prop-2-enol 	 1-amino-1-cyclopentane carboxylic acid 
tryptophol 	 2-amino isobutyric acid 
ethyl glycolate 	 L-alanine 
6.2.7.1.1 	Experimental conditions step 1 
A solution was prepared with concentration 0.63 M DSC and 0.27 M DMAP and 
distributed into reaction vessels on the Bodhan Neptune TM-MB Automated 
Workstation. 
The Neptune was used to prepare 2.00 M solutions of each of the 6 alcohols in 
reaction vessels. 
The DSC/DMAP solution (0.70 ml) was dispensed to 36 tubes in each of four 
MiniBlocks using the Neptune. 
Each alcohol solution (0.20 ml) was dispensed to a horizontal line of 6 tubes in 
each of the four MiniBlocks using the Neptune. 
The four MiniBlocks were shaken on the MiniBlockTM High Capacity Shaking 
and Washing Station for 4 h. 
The Neptune was used to prepare six amino acid solutions of concentration 0.40 
M amino acid and 0.40 M NEt3 in reaction vessels. 
Each amino acid/NEt3 solution (0.90 ml) was dispensed to a vertical line of 6 
tubes in each of the four MiniBlocks using the Neptune. 
The Miniblocks were shaken on the Shaking Station overnight. 
The four MiniBlocks were drained into four 96 well plates and the 
MeCN/NaHCO3 solutions concentrated under reduced pressure using the Christ 
ALPHA-2-4 Freeze Dryer, BETA-RVC Ceramic Vacuum Measurement system 
(4 h, 25 °C, 100; 6 h, 25 °C, 10). 
The samples in each 96 well plate were manually redissolved in MeCN/H20 
(1:1) immediately prior to running on the ZMD 4000. 
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Each plate was transferred in turn to the ZMD 4000 (7 min run, gradient 
H20/MeCN (95:5)—*(5:95), CV=25) for mass-directed purification of the 
samples. 
The fractions collected from the ZMD 4000 fraction collector were transferred 
from test tubes to labelled 20 ml reaction vials (compatible with the Christ 
fittings) and the H20/MeCN solutions concentrated under reduced pressure using 
the Christ. 
Samples from two of the blocks were then redissolved in DCM using the 
Neptune and manually transferred (in order to limit loss of sample) to a set of 
tared test tubes in a 48 position block (compatible with the Christ fittings) The 
samples were again concentrated under reduced pressure using the Christ, and the 
tubes reweighed in order to establish an average yield for the 36 samples per 
block prepared in step 1. 
The highest yield obtained from the sample sets studied was 73 %, corresponding to 
0.22 mmol of this particular sample. Reagents for step 2 were therefore added on a 
0.22 mmol scale. 
6.2.7.2 Synthesis step 2 
Dimedone analogues 
5,5-dimethyl-cyclohexane- 1,3-dione 
4-allyl-5,5-dimethyl-cyclohexane- 1 ,3-dione 
4-benzyl-5,5-dimethyl-cyclohexane- 1 ,3-dione 
4-cyclohexylmethyl-5 ,5-dimethyl-cyclohexane- 1,3 -dione 
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6.2.7.2.1 	Experimental conditions step 2 
The Neptune was used to prepare four 2.2 M solutions of NEt3, ethyl 
chloroformate, 4-allyldimedone and 4-benzyldimedone respectively, in DCM. 
The Neptune was used to prepare a solution of concentration 2.2 M dimedone 
and 2.2 M NEt3 (addition of NEt3 was required to get dimedone into solution) 
in DCM. 
The Neptune was used to prepare a solution of concentration 2.2 M 
4-cyclohexyldimedone and 2.2 M NEt3 in DCM. 
The 36 samples from each block were redissolved in DCM (0.5 ml) and 
manually transferred to one of four MiniBlocks. 
The four MiniBlocks were placed on the MiniBlock Shaking and Washing 
Station and cooled to —10 °C using the Julabo FP40. The blocks were shaken 
at setting 540. 
The triethylamine (0.10 ml) and ethyl chloroformate (0.10 in]) solutions were 
dispensed in turn to 36 tubes in each of four MiniBlocks using the Neptune. 
The Julabo FP40 was reset to 0 °C and shaking continued for 2 h. 
The dimedone solution (0.1 ml) was dispensed to 36 tubes of one MiniBlock. 
Similarly, the three 4-alkyldimedone solutions were dispensed to the other 
three MiniBlocks respectively. The reactions were allowed to warm to room 
temperature with shaking overnight. 
The four MiniBlocks were drained into four 96 well plates and the DCM 
solutions concentrated under reduced pressure using the Christ. 
The samples in each 96 well plate were manually redissolved in MeCN/1120 
(1:1) immediately prior to running on the ZMI) 4000. 
Each plate was transferred in turn to the ZMI) 4000 (7 min run, gradient 
H20!MeCN (95:5)—(5:95), CV=25) for mass-directed purification of the 
samples. 
The fractions collected from the ZMD 4000 fraction collector were 
transferred from test tubes to labelled 20 ml reaction vials (compatible with 
the Christ fittings) and the H20/MeCN solutions concentrated under reduced 
pressure using the Christ. 
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13. All 82 samples successfully collected from the ZMID 4000 were then 
manually redissolved in DCM and transferred to a set of tared test tubes for 
weighing (as in step 1, 13), before final transferral to a 96 well plate. 
6.2.8 Results and Discussion IV 
6.2.8.1 	3,5-dimethoxy-1,4-dihydrobenzoic acid (202) 
0 OH 
To a solution 3,4,5-trimethoxybenzoic acid (5.0 g, 24.0 mmol) in ethanol (35 ml) and 
liquid ammonia (230 ml) at —78 °C, was added sodium (2.9 g, 126 mmol) in small 
pieces. When the blue colouration had disappeared ammonium chloride (11.6 g, 216 
mmol) was added. The ammonia was allowed to evaporate overnight. The resulting 
residue was dissolved in ice-water (300 ml). Alternate additions of 2N HCl followed 
by immediate extraction with DCM were carried out until the solution reached pHi. 
The combined DCM extracts were washed with 1120 x 2, dried (MgSO4) and 
concentrated under reduced pressure to a white solid (3.73 g, 85 %): mp 117 °C, Lit.9 
118 °C; Rf=0.71 DCMIMeOH (9:1); Vmax(flUjOl) 2727br (OH), 1720 (acid C0), 
1592br (vinyl ether, CC); 8H (200 MHz, CDC13) 2.79 (211, dt, J 7.0, 1.0, 
CH2COCH3), 3.60 (6H, s, 2xOCH3), 3.97 (1H, if, J 7.0, 3.5, CHCOOH), 4.76 (211, 
dt, J 3.5, 1.0, 2xCH=COCH3); 6C  (63 MHz, CDC13) 36.8 (CHCOOH), 40.4 
(C112COCH3), 51.8 (OC143), 86.4 (CH=COCH3), 154.7 (CH=COCH3), 176.0 
(COOH); HRMS FAB (+ve) found m/z 185.08138 (MT{), C9H1304 requires 
185.08 133. 
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6.2.8.2 	5-carboxy-cyclohexane-1,3-dione (203) 
0 .  0 	 HO 	0
0 OH 	 0 OH 
Y - 
The bis enol ether 202 (0.21 g, 1.12 mmol) was suspended in 2.4 % HC1 solution 
(2 ml) and heated in a water bath at 60 °C for 15 mm. The resulting clear solution 
was concentrated under reduced pressure and the residue obtained was triturated with 
a small amount of ether and filtered to give a pale yellow solid (0.18 g, 99 %): mp 
191 °C, Lit.'° 182 °C; Vmax(flUjOl) 1721 (acid C=O), 1685 (ketone); oH (200 MHz, 
DMSO); 2.42 (411, d, J 7.0, 2xCH2CHCO2H), 2.88-3.03 (111, m, CHCO2H), 5.21 
(IH, s, COCHCOH); 0c  (63 MHz, DMSO) 34.6 (U7I2CHCO21-1), 37.9 (CF1C0H), 
104.0 (COCH=COH), 174.8 (CO), 186.6 (CO211); MS ESI (+ve) found m/z 82.8 
(100 %), 156.8 (MT{, 88), 197.8 (52), 313.1 (dimer, 24); HRMS FAB (+ve) found 
m/z 157.04942 (M1E1), C7H904 requires 157.05008. 
6.2.8.3 	3-benzylamino-5-oxo-cyclohex-3-enecarboxylic acid benzylamide 
(204) 
H 
To a stirred solution of 5-carboxy-cyclohexane-1,3-dione 203 (50 mg, 0.32 mmol), 
TBTU (103 mg, 0.32 mmol) and DIPEA (56 p1. 0.32 mmol) in DMF (1 ml) was 
added benzylamine (35 pi,  0.32 mmol) and the reaction stirred at room temperature 
for 48 h. The reaction mixture was diluted with ether resulting in a brown 
suspension. EtOAc and H20 were added, and the organic layer (containing 
precipitate) separated and concentrated under reduced pressure. The resulting yellow 
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residue was triturated with EtOAc, filtered and washed with ether to yield a pale 
yellow solid. 1 H NIvIIR and MS results were unclear so the solid was re-suspended in 
EtOAc, washed with 2N HC1, filtered and washed with ether to give a white solid 
(55 mg, 51 %): rnp 218 °C; vmax(crude oil) 3275 (N-H), 1651 (a43-unsaturated 
ketone), 1604 (enamine C=C), 1549 (amide IT); 6H (200 MHz, DMSO) 2.66 (2H, d, J 
6.0, CH2CHCON}T), 2.82 (2H, d, J 6.0, CH2CHCON}T), 3.05-3.10 (1H, m, 
C112CHCO), 4.25 (2H, s, CH2Ph), 4.53 (2H, d, J 4.5, CH2Ph), 5.74 (111, s, 
CH=CN}{), 7.24-7.34 (1011, m, Ar-H); MS ESI (+ve) found m/z 335.1 (MM, 100 
%); FIRMS FAB (+ve) found m/z 335.17523 (MW), C211123N202 requires 
335.17595. 




To a stirred solution of bis enol ether 202 (non-recrystallised sample) (0.11 g, 0.61 
mmol) in DMF (2 ml) were added DIPEA (0.10 ml, 0.61 mmol), TBTU (0.20 g, 0.61 
mmol) and benzylamine (0.07 ml, 0.61 mmol). The solution turned orange in colour 
on addition of TBTU, then went pale yellow. Stirring was continued overnight at 
room temperature. The resulting solution was diluted with ether, washed with H20 x 
2, and the ether layer dried (MgSO4) and concentrated under reduced pressure to a 
yellow oil (0.06 g), a complex mixture by TLC. Flash column chromatography 
yielded off-white crystals (0.02 g, 13 %): mp 108 °C; R0.37 hexane/EtOAc (1:1); 
vmax(nujol) 3283 (N-H), 1631 (aryl ether C=C), 1601 (Ar-H), 1533 (amide II); 6H 
(200 Mhz, CDC13) 3.80 (6H, s, 2xOCH3), 4.62 (211, d, J6.0, CH2Ph), 6.41 (111, br s, 
NH), 6.57 (111, t, J2.5, COCH3CHCOCH3), 6.91 (2H, d, J2.5, 2xCHCOCH3), 7.28-
7.36 (511, in, Ar-H); MS ESI (+ve) found m/z 334.8 (100 %). 
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A second fraction was also isolated from the column as an off-white residue (2 mg); 
Rf=0.21 hexane/EtOAc (1:1); oH (200 MHz, CDC13) 3.82 (3H, s, OCH3), 3.83 (6H, s, 
2x OCH3), 4.59 (2H, d, J 6.0, CH2Ph), 6.97 (211, s, 2xCHCOCH3), 7.22-7.36 (514, in, 
Ar-H); MS EST (+ve) found mlz 301.8 (MW, 21 %), 323.7 (MNa, 24), 336.9 (23), 
365.0 (100). The analysis corresponds to N-benzyl-3,4,5-trimethoxy-benzamide 
(226), formed from 201 starting material. 




3,5-Dimethoxy- 1 ,4-dihydrobenzoic acid 202 (1.0 g, 5.4 mmol) was added to a stirred 
solution of potassium amide (13 mmol, prepared in situ from potassium (0.5 g) in 
liquid ammonia (20 ml)). Methyl iodide (1.1 ml, 17 mmol) was added and the 
solution stirred for 30 mins. Ammonium chloride (1.65 g, 30.8 mmol) was added 
and the ammonia allowed to evaporate overnight. The resulting orange residue was 
dissolved in ice/water (20 ml) and acidified to pR5 at 0 T. The solution was 
extracted with DCM (2 x 30 ml), then gradually further acidified by addition of small 
portions of 2M HC1, followed immediately by extraction with DCM. Acidification 
progressed from pH5 to pHi, when extraction ceased. The combined DCM extracts 
were dried (MgSO4) and concentrated under reduced pressure to give an orange 
residue (0.88 g). Flash column chromatography on silica gel using DCMIMeOH 
(9.5:0.5) as eluent afforded a white solid (0.28 g, 26 %): mp 136 °C; R0.11 
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DCMIMeOH (9.5:0.5); Vmax(flUjOl) 1720 (C0), 1691 (C0), 1596 (C=C); 611 (250 
MHz, CDC13) 1.38 (3H, s, C(CH3)), 2.27-2.45 (21-1, m, CH2C(CH3)), 2.81-2.97 (2H, 
m, CH2C(CH3)), 3.70 (31-1, s, OCH3), 3.82 (31-1, s, OCH3), 5.40 (1H, s, 
COCH=COCI-13); MS ESI (+ve) found mlz 198.6 (MH, 77 %), 220.7 (MNa, 100). 
6.2.8.6 	3-methoxy-1-methyl-5-oxo-cyclohex-3-enecarboxylic acid (209) 
OH 
0 
To a stirred solution of 3,4,5-trimethoxybenzoic acid (5.0 g, 24 mmol) in anhydrous 
THF (50 ml) and ammonia (75 ml) at —78 °C, was added lithium metal (0.42 g, 
60 mmol) in small pieces, until a blue colour persisted. Mel (3.7 ml, 60 mmol) was 
added and the solution stirred for 1 h at —78 T. The ammonia was allowed to 
evaporate overnight and the resulting solution concentrated under reduced pressure 
to a brown/orange residue. H20 (25 ml) and CHCI3 (50 ml) were added to the 
residue. The stirred mixture was cooled to 0 °C and the aqueous layer acidified to 
pH3 by dropwise addition of 12M HC1. The aqueous layer was separated and 
extracted with CHC13 (50 ml, then 12 ml). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure to form an orange solid (4.70 g). 
The solid was triturated with hexane/EtOAc (1:3) and the resulting white precipitate 
removed. The filtrate was concentrated under reduced pressure to yield a white solid 
(3.30 g, 76 %): Vmax(flUjOl) 2604br (OH), 1702 (acid C=O), 1685 (C0), 1598 
(CC); 6H (250 MHz, CDC13) 1.37 (3H, s, C(CH3)), 2.26-2.44 (21-1, m, CH2C(CH3)), 
2.79-2.96 (21-1, m, CH2C(CH3)), 3.70 (31-1, s, OCH3), 5.40 (11-1, s, COCHCOCH3); 
MS ESI (+ve) found m/z 184.6 (MW, 100 %), 206.6 (MNa, 83). 
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6.2.8.7 	1-ethyl-3,5-dimethoxy-cyclohexa-2,5-dienecarboxyiic acid (211) 
OH 
To a stirred solution of 3,5-dimethoxybenzoic acid (4.0 g, 22 mmol) in anhydrous 
THF (40 ml) and ammonia (60 ml) at —78 °C, was added lithium metal (0.4 g, 58 
mmol) in small pieces, until a blue colour persisted. Bromoethane (4.1 ml, 55 mmol) 
was added in one portion (solution turned yellow, then colourless) and the solution 
stirred for I h at —78 °C. The ammonia was allowed to evaporate overnight and the 
remaining THIF solution concentrated under reduced pressure to yield a pale orange 
residue. The residue was dissolved in ice/water (100 ml) and CHC13 (200 in]) added. 
The solution was acidified to pHI using 2M FIC1. The CRC13 layer was separated 
and the aqueous layer extracted with CHC13 (3 x 100 ml). The combined organic 
extracts were dried (MgSO4) and concentrated under educed pressure to afford a pale 
orange solid which was recrystallised from DCMIPet.Ether (1:1) to yield white 
crystals (4.33 g, 86 %): mp 134 °C, Lit." 141-144 °C; R0.36 Hexane/EtOAc 
(19:1); vm (nujol) 2634br (OH), 1698 (C=O), 1686 (C=O), 1657 (vinyl ether C=C); 
(200 MHz, CDC13) 0.80 (3H, t, J 7.5, CH2CH3), 1.73 (2H, q, J 7.5, CH2CH3), 2.75 
(2H, s, CH2COCH3), 3.59 (6H, s, 2 x OCH3), 4.64 (2H, s, 2 x CH=COCH3); 6c  (63 
MHz, DEPT, CDC13) 8.5 (CH2CH3), 31.0 (CH2CH3), 33.6 (CH2COCH3), 50.2 
(C(CO2H)CH2CH3), 54.3 (2 x OCR3), 94.2 (2 x CH=COCH3), 153.2 (2 x 
CH=COCH3), 182.6 (CO2H); MS ESI (-ye) found mlz 210.8 ([M-H], 100 %); 
HRMS FAB (+ve) found m/z 213.11264 (MH), C1 1H1704 requires 213.11268. 
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To a stirred solution of 211 (1.50 g, 7.08 mmol in 1,4-dioxane (40 ml) was added 
triethylamine (1.10 ml, 7.78 mmol), TBTU (2.50 g, 7.78 mmol) and HOBt (0.48 g, 
3.54 mmol), followed by N-methylbenzylamine (1.00 ml, 7.78 mmol). The solution 
was stirred at room temperature overnight. The resulting orange mixture was diluted 
with ether (40 ml), washed with H20 (30 ml), dried (MgSO4) and concentrated under 
reduced pressure to yield a yellow oil (4.29 g). Flash column chromatography on 
silica gel using hexane:EtOAc (1:1) as eluent afforded a colourless oil (1.66 g, 75 
%): R0.58 hexane/EtOAc (1:1); vmax(crude oil) 2826-3086br (Ar & OH), 1738 
(C=O), 1689 (vinyl ether C=C), 1633 (amide C=O); 8H  (200 MHz, CDC13) 0.71 (3H, 
t, J7.5, CH2CH3), 1.86 (2H, q, J7.5, CH2CH3), 2.60 (1H, d, J21.0, CIf1H'3COCH3), 
2.81 (1H, d, J21.0, CHAHBCOCH3),  2.88 (311, s, NCH3), 3.22-3.52 (611, br s, 2 x 
COCH3), 4.47 (2H, s, CJ-I2Ph), 4.58 (2H, s, 2 x CH=COCH3), 7.10-7.34 (511, m, Ar-
I]); 6C (63 M1-Iz, DEPT, CDC13) 8.2 (CH2CH3), 31.1 (CH2CH3), 33.3 (CH2COCH3), 
35.8 (NCH3), 50.2 (CC112CH3), 52.8 (CH2Ph), 54.1 (2 x OCH3), 95.5 (2 x 
CH=COCH3), [126.7 (CH), 127.1 (CH), 128.0 (CH), 128.3 (CH), SC, Ar-H], 138.0 
(CH2Ph), 152.7 (2 x CH=COCH3), 175.3 (CONE); FIRMS FAB (+ve) found m/z 
316.19135 (MT{F),  C191-126NO3 requires 316.19127. 




:S  N 
0 
To a stirred solution of 212 (0.76 g, 2.43 mmol) in THF (70 ml) was added H20 (10 
ml), followed by 12 M HC1 (2 ml). The solution was stirred overnight at room 
temperature before concentration under reduced pressure to yield a pale yellow 
residue (0.96 g). Flash column chromatography on silica gel using hexane/EtOAc 
(1:5) as eluent afforded a sticky white solid (0.61 g, 87 %): R0.28 DCM/MeOH 
(9:1); vmax(nujol) 1636 (C=O), 1611 (amide C=O); oH (200 MHz, MeOD) 1.01 (3H, 
t, J 7.5, CHCH), 1.99 (2H, q, J 7.5, CH2CH3), 2.56 (211, d, J 16.5, 
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CH4HBCOCH2COCH4HB), 3.11 (3H, s, NCH3), 3.12 (2H, d, J 16.5, 
CHAI1BCOCH2COCHAH),  4.69 (2H, s, CH2Ph), 7.26-7.44 (5H, in, Ar-I]); 8c (63 
MHz, DEPT, MeOD) 7.1 (CH2CH3), 29.1 (CH2CH3), 34.7 (NCH3), 41.5 (2C, 
CH2COCH2COCH2), 49.5 (CCHCH3), 52.4 (CJ-I2Ph), 59.6 (COCH2CO), [126.6 
(CH), 126.7 (CH), 127.7 (CH), 5C, Ar-H], 136.4 (CH2Ph), 172.9 (CONH), 203.1 
(CO); MS ESI (+ve) found m/z 287.8 (MH, 78 %), 304.8 (MNFLt, 21), 309.8 
(MNa, 100); HRMS FAB (+ve) found m/z 288.15994 (MH), C17H22NO3 requires 
288. 15997. 
6.2.8.10 	Oxidative cleavage of N-[1-(4,4-dimethyl-2, 6-dioxocyclo 
hexylidene)-2-benzyloxycarbonylamino-3-methylbutylj 
phenylalanine methyl ester (59) 
o 	NZ o 
H 	









59 (0.22 g, 0.42 mmol) was dissolved in methanol (4 ml). A solution of Na104 (0.89 
g, 4.17 mmol) in H20 (2 ml) was added and the reaction refluxed at 60 °C for 4 h. 
H20 (12 ml) was added and the aqueous solution extracted with DCM (3 x 4 ml), 
dried (Mg504) and concentrated under reduced pressure to yield a yellow oil (0.20 
g). The oil was triturated with hexane/EtOAc (1:1) and the resulting white solid 
filtered off and dried in a desiccator over P205, to afford a white powder (5 mg, 3 %): 
H (250 MHz, CDC13); complex mixture; MS ESI (+ve) found m/z 435.1 (MNa, 100 
%), 451.0 (MK, 64). 
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6.2.8.10.2 	Ozonolysis 
59 (0.15 g, 0.28 mmol) was dissolved in anhydrous DCM (15 ml). The solution was 
cooled with stirring to —70 °C and subjected to a stream of ozone for 5 mm. The 
reaction was then treated with a solution of thiourea (32 mg, 0.42 mmol) in MeOH 
(5 ml) and the resulting mixture stirred at —60 °C for 1.5 h, before warming to room 
temperature. TLC CHC13/ether (1:1) of the crude reaction mixture indicated that no 
reaction had taken place. 
6.2.8.1 0.3 	Ruthenium (III) catalyst 
CC4 (2 ml), MeCN (2 ml) and H20 (3 ml) were added to 59 (0.15 g, 0.28 mmol). 
Na104 (0.25 g, 1.15 mmol) was added to the stirred reaction. To the resulting black 
biphasic solution, RuCI3.1-120 (4 mg) was added and the mixture stirred at room 
temperature overnight. The reaction was diluted with DCM (10 ml) and the 2 phases 
separated. The aqueous layer was washed with DCM (3 x 5 ml) and the combined 
organic extracts dried (MgSO4) and concentrated under reduced pressure to give a 
dark brown oil. The oil was diluted with ether (20 ml), filtered through Celite and 
concentrated under reduced pressure to afford an orange oil (0.14 g). Flash column 
chromatography on silica gel using CHC13/ether (1:1) as eluent yielded a yellow oil 
(16 mg, 14%):8H  (200 MHz, CDC13) complex mixture; MS EST (+ve) found m/z 
435.2 (MNa, 100 %), (179.6, PheOMe ester, 61). 
6.2.8.11 	2-(1-hydroxy-propylidene)-5,5-dimethyl-cyclohexane-1,3-dione 
(215) 
To a stirred solution of propionic acid 214 (1.0 ml, 13 mmol) in DMF (130 ml) was 
added DCC (2 68 g, 13 mmol) and DMAP (1.59 g, 13 mmol), followed by dimedone 
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(2.01 g, 14 mmol) and the solution stirred at room temperature overnight. The 
resulting white DCU precipitate was removed by filtration and the filtrate 
concentrated under reduced pressure. The residue obtained was diluted with EtOAc 
(200 in]) and further DCU filtered off. The filtrate was washed with 1M KHSO4 (50 
ml) and extracted with saturated NaHCO3 solution (2 x 150 ml). The aqueous layer 
was acidified with 2M HCl to pHi and the resulting milky solution extracted with 
DCM (2 x 150 ml). The combined DCM extracts were concentrated under reduced 
pressure to yield a pale yellow residue (1.92 g). Flash column chromatography on 
silica gel using hexane/EtOAc (1:3) as eluent afforded a bright yellow liquid (1.53 g, 
60 %): R0.62 hexane/EtOAc (1:3); vmax(nujol) 1671 (a43  -unsaturated ketone), 
1559 (C=C); 6H (250 MHz, CDCI3) 0.94 (6H, s, C(CH3)2), 0.98 (3H, t, J 7.0, 
CH2CH3), 2.22 (2H, s, CH2C(CH3)2), 2.41 (211, s, CH2C(CH3)2), 2.90 (2H, q, J 7.0, 
CH2CH3), 17.52 (111, s, OH); 6c (63 MHz, DEPT, CDC13) 7.9 (CH2CH3), 27.8 
(CH(CI-13)2), 30.3 (CH(CH3)2), 33.7 (CH2CH3), 46.2 (CH2C(CH3)2), 52.2 
(CH2C(CH3)2), 111.4 (COC=COH), 194.6 (COC=COH), 196.7 (COC=COH), 206.0 
(COC=COH); MS ESI (-ye) found ni!z 195.0 ([M-H], 100 %); HRMS FAB (+ve) 
found mlz 197.11780 (MW), C11H1703 requires 197.11777. 
6.2.8.12 	2-(1-benzylamino-propylidene)-5,5-dimethyl-cyclohexane-1,3-dione 
(216) 
215 (1.51 g, 7.70 mmol) was dissolved in DCM (5 ml) and DIPEA (1.34 ml, 7.70 
mmol) added followed by benzylamine (0.84 ml, 7.70 mmol). The reaction was 
stirred at room temperature overnight. The resulting orange solution was washed 
with 2M HC1 (5 ml), brine (5 ml) dried (MgSO4) and concentrated under reduced 
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pressure to afford pale yellow crystals (1.64 g, 75 %): mp 72 °C; R0.54 
hexane/EtOAc (1:3); Vmax(flUjOl) 1632 (a,3-unsaturated ketone), 1560 (C=C); 6H 
(250 MHz, CDC13) 1.02 (6H, s, C(CH3)2), 1.19 (3H, t, J 7.5, CH2CH3), 2.36 (411, s, 
CH2C(CH3)2CH2), 3.06 (2H, q, J7.5, CH2CH3), 4.61 (2H, dJ5.5, CH2Ph), 7.24-7.40 
(511, m, Ar-H), 13.77 (1H, br s, Nil); öc (63 MHz, DEPT, CDC13) 11.6 (CH2CH3), 
23.1 (CH2CH3),  28.1 (C(CH3)2), 29.8 (C(CH3)2), 46.4 (CH2Ph), 52.4 (CH2C(CH3)2), 
53.3 (CH2C(CH3)2), 106.8 (COC=COH), [127.0 (CH), 127.9 (CH), 128.9 (CH), 5C, 
Ar-H], 135.7 (CH2Ph), 177.9 (COCCOH), 196.2 (COCCOH), 199.8 
(COC=COH); MS ESI (+ve) found m/z 286.3 (MW, 100 %), 349.4 (72), 396.5 (53); 
HRMS FAB (+ve) found m/z 286.18111 (MR), C18H24NO2 requires 286.18070. 
6.2.8.13 
	











216 (0.10 g, 0.36 mmol) was dissolved in MeOH (2 nil). A solution of Na104 (0.31 
g, 1.43 mmol) in H20 (2 ml) was added and the solution heated under reflux 
overnight. The resulting brown/red solution was diluted with water (6 ml) and 
extracted with DCM (3 x 2m1). The combined organic extracts were dried (MgSO4) 
and concentrated under reduced pressure to yield a dark brown/red residue. Crude 
mixture MS ESI (+ve) found m/z 107.5 (benzylamine, 54 %), 163.5 (Iv1IH, 100), 
(185.5, MNa, 80). Flash column chromatography using hexane/EtOAc (1:3) as 
eluent afforded a yellow oil (14 mg, 24 %): Rf=0.40 hexane/EtOAc (1:3); oH (250 
MHz, CDC13) 1.17 (31-1, t, J7.5, CH2CH3), 2.24 (2H, q, J7.5, CH2CH3), 4.43 (2H, d, 
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J 5.5, CHPh), 5.74 (1H, br s, NH), 7.23-7.37 (5H, m, Ar-H); MS ESI (+ve) found 
mlz 163.5 (217 IVlIH, 82 %), (185.5, MNa, 100). 
	
6.2.8.13.2 	Selenium dioxide catalyst 
To a stirred soution of 216 (0.15 g, 0.53 mmol) and Se02 (6 mg, 0.05 mmol) in DCM 
(3 ml) was added a 53 % wt 11202 aqueous solution (0.10 ml, 1.16 mmol) dropwise 
over 2 min. After stirring for 2 h, the mixture was slowly poured into saturated 
Na2S03 solution (5 ml). The resulting solution was extracted with DCM (3 x 5 ml) 
and the combined organic layers dried (Na2SO4) and concentrated under reduced 
pressure to form pale yellow crystals (0.14 g): R0.54 hexane/EtOAc (1:3); MS ESI 
(+ve) found m!z 285.7 (216, 100 %). 
6.2.8.13.3 	Chromium oxide 
A solution of 216 (0.15 g, 0.53 mmol) in DCM (15 ml) and AcOH (7.5 ml) was 
cooled to —70 °C and Cr03 (0.16 g, 1.58 mmol) added in small portions. The 
solution turned dark green in colour. The reaction mixture was stirred at —40 °C for 
2 h, then poured into a mixture of 33 % NH3 solution (10 ml) and ice (60 ml). The 
organic layer was separated and the inorganic layer extracted with DCM (60 ml). 
The combined DCM extracts were dried (MgSO4) and concentrated under reduced 
pressure to form pale yellow crystals (0.10 g): Rf=0.54 hexane/EtOAc (1:3); MS ESI 
(+ve) found m!z 285.7 (216, 100 %). 
6.2.8.13.4 	Ammonium molybdated catalysed hydrogen peroxide 
To a suspension of 216 (0.15 g, 0.53 mmol) and ammonium molybdate (0.02 g, 0.01 
mmol) in acetic acid (3 ml), 11202:35 % wt solution in 1120 (0.38 ml, 4.31 mmol) 
was added dropwise with stirring. The reaction mixture was stirred at 35 °C for 
7.5 h. Crude mixture MS ESI (+ve) found m/z 107.5 (benzylamine, 57 %), 163.5 
(MW, 100), (185.5, MNa, 30). The resulting solution was diluted with water and 
extracted with CHC13. The combined extractions were washed with saturated 
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NaHCO3 solution, dried (MgSO4) and concentrated under reduced pressure to yield a 
colourless oil (0.03 g, 35 %): Rf=0.40 hexane/EtOAc (1:3); 8H (250 MHz, CDC13) 
1.17 (311, t, J7.5, C142CH3), 2.24 (2H, q, J7.5, CH2CH3), 4.43 (211, d, J5.5, CH2Ph), 
5.74 (1H, hr s, NH), 7.23-7.37 (51-1, m, Ar-H); MS ESI (+ve) found m/z 163.6 (217 




o Jr o 
The procedure outlined above (6.2.8.11) was followed using 215 (0.85 g, 4.34 mmol) 
and N-butylamine (0.43 ml, 4.34 mmol) to afford a yellow liquid (1.05 g, 96 %): 
R=0.49 hexane/EtOAc (1:3); vm(crude oil) 1639 (aj3-unsaturated ketone), 1575 
(CC); 6H (250 MHz, CDC13) 0.92 (3H, t, J 7.0, CH2CH2CH3), 0.98 (6H, s, 
C(CH3)2), 1.15 (3H, t, J7.5, CCH2CH3), 1.34-1.49 (2H, m, CH2CH2CH3), 1.57-1.68 
(2H, m, CH2CH2CH3), 2.31 (41-1, s, CH2C(CH3)2CH2), 2.98 (2H, q, J 7.5, CCH2CH3), 
3.38 (2H, dt, J7.0, 5.5, NHCH2), 13.39 (1H, br s, NH); 8c (63 MHz, DEPT, CDC13) 
11.5 (CCH2CH3), 13.5 (CH2CH2CH3), 19.9 (CH2GH2CH3), 23.0 (CH2CH2CH3), 28.0 
(C(CH3)2), 29.8 (C(CH3)2), 31.1 (NHCH2), 42.2 (CCH2CH3), 52.8 
(CH2C(CH3)2CH2), 106.4 (COC=CNH), 177.7 (COC=CNH), 196.0 (COC=CNH), 
198.6 (COC=CNH); MS ESI (+ve) found m/z 252.0 (IVll{1 , 100 %), 274.0 (MNa, 
19), 315.0 (39); HRMS FAB (+ve) found m/z 252.19672 (Ivll{), C151126NO2 requires 
252. 19635. 
6.2.8.15 	N-Butyl-propionamide (219) 
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To a suspension of 218 (0.20 g, 0.80 mmol) and ammonium molybdate (0.03 g, 0.02 
mmol) in acetic acid (3.5 ml), H202:35 % wt solution in H20 (0.57 ml, 6.54 mmol) 
was added dropwise with stirring. The reaction mixture was stirred at 35 °C for 
16.5 h. The resulting solution was diluted with water and extracted with CHC13. The 
combined extractions were washed with saturated NaHCO3 solution, dried (MgSO4) 
and concentrated under reduced pressure to yield a colourless oil (54 mg, 53 %): 
Rf=0.25 DCMIMeOH (9:1); oH (250 MHz, CDC13) 0.89 (311, t, J7.0, CH2CH2CH3), 
1.12 (31-1, t, J7.5, COCH2CH3), 1.22-1.53 (414, m, CH2CH2CH3), 2.17 (2H, q, J7.5, 
COCH2CH3), 3.21 (2H, q, J 7.0, NHCH2); MS ESI (+ve) found m/z 130.0 (MiIr, 
25 %), 153.0 (MNa, 100); HRMS FAB (+ve) found m/z 130.12273 (MH), 
C71416N0 requires 130.123 19. 
6.2.8.16 	1-ethyl-4-(1-hydroxy-propylidene)-3,5-dioxo-cyclohexane 





213 (0.37 g, 1.30 mmol) was dissolved in DMF (25 ml) with stirring. DCC (0.30 g, 
1.43 mmol), DMAP (0.18 g, 1.43 mmol) and propionic acid ( 0.11 ml, 1.43 mmol) 
were added and the resulting solution stirred at room temperature for 2 days. The 
resulting white DCU precipitate was removed and the filtrate concentrated under 
reduced pressure to a yellow residue. The residue was diluted with EtOAc (40 ml) 
and further DCU filtered off. The EtOAc filtrate was washed with 2M HC1, dried 
(MgSO4) and concentrated under reduced pressure to give a yellow liquid (0.52 g). 
Flash column chromatography on silica gel using hexane/EtOAc (1:3) as eluent 
yielded off-white needles (0.31 g, 70 %): mp 89 °C; Rf=0.43 Hexane/EtOAc (1:3); 
vmax(nujol) 3321br (0-14), 1670 (a,13-unsaturated ketone), 1613 (amide C0), 1556 
(C=C); 0H  (200 MHz, CDC13) 0.92 (311, t, J 7.5, CCH2CH3), 1.10 (311, t, J 7.5, 
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CC(OH)CH2CH3), 1.73 (111, dq, J 15.0, 7.5, CCH4HBCH3),  1.89 (11-1, dq, J 15.0, 
7.5, CCHhIJBCH3),  2.52 (1H, d, J 16.5, CHHBC0C(=C(Ofl)CH2CH3)COCHAHB), 
2.54 (1H, d, J 16.5, CHHBCOC(=C(OH)CH2CH3)COCHAHl3), 2.99 (311, s, NCH3), 
3.04 (21-1, d, J 7.5, C=C(OH)CH2CH3), 2.98-3.09 (111, m (masked), 
CH1HBCOC(=C(OH)CH2CH3)COCH4HB),  3.33 (11-1, dd, J 17.0, 3.0, 
CHHCOC(=C(0H)CH2CH3)COCHAHB),  4.50 (11-1, d, J 15.0, CH4HBPh),  4.60 
(111, d,J15.0, CHAHBPh),  7.09-7.32(5H, m, Ar-H), 18.26(111, s, 01]); 6c (63 M}Jz, 
DEPT, CDC13) 8.1 (CCH2CH3), 8.5 (C=C(OH)CH2C1713), 30.1 (CCH2CH3), 33.7 
(C=C(OH)CH2C113), 35.7 (NCH), 43.4 (GH2CO), 47.7 (CCH2CH3), 48.1 (CH2CO), 
53.5 (CHPh), 111.6 (C=C(OH)CH2CH3), [127.4 (CH), 127.5 (CH), 128.5 (CH), SC, 
Ar-H], 136.6 (CH2Ph), 172.0 (CONH), 192.5 (CC(OH)CH2CH3), 197.5 (CO), 
205.6 (CO); MS ESI (+ve) found m/z 343.9 (MW, 34 %), 366.0 (MNa, 100), 407.0 
(32); HRMS FAB (+ve) found mlz 344.18621 (Ml{), C201-126N04 requires 
344.18618. 
6.2.8.17 	4-(1-Butylamino-propylidene)-1-ethyl-3,5-dioxo-cyclohexane 
carboxylic acid benzyl-methyl-amide (221) 
220 (0.24 g, 0.70 mmol) was dissolved in DCM (1 ml) and DIPEA (0.13 ml, 0.77 
mmol) added followed by N-butylamine (0.08 ml, 0.77 mmol). The reaction was 
stirred at room temperature overnight. The resulting solution was diluted with DCM 
(10 ml) and washed with 2M HC1 (2 x 5 ml). The combined organic extracts were 
dried (MgSO4) and concentrated under reduced pressure to afford a colourless oil 
(0.27 g, 95 %): R=0.30 Hexane/EtOAc (1:3); vmax(nujol) 3458br (0-11 &N-H), 
1 634br (ketone & amide C=0), 1 574br (C=C); 6H (200 MHz, CDC13) 0.90 (31-1, t, J 
7.0, CH2CH2CH3), 0.95 (31-1, t, J 7.5, CCH2CH3), 1.16 (3H, t, J 7.5, C=CC112CH3), 
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1.39-1.5 1 (2H, m, CH2CH2CH3), 1.60-1.69 (211, m, CH2CH2CH3), 1.76 (2H, q, J7.5, 
CCH2CH3), 2.52 (2H, d, J 16.0, CH2CO), 2.98 (31-1, s, NCH3), 2.99 (2H, q, J 7.5, 
C=CCH2CH3), 3.12 (211, d, J 16.0, CH2CO), 3.36-3.44 (211, m, CH2NH), 4.56 (2H, s, 
CH2Ph), 7.12-7.28 (5H, m, Ar-H), 13.33 (IF!, s, NI]); öc (63 MHz, DEPT, CDC13) 
8.6 (CH2CH2CH3), 11.4 (CCH2CII3), 13.5 (C=CCH2CH3), 19.9 (CH2CH2CH3), 23.1 
CH2CH2CH3), 29.7 (CCH2CH3), 31.1 (C=CCH2CH3), 35.6 (NCH3), 42.4 (GH2NH), 
46.6 (CCH2CH3), 48.4 (CH2CO), 53.1 (CH2Ph), 106.2 (C=CCH2CH3), [127.1 (CH), 
127.6 (CH), 128.4 (CH), 5C, Ar-H], 137.0 (CH2Ph), 173.0 (CONH), 177.7 
(C=CCH2CH3), 195.9 (CO); MS ESI (+ve) found mlz 399.1 (MT{1 , 68 %), 421.1 
(MNa, 100), 462.1 (26); HRMS FAB (+ve) found m/z 399.26480 (MW), 
C241-135N203 requires 399.26477. 
6.2.8.18 Oxidation of 4-(1-butylamino-propylidene)-1-ethyl-3,5-dioxo-
cyclolsexanecarboxylic acid benzyl-methyl-amide (221 -* 219) 
The general procedure outlined above (6.2.8.14) was followed using 221(0.14 g, 
0.37 mmol) to yield a pale yellow oil (27 mg, 56 %): 6H  (250 MHz, CDC13) as 
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